(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB00526'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB00544'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
NsS'contraindication'
p11
NsS'researchStatementLabel'
p12
NsS'severity'
p13
NsS'label'
p14
NsS'effectConcept'
p15
NsS'source'
p16
S'DDI-Corpus-2013'
p17
sS'ddiPkEffect'
p18
NsS'evidenceType'
p19
NsS'homepage'
p20
NsS'pathway'
p21
NsS'ddiType'
p22
S'mechanism'
p23
sS'researchStatement'
p24
NsS'dateAnnotated'
p25
NsS'object'
p26
S'\xef\xbb\xbf5-FU'
p27
sS'evidenceSource'
p28
NsS'evidenceStatement'
p29
S'Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. | \r'
p30
sS'precipUri'
p31
NsS'certainty'
p32
NsS'uri'
p33
NsS'precip'
p34
NsS'numericVal'
p35
NsS'precaution'
p36
NsS'precipitant'
p37
S'Eloxatin'
p38
sa(dp39
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p40
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p41
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p42
sg24
Nsg25
Nsg26
S'Abilify'
p43
sg28
Nsg29
S'Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.| \r'
p44
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p45
sa(dp46
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p47
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p48
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p49
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p50
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p51
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p52
sa(dp53
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p54
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p55
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p56
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p57
sg28
Nsg29
S'Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| \r'
p58
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Busulfex'
p59
sa(dp60
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p61
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p62
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p63
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p64
sg28
Nsg29
S'Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.| Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.| \r'
p65
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAFFEINE'
p66
sa(dp67
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p68
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p69
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p70
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p71
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p72
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p73
sa(dp74
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p75
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p76
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p77
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p78
sg28
Nsg29
S'Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.| \r'
p79
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Gleevec'
p80
sa(dp81
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p82
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p83
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p84
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p85
sg28
Nsg29
S'Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.| \r'
p86
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p87
sa(dp88
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p89
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p90
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p91
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p92
sg28
Nsg29
S'Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p93
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p94
sa(dp95
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p96
sg5
S'http://bio2rdf.org/drugbank:DB00316'
p97
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p98
sg24
Nsg25
Nsg26
S'ACETAMINOPHEN'
p99
sg28
Nsg29
S'Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p100
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p101
sa(dp102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p103
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p105
sg24
Nsg25
Nsg26
S'ACETAZOLAMIDE'
p106
sg28
Nsg29
S'Acetazolamide may elevate cyclosporine levels.| \r'
p107
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p108
sa(dp109
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p110
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p111
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p112
sg24
Nsg25
Nsg26
S'ACETAZOLAMIDE'
p113
sg28
Nsg29
S'Acetazolamide increases lithium excretion and the lithium may be decreased.| \r'
p114
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p115
sa(dp116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p117
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p119
sg24
Nsg25
Nsg26
S'ACETAZOLAMIDE'
p120
sg28
Nsg29
S'Acetazolamide increases lithium excretion and the lithium may be decreased.| \r'
p121
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p122
sa(dp123
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p124
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p125
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p126
sg24
Nsg25
Nsg26
S'ACETAZOLAMIDE'
p127
sg28
Nsg29
S'Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.| \r'
p128
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p129
sa(dp130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p131
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p133
sg24
Nsg25
Nsg26
S'ACETAZOLAMIDE'
p134
sg28
Nsg29
S'Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.| \r'
p135
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SODIUM BICARBONATE'
p136
sa(dp137
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p138
sg5
S'http://bio2rdf.org/drugbank:DB03128'
p139
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p140
sg24
Nsg25
Nsg26
S'ACETYLCHOLINE CHLORIDE'
p141
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p142
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p143
sa(dp144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00166'
p145
sg5
S'http://bio2rdf.org/drugbank:DB08842'
p146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p147
sg24
Nsg25
Nsg26
S'acetyl-L-carnitine'
p148
sg28
Nsg29
S'(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.| \r'
p149
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'alpha-Lipoic acid'
p150
sa(dp151
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p152
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p153
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p154
sg24
Nsg25
Nsg26
S'ACITRETIN'
p155
sg28
Nsg29
S'Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.| \r'
p156
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p157
sa(dp158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p159
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p161
sg24
Nsg25
Nsg26
S'ACITRETIN'
p162
sg28
Nsg29
S'Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| \r'
p163
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Glibenclamide'
p164
sa(dp165
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p166
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p167
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p168
sg24
Nsg25
Nsg26
S'ACITRETIN'
p169
sg28
Nsg29
S'Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.| \r'
p170
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p171
sa(dp172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p173
sg5
S'http://bio2rdf.org/drugbank:DB01285'
p174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p175
sg24
Nsg25
Nsg26
S'ACTH'
p176
sg28
Nsg29
S'Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.| \r'
p177
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p178
sa(dp179
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p180
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p181
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p182
sg24
Nsg25
Nsg26
S'ADENOSINE PHOSPHATE'
p183
sg28
Nsg29
S'It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p184
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p185
sa(dp186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p187
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p189
sg24
Nsg25
Nsg26
S'ADENOSINE'
p190
sg28
Nsg29
S'The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| \r'
p191
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAFFEINE'
p192
sa(dp193
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p194
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p195
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p196
sg24
Nsg25
Nsg26
S'ADENOSINE'
p197
sg28
Nsg29
S'As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.| \r'
p198
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p199
sa(dp200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00975'
p201
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p203
sg24
Nsg25
Nsg26
S'ADENOSINE'
p204
sg28
Nsg29
S'Adenosine effects are potentiated by dipyridamole.| Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.| \r'
p205
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIPYRIDAMOLE'
p206
sa(dp207
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p208
sg5
S'http://bio2rdf.org/drugbank:DB00640'
p209
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p210
sg24
Nsg25
Nsg26
S'ADENOSINE'
p211
sg28
Nsg29
S'The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| \r'
p212
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p213
sa(dp214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p215
sg5
S'http://bio2rdf.org/drugbank:DB06274'
p216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p217
sg24
Nsg25
Nsg26
S'ADL 8-2698'
p218
sg28
Nsg29
S'ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.&#x0D;| We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.| \r'
p219
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p220
sa(dp221
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01159'
p222
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p223
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p224
sg24
Nsg25
Nsg26
S'Adrenaline'
p225
sg28
Nsg29
S'Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| \r'
p226
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fluothane'
p227
sa(dp228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p229
sg5
S'http://bio2rdf.org/drugbank:DB00775'
p230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p231
sg24
Nsg25
Nsg26
S'Aggrastat'
p232
sg28
Nsg29
S'The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see| \r'
p233
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p234
sa(dp235
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p236
sg5
S'http://bio2rdf.org/drugbank:DB00810'
p237
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p238
sg24
Nsg25
Nsg26
S'Akineton'
p239
sg28
Nsg29
S'Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| \r'
p240
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEPERIDINE'
p241
sa(dp242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p243
sg5
S'http://bio2rdf.org/drugbank:DB00810'
p244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p245
sg24
Nsg25
Nsg26
S'Akineton'
p246
sg28
Nsg29
S'Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| \r'
p247
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p248
sa(dp249
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01048'
p250
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p251
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p252
sg24
Nsg25
Nsg26
S'ALCOHOL'
p253
sg28
Nsg29
S'Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. | \r'
p254
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ABACAVIR'
p255
sa(dp256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p257
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p259
sg24
Nsg25
Nsg26
S'ALCOHOL'
p260
sg28
Nsg29
S'As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| \r'
p261
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Abilify'
p262
sa(dp263
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01213'
p264
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p265
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p266
sg24
Nsg25
Nsg26
S'ALCOHOL'
p267
sg28
Nsg29
S'Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.| \r'
p268
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Antizol'
p269
sa(dp270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p271
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p273
sg24
Nsg25
Nsg26
S'ALCOHOL'
p274
sg28
Nsg29
S'Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| \r'
p275
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p276
sa(dp277
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00327'
p278
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p279
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p280
sg24
Nsg25
Nsg26
S'ALCOHOL'
p281
sg28
Nsg29
S'Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.| \r'
p282
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dilaudid'
p283
sa(dp284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p285
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p287
sg24
Nsg25
Nsg26
S'ALCOHOL'
p288
sg28
Nsg29
S'Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. | \r'
p289
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DISULFIRAM'
p290
sa(dp291
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00956'
p292
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p293
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p294
sg24
Nsg25
Nsg26
S'ALCOHOL'
p295
sg28
Nsg29
S'Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.| \r'
p296
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCODONE'
p297
sa(dp298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p299
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p301
sg24
Nsg25
Nsg26
S'ALCOHOL'
p302
sg28
Nsg29
S'Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| \r'
p303
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lexapro'
p304
sa(dp305
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01107'
p306
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p307
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p308
sg24
Nsg25
Nsg26
S'ALCOHOL'
p309
sg28
Nsg29
S'Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.| \r'
p310
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Methyprylon'
p311
sa(dp312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p313
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p315
sg24
Nsg25
Nsg26
S'ALCOHOL'
p316
sg28
Nsg29
S'Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.| \r'
p317
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAZOCINE, (-)-'
p318
sa(dp319
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00140'
p320
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p321
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p322
sg24
Nsg25
Nsg26
S'ALCOHOL'
p323
sg28
Nsg29
S'Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin| \r'
p324
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIBOFLAVIN'
p325
sa(dp326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01142'
p327
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p329
sg24
Nsg25
Nsg26
S'ALCOHOL'
p330
sg28
Nsg29
S'Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.| \r'
p331
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sinequan'
p332
sa(dp333
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p334
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p335
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p336
sg24
Nsg25
Nsg26
S'ALCOHOL'
p337
sg28
Nsg29
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p338
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TIAGABINE'
p339
sa(dp340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p341
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p343
sg24
Nsg25
Nsg26
S'ALCOHOL'
p344
sg28
Nsg29
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p345
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p346
sa(dp347
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p348
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p349
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p350
sg24
Nsg25
Nsg26
S'ALCOHOL'
p351
sg28
Nsg29
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p352
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Wellbutrin'
p353
sa(dp354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p355
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p357
sg24
Nsg25
Nsg26
S'ALCOHOL'
p358
sg28
Nsg29
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p359
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Wellbutrin'
p360
sa(dp361
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p362
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p363
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p364
sg24
Nsg25
Nsg26
S'ALFENTANIL'
p365
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p366
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p367
sa(dp368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p369
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p371
sg24
Nsg25
Nsg26
S'Alfentanyl'
p372
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p373
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p374
sa(dp375
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p376
sg5
S'http://bio2rdf.org/drugbank:DB00802'
p377
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p378
sg24
Nsg25
Nsg26
S'Alfentanyl'
p379
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p380
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p381
sa(dp382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p383
sg5
S'http://bio2rdf.org/drugbank:DB01258'
p384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p385
sg24
Nsg25
Nsg26
S'ALISKIREN'
p386
sg28
Nsg29
S'Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.| \r'
p387
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p388
sa(dp389
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p390
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p391
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p392
sg24
Nsg25
Nsg26
S'Allegra'
p393
sg28
Nsg29
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p394
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p395
sa(dp396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p397
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p399
sg24
Nsg25
Nsg26
S'Allegra'
p400
sg28
Nsg29
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p401
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p402
sa(dp403
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p404
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p405
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p406
sg24
Nsg25
Nsg26
S'Allegra'
p407
sg28
Nsg29
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p408
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p409
sa(dp410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p411
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p413
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p414
sg28
Nsg29
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p415
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ADENOSINE PHOSPHATE'
p416
sa(dp417
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p418
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p419
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p420
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p421
sg28
Nsg29
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p422
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p423
sa(dp424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p425
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p427
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p428
sg28
Nsg29
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p429
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AZATHIOPRINE'
p430
sa(dp431
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p432
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p433
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p434
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p435
sg28
Nsg29
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p436
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AZATHIOPRINE'
p437
sa(dp438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p439
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p441
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p442
sg28
Nsg29
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p443
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORPROPAMIDE'
p444
sa(dp445
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p446
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p447
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p448
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p449
sg28
Nsg29
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p450
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORPROPAMIDE'
p451
sa(dp452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p453
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p455
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p456
sg28
Nsg29
S'Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.| \r'
p457
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DICUMAROL'
p458
sa(dp459
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01033'
p460
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p461
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p462
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p463
sg28
Nsg29
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p464
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MERCAPTOPURINE'
p465
sa(dp466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01033'
p467
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p469
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p470
sg28
Nsg29
S'In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| \r'
p471
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MERCAPTOPURINE'
p472
sa(dp473
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p474
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p475
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p476
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p477
sg28
Nsg29
S'Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| \r'
p478
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p479
sa(dp480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p481
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p483
sg24
Nsg25
Nsg26
S'ALMOTRIPTAN'
p484
sg28
Nsg29
S'Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| \r'
p485
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p486
sa(dp487
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p488
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p489
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p490
sg24
Nsg25
Nsg26
S'ALMOTRIPTAN'
p491
sg28
Nsg29
S'Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| \r'
p492
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p493
sa(dp494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p495
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p497
sg24
Nsg25
Nsg26
S'ALOSETRON'
p498
sg28
Nsg29
S'Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.| \r'
p499
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p500
sa(dp501
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p502
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p503
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p504
sg24
Nsg25
Nsg26
S'ALOSETRON'
p505
sg28
Nsg29
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p506
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p507
sa(dp508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p509
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p511
sg24
Nsg25
Nsg26
S'ALOSETRON'
p512
sg28
Nsg29
S'Concomitant administration of alosetron and fluvoxamine is contraindicated.| \r'
p513
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p514
sa(dp515
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p516
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p517
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p518
sg24
Nsg25
Nsg26
S'ALOSETRON'
p519
sg28
Nsg29
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p520
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDRALAZINE'
p521
sa(dp522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p523
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p525
sg24
Nsg25
Nsg26
S'ALOSETRON'
p526
sg28
Nsg29
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p527
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p528
sa(dp529
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p530
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p531
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p532
sg24
Nsg25
Nsg26
S'ALOSETRON'
p533
sg28
Nsg29
S'Caution should be used when alosetron and ketoconazole are administered concomitantly.| \r'
p534
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p535
sa(dp536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p537
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p539
sg24
Nsg25
Nsg26
S'ALOSETRON'
p540
sg28
Nsg29
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p541
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p542
sa(dp543
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p544
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p545
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p546
sg24
Nsg25
Nsg26
S'ALOSETRON'
p547
sg28
Nsg29
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p548
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TELITHROMYCIN'
p549
sa(dp550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p551
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p553
sg24
Nsg25
Nsg26
S'ALOSETRON'
p554
sg28
Nsg29
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p555
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VORICONAZOLE'
p556
sa(dp557
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p558
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p559
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p560
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p561
sg28
Nsg29
S'The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.| \r'
p562
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p563
sa(dp564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p565
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p567
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p568
sg28
Nsg29
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p569
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p570
sa(dp571
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p572
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p573
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p574
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p575
sg28
Nsg29
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p576
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p577
sa(dp578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p579
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p581
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p582
sg28
Nsg29
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p583
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p584
sa(dp585
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p586
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p587
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p588
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p589
sg28
Nsg29
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p590
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p591
sa(dp592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p593
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p595
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p596
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p597
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p598
sa(dp599
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p600
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p601
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p602
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p603
sg28
Nsg29
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p604
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p605
sa(dp606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p607
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p609
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p610
sg28
Nsg29
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p611
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERGOTAMINE'
p612
sa(dp613
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p614
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p615
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p616
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p617
sg28
Nsg29
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p618
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p619
sa(dp620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p621
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p623
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p624
sg28
Nsg29
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p625
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p626
sa(dp627
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p628
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p629
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p630
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p631
sg28
Nsg29
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p632
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p633
sa(dp634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p635
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p637
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p638
sg28
Nsg29
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p639
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p640
sa(dp641
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p642
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p643
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p644
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p645
sg28
Nsg29
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p646
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p647
sa(dp648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p649
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p651
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p652
sg28
Nsg29
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p653
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIFEDIPINE'
p654
sa(dp655
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p656
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p657
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p658
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p659
sg28
Nsg29
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p660
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p661
sa(dp662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p663
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p665
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p666
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p667
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p668
sa(dp669
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p670
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p671
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p672
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p673
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p674
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p675
sa(dp676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p677
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p679
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p680
sg28
Nsg29
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p681
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p682
sa(dp683
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p684
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p685
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p686
sg24
Nsg25
Nsg26
S'ALUMINUM HYDROXIDE'
p687
sg28
Nsg29
S'Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| \r'
p688
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p689
sa(dp690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00492'
p691
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p693
sg24
Nsg25
Nsg26
S'ALUMINUM HYDROXIDE'
p694
sg28
Nsg29
S'Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.| \r'
p695
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FOSINOPRIL'
p696
sa(dp697
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p698
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p699
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p700
sg24
Nsg25
Nsg26
S'ALUMINUM'
p701
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p702
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p703
sa(dp704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p705
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p707
sg24
Nsg25
Nsg26
S'ALUMINUM'
p708
sg28
Nsg29
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p709
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IBANDRONIC ACID'
p710
sa(dp711
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p712
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p713
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p714
sg24
Nsg25
Nsg26
S'ALUMINUM'
p715
sg28
Nsg29
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p716
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Skelid'
p717
sa(dp718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p719
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p721
sg24
Nsg25
Nsg26
S'ALUMINUM'
p722
sg28
Nsg29
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p723
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p724
sa(dp725
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p726
sg5
S'http://bio2rdf.org/drugbank:DB00594'
p727
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p728
sg24
Nsg25
Nsg26
S'AMILORIDE'
p729
sg28
Nsg29
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p730
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p731
sa(dp732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p733
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p735
sg24
Nsg25
Nsg26
S'AMINOSALICYLIC ACID'
p736
sg28
Nsg29
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p737
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p738
sa(dp739
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p740
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p741
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p742
sg24
Nsg25
Nsg26
S'AMINOSALICYLIC ACID'
p743
sg28
Nsg29
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p744
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lanoxin'
p745
sa(dp746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p747
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p749
sg24
Nsg25
Nsg26
S'AMINOSALICYLIC ACID'
p750
sg28
Nsg29
S'Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.| \r'
p751
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p752
sa(dp753
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p754
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p755
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p756
sg24
Nsg25
Nsg26
S'AMIODARONE'
p757
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). | Amiodarone is known to raise serum digoxin levels. | \r'
p758
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p759
sa(dp760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p761
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p763
sg24
Nsg25
Nsg26
S'AMIODARONE'
p764
sg28
Nsg29
S'A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.| \r'
p765
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p766
sa(dp767
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p768
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p769
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p770
sg24
Nsg25
Nsg26
S'AMIODARONE'
p771
sg28
Nsg29
S'A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.| \r'
p772
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p773
sa(dp774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p775
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p777
sg24
Nsg25
Nsg26
S'AMIODARONE'
p778
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p779
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p780
sa(dp781
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p782
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p783
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p784
sg24
Nsg25
Nsg26
S'AMIODARONE'
p785
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p786
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p787
sa(dp788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p789
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p791
sg24
Nsg25
Nsg26
S'AMIODARONE'
p792
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p793
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p794
sa(dp795
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p796
sg5
S'http://bio2rdf.org/drugbank:DB00321'
p797
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p798
sg24
Nsg25
Nsg26
S'AMITRIPTYLINE'
p799
sg28
Nsg29
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p800
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONIDINE'
p801
sa(dp802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p803
sg5
S'http://bio2rdf.org/drugbank:DB01060'
p804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p805
sg24
Nsg25
Nsg26
S'AMOXICILLIN ANHYDROUS'
p806
sg28
Nsg29
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p807
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p808
sa(dp809
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p810
sg5
S'http://bio2rdf.org/drugbank:DB01060'
p811
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p812
sg24
Nsg25
Nsg26
S'AMOXICILLIN'
p813
sg28
Nsg29
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p814
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p815
sa(dp816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p817
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p819
sg24
Nsg25
Nsg26
S'AMPHOTERICIN B'
p820
sg28
Nsg29
S'Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.| \r'
p821
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCYTOSINE'
p822
sa(dp823
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00741'
p824
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p825
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p826
sg24
Nsg25
Nsg26
S'AMPHOTERICIN B'
p827
sg28
Nsg29
S'In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| \r'
p828
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCORTISONE'
p829
sa(dp830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p831
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p833
sg24
Nsg25
Nsg26
S'AMPHOTERICIN B'
p834
sg28
Nsg29
S'Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).| \r'
p835
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TUBOCURARINE'
p836
sa(dp837
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p838
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p839
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p840
sg24
Nsg25
Nsg26
S'Amphotericin'
p841
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p842
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p843
sa(dp844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p845
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p847
sg24
Nsg25
Nsg26
S'Amphotericin'
p848
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p849
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p850
sa(dp851
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p852
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p853
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p854
sg24
Nsg25
Nsg26
S'AMPICILLIN'
p855
sg28
Nsg29
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| \r'
p856
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p857
sa(dp858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p859
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p861
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p862
sg28
Nsg29
S'Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | \r'
p863
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p864
sa(dp865
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p866
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p867
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p868
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p869
sg28
Nsg29
S'Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | \r'
p870
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p871
sa(dp872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p873
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p875
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p876
sg28
Nsg29
S'Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| \r'
p877
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p878
sa(dp879
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p880
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p881
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p882
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p883
sg28
Nsg29
S'Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| \r'
p884
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p885
sa(dp886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p887
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p889
sg24
Nsg25
Nsg26
S'Anafranil'
p890
sg28
Nsg29
S'Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| \r'
p891
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p892
sa(dp893
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p894
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p895
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p896
sg24
Nsg25
Nsg26
S'ANAGRELIDE'
p897
sg28
Nsg29
S'Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| \r'
p898
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p899
sa(dp900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p901
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p903
sg24
Nsg25
Nsg26
S'ANAGRELIDE'
p904
sg28
Nsg29
S'Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.| \r'
p905
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p906
sa(dp907
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p908
sg5
S'http://bio2rdf.org/drugbank:DB01217'
p909
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p910
sg24
Nsg25
Nsg26
S'ANASTROZOLE'
p911
sg28
Nsg29
S'Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| \r'
p912
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TAMOXIFEN'
p913
sa(dp914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p915
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p917
sg24
Nsg25
Nsg26
S'Antizol'
p918
sg28
Nsg29
S'Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.| \r'
p919
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p920
sa(dp921
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p922
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p923
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p924
sg24
Nsg25
Nsg26
S'Antizol'
p925
sg28
Nsg29
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p926
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p927
sa(dp928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p929
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p931
sg24
Nsg25
Nsg26
S'Antizol'
p932
sg28
Nsg29
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p933
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p934
sa(dp935
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p936
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p937
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p938
sg24
Nsg25
Nsg26
S'Antizol'
p939
sg28
Nsg29
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p940
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p941
sa(dp942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p943
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p945
sg24
Nsg25
Nsg26
S'Antizol'
p946
sg28
Nsg29
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p947
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p948
sa(dp949
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p950
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p951
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p952
sg24
Nsg25
Nsg26
S'APOMORPHINE'
p953
sg28
Nsg29
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p954
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALOSETRON'
p955
sa(dp956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00757'
p957
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p959
sg24
Nsg25
Nsg26
S'APOMORPHINE'
p960
sg28
Nsg29
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p961
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOLASETRON'
p962
sa(dp963
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00889'
p964
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p965
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p966
sg24
Nsg25
Nsg26
S'APOMORPHINE'
p967
sg28
Nsg29
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p968
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GRANISETRON'
p969
sa(dp970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00377'
p971
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p973
sg24
Nsg25
Nsg26
S'APOMORPHINE'
p974
sg28
Nsg29
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p975
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PALONOSETRON'
p976
sa(dp977
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p978
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p979
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p980
sg24
Nsg25
Nsg26
S'APREPITANT'
p981
sg28
Nsg29
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p982
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p983
sa(dp984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p985
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p987
sg24
Nsg25
Nsg26
S'APREPITANT'
p988
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p989
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p990
sa(dp991
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p992
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p993
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p994
sg24
Nsg25
Nsg26
S'APREPITANT'
p995
sg28
Nsg29
S'Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| \r'
p996
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p997
sa(dp998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p999
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1001
sg24
Nsg25
Nsg26
S'APREPITANT'
p1002
sg28
Nsg29
S'Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.| \r'
p1003
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p1004
sa(dp1005
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p1006
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1007
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1008
sg24
Nsg25
Nsg26
S'APREPITANT'
p1009
sg28
Nsg29
S'Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| \r'
p1010
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p1011
sa(dp1012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1013
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1015
sg24
Nsg25
Nsg26
S'APREPITANT'
p1016
sg28
Nsg29
S'Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1017
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1018
sa(dp1019
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1020
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1021
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1022
sg24
Nsg25
Nsg26
S'APREPITANT'
p1023
sg28
Nsg29
S'Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1024
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1025
sa(dp1026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p1027
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1029
sg24
Nsg25
Nsg26
S'APREPITANT'
p1030
sg28
Nsg29
S'Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| \r'
p1031
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p1032
sa(dp1033
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p1034
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1035
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1036
sg24
Nsg25
Nsg26
S'APREPITANT'
p1037
sg28
Nsg29
S'Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| \r'
p1038
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p1039
sa(dp1040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p1041
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1043
sg24
Nsg25
Nsg26
S'APREPITANT'
p1044
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1045
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p1046
sa(dp1047
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p1048
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1049
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1050
sg24
Nsg25
Nsg26
S'APREPITANT'
p1051
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1052
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p1053
sa(dp1054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p1055
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1057
sg24
Nsg25
Nsg26
S'APREPITANT'
p1058
sg28
Nsg29
S'Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| \r'
p1059
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORETHINDRONE'
p1060
sa(dp1061
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p1062
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1063
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1064
sg24
Nsg25
Nsg26
S'APREPITANT'
p1065
sg28
Nsg29
S'Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.| \r'
p1066
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p1067
sa(dp1068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1069
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1071
sg24
Nsg25
Nsg26
S'APREPITANT'
p1072
sg28
Nsg29
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.| \r'
p1073
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p1074
sa(dp1075
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1076
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1077
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1078
sg24
Nsg25
Nsg26
S'APREPITANT'
p1079
sg28
Nsg29
S'Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p1080
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p1081
sa(dp1082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1083
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1085
sg24
Nsg25
Nsg26
S'APREPITANT'
p1086
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1087
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p1088
sa(dp1089
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1090
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1091
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1092
sg24
Nsg25
Nsg26
S'APREPITANT'
p1093
sg28
Nsg29
S'Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.| \r'
p1094
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p1095
sa(dp1096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p1097
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p1098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1099
sg24
Nsg25
Nsg26
S'APREPITANT'
p1100
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p1101
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p1102
sa(dp1103
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p1104
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p1105
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1106
sg24
Nsg25
Nsg26
S'Arava'
p1107
sg28
Nsg29
S'In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.| \r'
p1108
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p1109
sa(dp1110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1111
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p1112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1113
sg24
Nsg25
Nsg26
S'Arava'
p1114
sg28
Nsg29
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p1115
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p1116
sa(dp1117
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1118
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p1119
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1120
sg24
Nsg25
Nsg26
S'Arava'
p1121
sg28
Nsg29
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p1122
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p1123
sa(dp1124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p1125
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p1126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1127
sg24
Nsg25
Nsg26
S'ARIPIPRAZOLE'
p1128
sg28
Nsg29
S'Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.| \r'
p1129
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p1130
sa(dp1131
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p1132
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1133
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1134
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1135
sg28
Nsg29
S'However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| \r'
p1136
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celebrex'
p1137
sa(dp1138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p1139
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1141
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1142
sg28
Nsg29
S'ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. | \r'
p1143
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Disalcid'
p1144
sa(dp1145
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p1146
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1147
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1148
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1149
sg28
Nsg29
S'The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| \r'
p1150
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fenoprofen'
p1151
sa(dp1152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00712'
p1153
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1155
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1156
sg28
Nsg29
S'Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.| \r'
p1157
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Flurbiprofen'
p1158
sa(dp1159
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p1160
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1161
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1162
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1163
sg28
Nsg29
S'However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.| \r'
p1164
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IBANDRONIC ACID'
p1165
sa(dp1166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p1167
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1169
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1170
sg28
Nsg29
S'In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.| \r'
p1171
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p1172
sa(dp1173
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p1174
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1175
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1176
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1177
sg28
Nsg29
S'Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. | \r'
p1178
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MELOXICAM'
p1179
sa(dp1180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00703'
p1181
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1183
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1184
sg28
Nsg29
S'Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.| \r'
p1185
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHAZOLAMIDE'
p1186
sa(dp1187
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p1188
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1189
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1190
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1191
sg28
Nsg29
S'Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. | \r'
p1192
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mobic'
p1193
sa(dp1194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p1195
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1197
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1198
sg28
Nsg29
S'Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| \r'
p1199
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nalfon'
p1200
sa(dp1201
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00627'
p1202
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1203
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1204
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1205
sg28
Nsg29
S'Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| \r'
p1206
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nicotinic Acid'
p1207
sa(dp1208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00585'
p1209
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1211
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1212
sg28
Nsg29
S'In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| \r'
p1213
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIZATIDINE'
p1214
sa(dp1215
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p1216
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1217
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1218
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1219
sg28
Nsg29
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p1220
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p1221
sa(dp1222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p1223
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1225
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1226
sg28
Nsg29
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p1227
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p1228
sa(dp1229
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00015'
p1230
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1231
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1232
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1233
sg28
Nsg29
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| \r'
p1234
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Retavase'
p1235
sa(dp1236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p1237
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1239
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1240
sg28
Nsg29
S'Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. | \r'
p1241
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Skelid'
p1242
sa(dp1243
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1244
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1245
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1246
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1247
sg28
Nsg29
S'Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| \r'
p1248
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p1249
sa(dp1250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p1251
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1253
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1254
sg28
Nsg29
S'Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| \r'
p1255
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vioxx'
p1256
sa(dp1257
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00009'
p1258
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1259
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1260
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1261
sg28
Nsg29
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.| \r'
p1262
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Activase'
p1263
sa(dp1264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00031'
p1265
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p1266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1267
sg24
Nsg25
Nsg26
S'ASPIRIN'
p1268
sg28
Nsg29
S'Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. | \r'
p1269
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TNKase'
p1270
sa(dp1271
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1272
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p1273
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1274
sg24
Nsg25
Nsg26
S'ASTEMIZOLE'
p1275
sg28
Nsg29
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p1276
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1277
sa(dp1278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1279
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p1280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1281
sg24
Nsg25
Nsg26
S'ASTEMIZOLE'
p1282
sg28
Nsg29
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p1283
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1284
sa(dp1285
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1286
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p1287
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1288
sg24
Nsg25
Nsg26
S'ASTEMIZOLE'
p1289
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1290
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p1291
sa(dp1292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p1293
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1295
sg24
Nsg25
Nsg26
S'ATORVASTATIN'
p1296
sg28
Nsg29
S'Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.| \r'
p1297
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALISKIREN'
p1298
sa(dp1299
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p1300
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1301
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1302
sg24
Nsg25
Nsg26
S'ATORVASTATIN'
p1303
sg28
Nsg29
S'Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.| \r'
p1304
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Crixivan'
p1305
sa(dp1306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1307
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1309
sg24
Nsg25
Nsg26
S'ATORVASTATIN'
p1310
sg28
Nsg29
S'Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.| \r'
p1311
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1312
sa(dp1313
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p1314
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1315
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1316
sg24
Nsg25
Nsg26
S'ATORVASTATIN'
p1317
sg28
Nsg29
S'Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.| \r'
p1318
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p1319
sa(dp1320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p1321
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1323
sg24
Nsg25
Nsg26
S'ATORVASTATIN'
p1324
sg28
Nsg29
S'Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.| Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.| \r'
p1325
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p1326
sa(dp1327
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p1328
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p1329
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1330
sg24
Nsg25
Nsg26
S'ATORVASTATIN'
p1331
sg28
Nsg29
S'Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.| Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.| \r'
p1332
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORETHINDRONE'
p1333
sa(dp1334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1335
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p1336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1337
sg24
Nsg25
Nsg26
S'Atromid-S'
p1338
sg28
Nsg29
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p1339
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p1340
sa(dp1341
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1342
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p1343
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1344
sg24
Nsg25
Nsg26
S'Atromid-S'
p1345
sg28
Nsg29
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p1346
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p1347
sa(dp1348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p1349
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p1350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1351
sg24
Nsg25
Nsg26
S'Atropine'
p1352
sg28
Nsg29
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p1353
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRALIDOXIME'
p1354
sa(dp1355
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p1356
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p1357
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1358
sg24
Nsg25
Nsg26
S'Atropine'
p1359
sg28
Nsg29
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p1360
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRALIDOXIME'
p1361
sa(dp1362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00427'
p1363
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p1364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1365
sg24
Nsg25
Nsg26
S'Atropine'
p1366
sg28
Nsg29
S'The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. | \r'
p1367
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIPROLIDINE'
p1368
sa(dp1369
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p1370
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p1371
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1372
sg24
Nsg25
Nsg26
S'AURANOFIN'
p1373
sg28
Nsg29
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p1374
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cuprimine'
p1375
sa(dp1376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p1377
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p1378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1379
sg24
Nsg25
Nsg26
S'AURANOFIN'
p1380
sg28
Nsg29
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p1381
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Depen'
p1382
sa(dp1383
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p1384
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p1385
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1386
sg24
Nsg25
Nsg26
S'AURANOFIN'
p1387
sg28
Nsg29
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p1388
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENICILLAMINE'
p1389
sa(dp1390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00108'
p1391
sg5
S'http://bio2rdf.org/drugbank:DB00060'
p1392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1393
sg24
Nsg25
Nsg26
S'Avonex'
p1394
sg28
Nsg29
S'After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.| \r'
p1395
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tysabri'
p1396
sa(dp1397
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1398
sg5
S'http://bio2rdf.org/drugbank:DB00993'
p1399
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1400
sg24
Nsg25
Nsg26
S'AZATHIOPRINE'
p1401
sg28
Nsg29
S'Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| \r'
p1402
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p1403
sa(dp1404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1405
sg5
S'http://bio2rdf.org/drugbank:DB00993'
p1406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1407
sg24
Nsg25
Nsg26
S'AZATHIOPRINE'
p1408
sg28
Nsg29
S'Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| \r'
p1409
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p1410
sa(dp1411
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p1412
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1413
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1414
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p1415
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1416
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIKACIN'
p1417
sa(dp1418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p1419
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1421
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p1422
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1423
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p1424
sa(dp1425
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00955'
p1426
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1427
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1428
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p1429
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1430
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NETILMICIN'
p1431
sa(dp1432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p1433
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p1434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1435
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p1436
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p1437
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOBRAMYCIN'
p1438
sa(dp1439
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p1440
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1441
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1442
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1443
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1444
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p1445
sa(dp1446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01086'
p1447
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1449
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1450
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1451
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BENZOCAINE'
p1452
sa(dp1453
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p1454
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1455
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1456
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1457
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1458
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORAMPHENICOL'
p1459
sa(dp1460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p1461
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1463
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1464
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1465
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Chloromycetin'
p1466
sa(dp1467
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05291'
p1468
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1469
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1470
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1471
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1472
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LIDOCAINE'
p1473
sa(dp1474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p1475
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1477
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1478
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1479
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p1480
sa(dp1481
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p1482
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1483
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1484
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1485
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1486
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pronestyl'
p1487
sa(dp1488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p1489
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p1490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1491
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p1492
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p1493
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tylenol'
p1494
sa(dp1495
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1496
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1497
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1498
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p1499
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1500
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p1501
sa(dp1502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p1503
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1505
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p1506
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1507
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aleve'
p1508
sa(dp1509
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1510
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1511
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1512
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p1513
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1514
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p1515
sa(dp1516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1517
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1519
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p1520
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1521
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p1522
sa(dp1523
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p1524
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p1525
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1526
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p1527
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p1528
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NOREPINEPHRINE'
p1529
sa(dp1530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p1531
sg5
S'http://bio2rdf.org/drugbank:DB01210'
p1532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1533
sg24
Nsg25
Nsg26
S'Betagan'
p1534
sg28
Nsg29
S'Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.| \r'
p1535
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPINEPHRINE'
p1536
sa(dp1537
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01435'
p1538
sg5
S'http://bio2rdf.org/drugbank:DB00068'
p1539
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1540
sg24
Nsg25
Nsg26
S'Betaseron'
p1541
sg28
Nsg29
S'Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| \r'
p1542
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANTIPYRINE'
p1543
sa(dp1544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1545
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1547
sg24
Nsg25
Nsg26
S'Bextra'
p1548
sg28
Nsg29
S'Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| \r'
p1549
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p1550
sa(dp1551
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p1552
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1553
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1554
sg24
Nsg25
Nsg26
S'Bextra'
p1555
sg28
Nsg29
S'Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| \r'
p1556
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p1557
sa(dp1558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p1559
sg5
S'http://bio2rdf.org/drugbank:DB01294'
p1560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1561
sg24
Nsg25
Nsg26
S'BISMUTH SUBSALICYLATE'
p1562
sg28
Nsg29
S'Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| \r'
p1563
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p1564
sa(dp1565
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p1566
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1567
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1568
sg24
Nsg25
Nsg26
S'BOSENTAN ANHYDROUS'
p1569
sg28
Nsg29
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1570
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATORVASTATIN'
p1571
sa(dp1572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p1573
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1575
sg24
Nsg25
Nsg26
S'BOSENTAN ANHYDROUS'
p1576
sg28
Nsg29
S'Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| \r'
p1577
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p1578
sa(dp1579
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1580
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1581
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1582
sg24
Nsg25
Nsg26
S'BOSENTAN ANHYDROUS'
p1583
sg28
Nsg29
S'Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.| \r'
p1584
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1585
sa(dp1586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1587
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1589
sg24
Nsg25
Nsg26
S'BOSENTAN ANHYDROUS'
p1590
sg28
Nsg29
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1591
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOVASTATIN'
p1592
sa(dp1593
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p1594
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1595
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1596
sg24
Nsg25
Nsg26
S'BOSENTAN ANHYDROUS'
p1597
sg28
Nsg29
S'Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.| \r'
p1598
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SIMVASTATIN'
p1599
sa(dp1600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p1601
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1603
sg24
Nsg25
Nsg26
S'BOSENTAN'
p1604
sg28
Nsg29
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1605
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATORVASTATIN'
p1606
sa(dp1607
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p1608
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1609
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1610
sg24
Nsg25
Nsg26
S'BOSENTAN'
p1611
sg28
Nsg29
S'Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| \r'
p1612
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p1613
sa(dp1614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1615
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1617
sg24
Nsg25
Nsg26
S'BOSENTAN'
p1618
sg28
Nsg29
S'Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.| \r'
p1619
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1620
sa(dp1621
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p1622
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1623
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1624
sg24
Nsg25
Nsg26
S'BOSENTAN'
p1625
sg28
Nsg29
S'Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| \r'
p1626
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOVASTATIN'
p1627
sa(dp1628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p1629
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p1630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1631
sg24
Nsg25
Nsg26
S'BOSENTAN'
p1632
sg28
Nsg29
S'Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.| \r'
p1633
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SIMVASTATIN'
p1634
sa(dp1635
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1636
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1637
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1638
sg24
Nsg25
Nsg26
S'Brevibloc'
p1639
sg28
Nsg29
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p1640
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1641
sa(dp1642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p1643
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1645
sg24
Nsg25
Nsg26
S'Brevibloc'
p1646
sg28
Nsg29
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p1647
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOPAMINE'
p1648
sa(dp1649
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p1650
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1651
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1652
sg24
Nsg25
Nsg26
S'Brevibloc'
p1653
sg28
Nsg29
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p1654
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPINEPHRINE'
p1655
sa(dp1656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p1657
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1659
sg24
Nsg25
Nsg26
S'Brevibloc'
p1660
sg28
Nsg29
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| \r'
p1661
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p1662
sa(dp1663
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p1664
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1665
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1666
sg24
Nsg25
Nsg26
S'Brevibloc'
p1667
sg28
Nsg29
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| \r'
p1668
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p1669
sa(dp1670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p1671
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1673
sg24
Nsg25
Nsg26
S'Brevibloc'
p1674
sg28
Nsg29
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p1675
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NOREPINEPHRINE'
p1676
sa(dp1677
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p1678
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1679
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1680
sg24
Nsg25
Nsg26
S'Brevibloc'
p1681
sg28
Nsg29
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p1682
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p1683
sa(dp1684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1685
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p1686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1687
sg24
Nsg25
Nsg26
S'Brevibloc'
p1688
sg28
Nsg29
S'Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| \r'
p1689
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p1690
sa(dp1691
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1692
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p1693
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1694
sg24
Nsg25
Nsg26
S'BUPRENORPHINE'
p1695
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1696
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p1697
sa(dp1698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1699
sg5
S'http://bio2rdf.org/drugbank:DB00490'
p1700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1701
sg24
Nsg25
Nsg26
S'BUSPIRONE'
p1702
sg28
Nsg29
S'In vitro, buspirone may displace less firmly bound drugs like digoxin.| \r'
p1703
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1704
sa(dp1705
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1706
sg5
S'http://bio2rdf.org/drugbank:DB01008'
p1707
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1708
sg24
Nsg25
Nsg26
S'Busulfex'
p1709
sg28
Nsg29
S'Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.| \r'
p1710
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p1711
sa(dp1712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1713
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p1714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1715
sg24
Nsg25
Nsg26
S'BUTALBITAL'
p1716
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1717
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p1718
sa(dp1719
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p1720
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p1721
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1722
sg24
Nsg25
Nsg26
S'BUTALBITAL'
p1723
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1724
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p1725
sa(dp1726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1727
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p1728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1729
sg24
Nsg25
Nsg26
S'BUTORPHANOL'
p1730
sg28
Nsg29
S'Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| \r'
p1731
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p1732
sa(dp1733
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p1734
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p1735
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1736
sg24
Nsg25
Nsg26
S'BUTORPHANOL'
p1737
sg28
Nsg29
S'It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.| \r'
p1738
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p1739
sa(dp1740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1741
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p1742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1743
sg24
Nsg25
Nsg26
S'BUTORPHANOL'
p1744
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1745
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p1746
sa(dp1747
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1748
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1749
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1750
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1751
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1752
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p1753
sa(dp1754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p1755
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1757
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1758
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p1759
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p1760
sa(dp1761
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p1762
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1763
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1764
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1765
sg28
Nsg29
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1766
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p1767
sa(dp1768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p1769
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1771
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1772
sg28
Nsg29
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p1773
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p1774
sa(dp1775
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p1776
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1777
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1778
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1779
sg28
Nsg29
S'Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| \r'
p1780
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p1781
sa(dp1782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p1783
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1785
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1786
sg28
Nsg29
S'Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| \r'
p1787
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p1788
sa(dp1789
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1790
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1791
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1792
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1793
sg28
Nsg29
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1794
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1795
sa(dp1796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01403'
p1797
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1799
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1800
sg28
Nsg29
S'Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | \r'
p1801
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVOMEPROMAZINE'
p1802
sa(dp1803
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p1804
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1805
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1806
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1807
sg28
Nsg29
S'Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .| \r'
p1808
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p1809
sa(dp1810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1811
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1813
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1814
sg28
Nsg29
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1815
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p1816
sa(dp1817
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1818
sg5
S'http://bio2rdf.org/drugbank:DB00201'
p1819
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1820
sg24
Nsg25
Nsg26
S'CAFFEINE'
p1821
sg28
Nsg29
S'Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| \r'
p1822
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p1823
sa(dp1824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00630'
p1825
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1827
sg24
Nsg25
Nsg26
S'CALCIUM'
p1828
sg28
Nsg29
S'Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.| \r'
p1829
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALENDRONIC ACID'
p1830
sa(dp1831
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01196'
p1832
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1833
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1834
sg24
Nsg25
Nsg26
S'CALCIUM'
p1835
sg28
Nsg29
S'Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.| \r'
p1836
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Emcyt'
p1837
sa(dp1838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p1839
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1841
sg24
Nsg25
Nsg26
S'CALCIUM'
p1842
sg28
Nsg29
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p1843
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IBANDRONIC ACID'
p1844
sa(dp1845
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p1846
sg5
S'http://bio2rdf.org/drugbank:DB01373'
p1847
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1848
sg24
Nsg25
Nsg26
S'CALCIUM'
p1849
sg28
Nsg29
S'However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. | \r'
p1850
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRON'
p1851
sa(dp1852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1853
sg5
S'http://bio2rdf.org/drugbank:DB00762'
p1854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1855
sg24
Nsg25
Nsg26
S'Camptosar'
p1856
sg28
Nsg29
S'Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.| \r'
p1857
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p1858
sa(dp1859
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p1860
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1861
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1862
sg24
Nsg25
Nsg26
S'Cancidas'
p1863
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1864
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p1865
sa(dp1866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p1867
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1869
sg24
Nsg25
Nsg26
S'Cancidas'
p1870
sg28
Nsg29
S'There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.| \r'
p1871
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p1872
sa(dp1873
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1874
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1875
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1876
sg24
Nsg25
Nsg26
S'Cancidas'
p1877
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1878
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p1879
sa(dp1880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p1881
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1883
sg24
Nsg25
Nsg26
S'Cancidas'
p1884
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1885
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p1886
sa(dp1887
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p1888
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1889
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1890
sg24
Nsg25
Nsg26
S'Cancidas'
p1891
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1892
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEVIRAPINE'
p1893
sa(dp1894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p1895
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1897
sg24
Nsg25
Nsg26
S'Cancidas'
p1898
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1899
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p1900
sa(dp1901
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p1902
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1903
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1904
sg24
Nsg25
Nsg26
S'Cancidas'
p1905
sg28
Nsg29
S'CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.| \r'
p1906
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS ANHYDROUS'
p1907
sa(dp1908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p1909
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1911
sg24
Nsg25
Nsg26
S'Cancidas'
p1912
sg28
Nsg29
S'CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.| \r'
p1913
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS'
p1914
sa(dp1915
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p1916
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p1917
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1918
sg24
Nsg25
Nsg26
S'CARBACHOL'
p1919
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p1920
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p1921
sa(dp1922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p1923
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1925
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1926
sg28
Nsg29
S'Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.| Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| \r'
p1927
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p1928
sa(dp1929
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p1930
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1931
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1932
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1933
sg28
Nsg29
S'Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.| Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| \r'
p1934
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p1935
sa(dp1936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p1937
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1939
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1940
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p1941
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p1942
sa(dp1943
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p1944
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1945
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1946
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1947
sg28
Nsg29
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p1948
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONAZEPAM'
p1949
sa(dp1950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p1951
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1953
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1954
sg28
Nsg29
S'Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| \r'
p1955
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p1956
sa(dp1957
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p1958
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1959
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1960
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1961
sg28
Nsg29
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| \r'
p1962
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXYCYCLINE'
p1963
sa(dp1964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p1965
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1967
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1968
sg28
Nsg29
S'Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| \r'
p1969
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM OXALATE'
p1970
sa(dp1971
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p1972
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1973
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1974
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1975
sg28
Nsg29
S'Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| \r'
p1976
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM'
p1977
sa(dp1978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p1979
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1981
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1982
sg28
Nsg29
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p1983
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p1984
sa(dp1985
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p1986
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1987
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1988
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1989
sg28
Nsg29
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p1990
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EXEMESTANE'
p1991
sa(dp1992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p1993
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p1994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1995
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p1996
sg28
Nsg29
S'The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.| \r'
p1997
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FELBAMATE'
p1998
sa(dp1999
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p2000
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2001
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2002
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2003
sg28
Nsg29
S'Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| \r'
p2004
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Felbatol'
p2005
sa(dp2006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p2007
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2009
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2010
sg28
Nsg29
S'Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| \r'
p2011
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p2012
sa(dp2013
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2014
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2015
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2016
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2017
sg28
Nsg29
S'Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.| \r'
p2018
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB DITOSYLATE'
p2019
sa(dp2020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2021
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2023
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2024
sg28
Nsg29
S'Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.| \r'
p2025
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB'
p2026
sa(dp2027
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2028
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2029
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2030
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2031
sg28
Nsg29
S'Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| \r'
p2032
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p2033
sa(dp2034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2035
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2037
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2038
sg28
Nsg29
S'Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| \r'
p2039
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p2040
sa(dp2041
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p2042
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2043
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2044
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2045
sg28
Nsg29
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p2046
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p2047
sa(dp2048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p2049
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2051
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2052
sg28
Nsg29
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p2053
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p2054
sa(dp2055
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p2056
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2057
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2058
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2059
sg28
Nsg29
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. | \r'
p2060
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mivacron'
p2061
sa(dp2062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2063
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2065
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2066
sg28
Nsg29
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.| \r'
p2067
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p2068
sa(dp2069
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2070
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2071
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2072
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2073
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p2074
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p2075
sa(dp2076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2077
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2079
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2080
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p2081
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p2082
sa(dp2083
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00671'
p2084
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p2085
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2086
sg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p2087
sg28
Nsg29
S'Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.| \r'
p2088
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprax'
p2089
sa(dp2090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p2091
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p2092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2093
sg24
Nsg25
Nsg26
S'Carboptic'
p2094
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p2095
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p2096
sa(dp2097
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p2098
sg5
S'http://bio2rdf.org/drugbank:DB00535'
p2099
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2100
sg24
Nsg25
Nsg26
S'CEFDINIR'
p2101
sg28
Nsg29
S'The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.| Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.| \r'
p2102
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRON'
p2103
sa(dp2104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2105
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2107
sg24
Nsg25
Nsg26
S'Celebrex'
p2108
sg28
Nsg29
S'Aspirin: CELEBREX can be used with low dose aspirin.| \r'
p2109
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p2110
sa(dp2111
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2112
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2113
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2114
sg24
Nsg25
Nsg26
S'Celebrex'
p2115
sg28
Nsg29
S'CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| \r'
p2116
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p2117
sa(dp2118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p2119
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2121
sg24
Nsg25
Nsg26
S'CELECOXIB'
p2122
sg28
Nsg29
S'We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. | \r'
p2123
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p2124
sa(dp2125
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2126
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2127
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2128
sg24
Nsg25
Nsg26
S'CELECOXIB'
p2129
sg28
Nsg29
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p2130
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p2131
sa(dp2132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2133
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2135
sg24
Nsg25
Nsg26
S'CELECOXIB'
p2136
sg28
Nsg29
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p2137
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p2138
sa(dp2139
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2140
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2141
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2142
sg24
Nsg25
Nsg26
S'CELECOXIB'
p2143
sg28
Nsg29
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| \r'
p2144
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p2145
sa(dp2146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2147
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p2148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2149
sg24
Nsg25
Nsg26
S'CELECOXIB'
p2150
sg28
Nsg29
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| \r'
p2151
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p2152
sa(dp2153
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2154
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2155
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2156
sg24
Nsg25
Nsg26
S'CEPHALEXIN ANHYDROUS'
p2157
sg28
Nsg29
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p2158
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p2159
sa(dp2160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2161
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2163
sg24
Nsg25
Nsg26
S'CEPHALEXIN ANHYDROUS'
p2164
sg28
Nsg29
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p2165
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p2166
sa(dp2167
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2168
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2169
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2170
sg24
Nsg25
Nsg26
S'CEPHALEXIN ANHYDROUS'
p2171
sg28
Nsg29
S'Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p2172
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p2173
sa(dp2174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2175
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2177
sg24
Nsg25
Nsg26
S'CEPHALEXIN'
p2178
sg28
Nsg29
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| \r'
p2179
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p2180
sa(dp2181
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p2182
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2183
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2184
sg24
Nsg25
Nsg26
S'CEPHALEXIN'
p2185
sg28
Nsg29
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| \r'
p2186
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p2187
sa(dp2188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2189
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p2190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2191
sg24
Nsg25
Nsg26
S'CEPHALEXIN'
p2192
sg28
Nsg29
S'Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p2193
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p2194
sa(dp2195
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p2196
sg5
S'http://bio2rdf.org/drugbank:DB00053'
p2197
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2198
sg24
Nsg25
Nsg26
S'Cerezyme'
p2199
sg28
Nsg29
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p2200
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zavesca'
p2201
sa(dp2202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2203
sg5
S'http://bio2rdf.org/drugbank:DB00439'
p2204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2205
sg24
Nsg25
Nsg26
S'CERIVASTATIN'
p2206
sg28
Nsg29
S'ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.| \r'
p2207
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p2208
sa(dp2209
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p2210
sg5
S'http://bio2rdf.org/drugbank:DB00694'
p2211
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2212
sg24
Nsg25
Nsg26
S'Cerubidine'
p2213
sg28
Nsg29
S'Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.| Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.| \r'
p2214
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p2215
sa(dp2216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p2217
sg5
S'http://bio2rdf.org/drugbank:DB00694'
p2218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2219
sg24
Nsg25
Nsg26
S'Cerubidine'
p2220
sg28
Nsg29
S'Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.| Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.| \r'
p2221
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p2222
sa(dp2223
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00438'
p2224
sg5
S'http://bio2rdf.org/drugbank:DB00446'
p2225
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2226
sg24
Nsg25
Nsg26
S'CHLORAMPHENICOL'
p2227
sg28
Nsg29
S'Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.| \r'
p2228
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFTAZIDIME'
p2229
sa(dp2230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2231
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2233
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2234
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2235
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p2236
sa(dp2237
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p2238
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2239
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2240
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2241
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2242
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BROMOCRIPTINE'
p2243
sa(dp2244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p2245
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2247
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2248
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2249
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCIUM'
p2250
sa(dp2251
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2252
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2253
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2254
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2255
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2256
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p2257
sa(dp2258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01219'
p2259
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2261
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2262
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2263
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DANTROLENE'
p2264
sa(dp2265
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00184'
p2266
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2267
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2268
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2269
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2270
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NICOTINE'
p2271
sa(dp2272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00052'
p2273
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2275
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2276
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2277
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Somatropin'
p2278
sa(dp2279
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p2280
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p2281
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2282
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p2283
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p2284
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TAMOXIFEN'
p2285
sa(dp2286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p2287
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p2288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2289
sg24
Nsg25
Nsg26
S'CHLORPROMAZINE'
p2290
sg28
Nsg29
S'The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| \r'
p2291
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMITRIPTYLINE'
p2292
sa(dp2293
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p2294
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p2295
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2296
sg24
Nsg25
Nsg26
S'CHLORPROPAMIDE'
p2297
sg28
Nsg29
S'Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p2298
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p2299
sa(dp2300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p2301
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p2302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2303
sg24
Nsg25
Nsg26
S'CHLORPROPAMIDE'
p2304
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p2305
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p2306
sa(dp2307
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2308
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p2309
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2310
sg24
Nsg25
Nsg26
S'CHLORPROTHIXENE'
p2311
sg28
Nsg29
S'Chlorprothixene may increase the plasma-level of concomitantly given lithium.| \r'
p2312
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p2313
sa(dp2314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p2315
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p2316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2317
sg24
Nsg25
Nsg26
S'CHLORPROTHIXENE'
p2318
sg28
Nsg29
S'Chlorprothixene may increase the plasma-level of concomitantly given lithium.| \r'
p2319
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p2320
sa(dp2321
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00193'
p2322
sg5
S'http://bio2rdf.org/drugbank:DB01239'
p2323
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2324
sg24
Nsg25
Nsg26
S'CHLORPROTHIXENE'
p2325
sg28
Nsg29
S'Avoid the concomitant use of chlorprothixene and tramadol (Ultram).| \r'
p2326
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ultram'
p2327
sa(dp2328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2329
sg5
S'http://bio2rdf.org/drugbank:DB01410'
p2330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2331
sg24
Nsg25
Nsg26
S'CICLESONIDE'
p2332
sg28
Nsg29
S'In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.| \r'
p2333
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2334
sa(dp2335
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p2336
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p2337
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2338
sg24
Nsg25
Nsg26
S'CILOSTAZOL'
p2339
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p2340
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p2341
sa(dp2342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2343
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p2344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2345
sg24
Nsg25
Nsg26
S'CILOSTAZOL'
p2346
sg28
Nsg29
S'Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..| \r'
p2347
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p2348
sa(dp2349
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p2350
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2351
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2352
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2353
sg28
Nsg29
S'Cimetidine reduces the clearance of ALFENTA.| \r'
p2354
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alfenta'
p2355
sa(dp2356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p2357
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2359
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2360
sg28
Nsg29
S'Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.| \r'
p2361
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALTRETAMINE'
p2362
sa(dp2363
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2364
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2365
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2366
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2367
sg28
Nsg29
S'The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.| \r'
p2368
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2369
sa(dp2370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p2371
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2373
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2374
sg28
Nsg29
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p2375
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p2376
sa(dp2377
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2378
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2379
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2380
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2381
sg28
Nsg29
S'A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.| The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.| \r'
p2382
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p2383
sa(dp2384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2385
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2387
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2388
sg28
Nsg29
S'Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).| \r'
p2389
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p2390
sa(dp2391
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00445'
p2392
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2393
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2394
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2395
sg28
Nsg29
S'Cimetidine treatment should be stopped during treatment with ELLENCE.| \r'
p2396
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ellence'
p2397
sa(dp2398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00445'
p2399
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2401
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2402
sg28
Nsg29
S'Cimetidine increased the AUC of epirubicin by 50%.| \r'
p2403
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPIRUBICIN'
p2404
sa(dp2405
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p2406
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2407
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2408
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2409
sg28
Nsg29
S'Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.| Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.| \r'
p2410
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GABAPENTIN'
p2411
sa(dp2412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00317'
p2413
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2415
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2416
sg28
Nsg29
S'Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.| \r'
p2417
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Iressa'
p2418
sa(dp2419
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00643'
p2420
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2421
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2422
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2423
sg28
Nsg29
S'Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.| \r'
p2424
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEBENDAZOLE'
p2425
sa(dp2426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p2427
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2429
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2430
sg28
Nsg29
S'Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; | \r'
p2431
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p2432
sa(dp2433
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p2434
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2435
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2436
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2437
sg28
Nsg29
S'Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.| \r'
p2438
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIFEDIPINE'
p2439
sa(dp2440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p2441
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2443
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2444
sg28
Nsg29
S'Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). | Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p2445
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p2446
sa(dp2447
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p2448
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2449
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2450
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2451
sg28
Nsg29
S'Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.| \r'
p2452
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ROFECOXIB'
p2453
sa(dp2454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2455
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2457
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2458
sg28
Nsg29
S'Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.| \r'
p2459
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p2460
sa(dp2461
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p2462
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2463
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2464
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2465
sg28
Nsg29
S'In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. | \r'
p2466
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIMETREXATE'
p2467
sa(dp2468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2469
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2471
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2472
sg28
Nsg29
S'Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| \r'
p2473
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Xanax'
p2474
sa(dp2475
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2476
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2477
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2478
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2479
sg28
Nsg29
S'Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| \r'
p2480
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p2481
sa(dp2482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p2483
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p2484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2485
sg24
Nsg25
Nsg26
S'CIMETIDINE'
p2486
sg28
Nsg29
S'Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.| \r'
p2487
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALEPLON'
p2488
sa(dp2489
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p2490
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p2491
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2492
sg24
Nsg25
Nsg26
S'CINACALCET'
p2493
sg28
Nsg29
S'Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| \r'
p2494
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMITRIPTYLINE'
p2495
sa(dp2496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p2497
sg5
S'http://bio2rdf.org/drugbank:DB00827'
p2498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2499
sg24
Nsg25
Nsg26
S'CINOXACIN'
p2500
sg28
Nsg29
S'Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.| \r'
p2501
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAFFEINE'
p2502
sa(dp2503
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p2504
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2505
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2506
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2507
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2508
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p2509
sa(dp2510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p2511
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2513
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2514
sg28
Nsg29
S'Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.| \r'
p2515
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAFFEINE'
p2516
sa(dp2517
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p2518
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2519
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2520
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2521
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2522
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCIUM'
p2523
sa(dp2524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p2525
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2527
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2528
sg28
Nsg29
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2529
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p2530
sa(dp2531
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2532
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2533
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2534
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2535
sg28
Nsg29
S'Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.| \r'
p2536
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p2537
sa(dp2538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2539
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2541
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2542
sg28
Nsg29
S'In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| \r'
p2543
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p2544
sa(dp2545
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p2546
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2547
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2548
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2549
sg28
Nsg29
S'Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.| \r'
p2550
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p2551
sa(dp2552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p2553
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2555
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2556
sg28
Nsg29
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2557
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRON'
p2558
sa(dp2559
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p2560
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2561
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2562
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2563
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2564
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p2565
sa(dp2566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p2567
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2569
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2570
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2571
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p2572
sa(dp2573
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2574
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2575
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2576
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2577
sg28
Nsg29
S'Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. | \r'
p2578
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p2579
sa(dp2580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2581
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2583
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2584
sg28
Nsg29
S'Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.| \r'
p2585
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p2586
sa(dp2587
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2588
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2589
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2590
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2591
sg28
Nsg29
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.| \r'
p2592
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p2593
sa(dp2594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01593'
p2595
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p2596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2597
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p2598
sg28
Nsg29
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p2599
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZINC'
p2600
sa(dp2601
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2602
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2603
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2604
sg24
Nsg25
Nsg26
S'Cisapride'
p2605
sg28
Nsg29
S'There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| \r'
p2606
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p2607
sa(dp2608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2609
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2611
sg24
Nsg25
Nsg26
S'Cisapride'
p2612
sg28
Nsg29
S'A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p2613
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2614
sa(dp2615
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2616
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2617
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2618
sg24
Nsg25
Nsg26
S'Cisapride'
p2619
sg28
Nsg29
S'A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p2620
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2621
sa(dp2622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p2623
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2625
sg24
Nsg25
Nsg26
S'Cisapride'
p2626
sg28
Nsg29
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p2627
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p2628
sa(dp2629
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p2630
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2631
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2632
sg24
Nsg25
Nsg26
S'Cisapride'
p2633
sg28
Nsg29
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p2634
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p2635
sa(dp2636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00489'
p2637
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2639
sg24
Nsg25
Nsg26
S'Cisapride'
p2640
sg28
Nsg29
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p2641
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sotalol'
p2642
sa(dp2643
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p2644
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p2645
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2646
sg24
Nsg25
Nsg26
S'Cisapride'
p2647
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p2648
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p2649
sa(dp2650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2651
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2653
sg24
Nsg25
Nsg26
S'CLARITHROMYCIN'
p2654
sg28
Nsg29
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p2655
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2656
sa(dp2657
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2658
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2659
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2660
sg24
Nsg25
Nsg26
S'CLARITHROMYCIN'
p2661
sg28
Nsg29
S'Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p2662
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p2663
sa(dp2664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p2665
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2667
sg24
Nsg25
Nsg26
S'CLARITHROMYCIN'
p2668
sg28
Nsg29
S'Clarithromycin exposure was significantly decreased by nevirapine;| \r'
p2669
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEVIRAPINE'
p2670
sa(dp2671
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p2672
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2673
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2674
sg24
Nsg25
Nsg26
S'CLARITHROMYCIN'
p2675
sg28
Nsg29
S'Concomitant administration of clarithromycin with pimozide is contraindicated.| \r'
p2676
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PIMOZIDE'
p2677
sa(dp2678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p2679
sg5
S'http://bio2rdf.org/drugbank:DB01211'
p2680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2681
sg24
Nsg25
Nsg26
S'CLARITHROMYCIN'
p2682
sg28
Nsg29
S'DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. | \r'
p2683
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SIMVASTATIN'
p2684
sa(dp2685
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p2686
sg5
S'http://bio2rdf.org/drugbank:DB01190'
p2687
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2688
sg24
Nsg25
Nsg26
S'CLINDAMYCIN'
p2689
sg28
Nsg29
S'Antagonism has been demonstrated between clindamycin and erythromycin in vitro.| \r'
p2690
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p2691
sa(dp2692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00782'
p2693
sg5
S'http://bio2rdf.org/drugbank:DB01068'
p2694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2695
sg24
Nsg25
Nsg26
S'CLONAZEPAM'
p2696
sg28
Nsg29
S'In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| \r'
p2697
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROPANTHELINE'
p2698
sa(dp2699
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2700
sg5
S'http://bio2rdf.org/drugbank:DB00575'
p2701
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2702
sg24
Nsg25
Nsg26
S'CLONIDINE'
p2703
sg28
Nsg29
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p2704
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p2705
sa(dp2706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00736'
p2707
sg5
S'http://bio2rdf.org/drugbank:DB00758'
p2708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2709
sg24
Nsg25
Nsg26
S'CLOPIDOGREL'
p2710
sg28
Nsg29
S'Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. | \r'
p2711
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESOMEPRAZOLE'
p2712
sa(dp2713
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p2714
sg5
S'http://bio2rdf.org/drugbank:DB00257'
p2715
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2716
sg24
Nsg25
Nsg26
S'CLOTRIMAZOLE'
p2717
sg28
Nsg29
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p2718
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIMETREXATE'
p2719
sa(dp2720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2721
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2723
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2724
sg28
Nsg29
S'Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.| \r'
p2725
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p2726
sa(dp2727
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p2728
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2729
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2730
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2731
sg28
Nsg29
S'Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| \r'
p2732
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atropine'
p2733
sa(dp2734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p2735
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2737
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2738
sg28
Nsg29
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| \r'
p2739
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p2740
sa(dp2741
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01228'
p2742
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2743
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2744
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2745
sg28
Nsg29
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p2746
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Encainide'
p2747
sa(dp2748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p2749
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2751
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2752
sg28
Nsg29
S'Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.| \r'
p2753
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p2754
sa(dp2755
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p2756
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2757
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2758
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2759
sg28
Nsg29
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p2760
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p2761
sa(dp2762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p2763
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2765
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2766
sg28
Nsg29
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p2767
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p2768
sa(dp2769
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p2770
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p2771
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2772
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p2773
sg28
Nsg29
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p2774
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p2775
sa(dp2776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01452'
p2777
sg5
S'http://bio2rdf.org/drugbank:DB00907'
p2778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2779
sg24
Nsg25
Nsg26
S'COCAINE'
p2780
sg28
Nsg29
S'Cocaine sometimes proves to be fatal when used in combination with heroin.| \r'
p2781
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIACETYLMORPHINE'
p2782
sa(dp2783
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p2784
sg5
S'http://bio2rdf.org/drugbank:DB00907'
p2785
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2786
sg24
Nsg25
Nsg26
S'COCAINE'
p2787
sg28
Nsg29
S'The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. | \r'
p2788
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NOREPINEPHRINE'
p2789
sa(dp2790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2791
sg5
S'http://bio2rdf.org/drugbank:DB00318'
p2792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2793
sg24
Nsg25
Nsg26
S'CODEINE'
p2794
sg28
Nsg29
S'The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.| Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.| \r'
p2795
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p2796
sa(dp2797
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p2798
sg5
S'http://bio2rdf.org/drugbank:DB01394'
p2799
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2800
sg24
Nsg25
Nsg26
S'COLCHICINE'
p2801
sg28
Nsg29
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p2802
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p2803
sa(dp2804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2805
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p2806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2807
sg24
Nsg25
Nsg26
S'Copegus'
p2808
sg28
Nsg29
S'Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| \r'
p2809
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p2810
sa(dp2811
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2812
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p2813
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2814
sg24
Nsg25
Nsg26
S'Coreg'
p2815
sg28
Nsg29
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.| \r'
p2816
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p2817
sa(dp2818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2819
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p2820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2821
sg24
Nsg25
Nsg26
S'Coreg'
p2822
sg28
Nsg29
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.| \r'
p2823
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p2824
sa(dp2825
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p2826
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p2827
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2828
sg24
Nsg25
Nsg26
S'Coreg'
p2829
sg28
Nsg29
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| \r'
p2830
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p2831
sa(dp2832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p2833
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2835
sg24
Nsg25
Nsg26
S'Crixivan'
p2836
sg28
Nsg29
S'Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| \r'
p2837
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p2838
sa(dp2839
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00705'
p2840
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2841
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2842
sg24
Nsg25
Nsg26
S'Crixivan'
p2843
sg28
Nsg29
S'Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| \r'
p2844
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DELAVIRDINE'
p2845
sa(dp2846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2847
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2849
sg24
Nsg25
Nsg26
S'Crixivan'
p2850
sg28
Nsg29
S'CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.| \r'
p2851
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p2852
sa(dp2853
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2854
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p2855
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2856
sg24
Nsg25
Nsg26
S'Crixivan'
p2857
sg28
Nsg29
S'CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.| \r'
p2858
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p2859
sa(dp2860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p2861
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p2862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2863
sg24
Nsg25
Nsg26
S'Cyclophosphamide'
p2864
sg28
Nsg29
S'Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| \r'
p2865
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p2866
sa(dp2867
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00694'
p2868
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p2869
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2870
sg24
Nsg25
Nsg26
S'Cyclophosphamide'
p2871
sg28
Nsg29
S'Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.| \r'
p2872
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cerubidine'
p2873
sa(dp2874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2875
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p2876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2877
sg24
Nsg25
Nsg26
S'Cyclophosphamide'
p2878
sg28
Nsg29
S'The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| \r'
p2879
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p2880
sa(dp2881
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00773'
p2882
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2883
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2884
sg24
Nsg25
Nsg26
S'Cyclosporin A'
p2885
sg28
Nsg29
S'High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| \r'
p2886
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETOPOSIDE'
p2887
sa(dp2888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2889
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2891
sg24
Nsg25
Nsg26
S'CYCLOSPORINE'
p2892
sg28
Nsg29
S'In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.| If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| \r'
p2893
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p2894
sa(dp2895
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p2896
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2897
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2898
sg24
Nsg25
Nsg26
S'CYCLOSPORINE'
p2899
sg28
Nsg29
S'In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.| If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| \r'
p2900
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p2901
sa(dp2902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p2903
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2905
sg24
Nsg25
Nsg26
S'CYCLOSPORINE'
p2906
sg28
Nsg29
S'Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.| \r'
p2907
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p2908
sa(dp2909
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2910
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2911
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2912
sg24
Nsg25
Nsg26
S'CYCLOSPORINE'
p2913
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2914
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p2915
sa(dp2916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2917
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2919
sg24
Nsg25
Nsg26
S'CYCLOSPORINE'
p2920
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2921
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p2922
sa(dp2923
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p2924
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p2925
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2926
sg24
Nsg25
Nsg26
S'CYCLOSPORINE'
p2927
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p2928
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p2929
sa(dp2930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p2931
sg5
S'http://bio2rdf.org/drugbank:DB00357'
p2932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2933
sg24
Nsg25
Nsg26
S'Cytadren'
p2934
sg28
Nsg29
S'Cytadren accelerates the metabolism of dexamethasone;| \r'
p2935
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p2936
sa(dp2937
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p2938
sg5
S'http://bio2rdf.org/drugbank:DB00987'
p2939
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2940
sg24
Nsg25
Nsg26
S'Cytosine arabinoside'
p2941
sg28
Nsg29
S'Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| \r'
p2942
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCYTOSINE'
p2943
sa(dp2944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p2945
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p2946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2947
sg24
Nsg25
Nsg26
S'd-amphetamine'
p2948
sg28
Nsg29
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p2949
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DESIPRAMINE'
p2950
sa(dp2951
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00344'
p2952
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p2953
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2954
sg24
Nsg25
Nsg26
S'd-amphetamine'
p2955
sg28
Nsg29
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p2956
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROTRIPTYLINE'
p2957
sa(dp2958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p2959
sg5
S'http://bio2rdf.org/drugbank:DB01406'
p2960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2961
sg24
Nsg25
Nsg26
S'DANAZOL'
p2962
sg28
Nsg29
S'Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).| \r'
p2963
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOVASTATIN'
p2964
sa(dp2965
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p2966
sg5
S'http://bio2rdf.org/drugbank:DB01219'
p2967
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2968
sg24
Nsg25
Nsg26
S'DANTROLENE'
p2969
sg28
Nsg29
S'Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| \r'
p2970
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VECURONIUM'
p2971
sa(dp2972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p2973
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2975
sg24
Nsg25
Nsg26
S'DAPSONE'
p2976
sg28
Nsg29
S'If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.| \r'
p2977
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFAZIMINE'
p2978
sa(dp2979
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p2980
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2981
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2982
sg24
Nsg25
Nsg26
S'DAPSONE'
p2983
sg28
Nsg29
S'Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.| \r'
p2984
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lamprene'
p2985
sa(dp2986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00205'
p2987
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2989
sg24
Nsg25
Nsg26
S'DAPSONE'
p2990
sg28
Nsg29
S'With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| \r'
p2991
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PYRIMETHAMINE'
p2992
sa(dp2993
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2994
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p2995
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2996
sg24
Nsg25
Nsg26
S'DAPSONE'
p2997
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p2998
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p2999
sa(dp3000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3001
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p3002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3003
sg24
Nsg25
Nsg26
S'DAPSONE'
p3004
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p3005
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p3006
sa(dp3007
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p3008
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p3009
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3010
sg24
Nsg25
Nsg26
S'DASATINIB ANHYDROUS'
p3011
sg28
Nsg29
S'Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); | HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. | Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. | The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#x0D;| Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.| \r'
p3012
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PACLITAXEL'
p3013
sa(dp3014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p3015
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p3016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3017
sg24
Nsg25
Nsg26
S'DASATINIB'
p3018
sg28
Nsg29
S'HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. | Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.| The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#x0D;| Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); | Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. | \r'
p3019
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PACLITAXEL'
p3020
sa(dp3021
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p3022
sg5
S'http://bio2rdf.org/drugbank:DB01245'
p3023
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3024
sg24
Nsg25
Nsg26
S'DECAMETHONIUM'
p3025
sg28
Nsg29
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p3026
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coly-Mycin M'
p3027
sa(dp3028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3029
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p3030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3031
sg24
Nsg25
Nsg26
S'DELAVIRDINE'
p3032
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p3033
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p3034
sa(dp3035
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3036
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p3037
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3038
sg24
Nsg25
Nsg26
S'DELAVIRDINE'
p3039
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p3040
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p3041
sa(dp3042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3043
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p3044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3045
sg24
Nsg25
Nsg26
S'Demser'
p3046
sg28
Nsg29
S'Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.| \r'
p3047
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p3048
sa(dp3049
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p3050
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p3051
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3052
sg24
Nsg25
Nsg26
S'Demser'
p3053
sg28
Nsg29
S'Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. | \r'
p3054
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p3055
sa(dp3056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p3057
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3059
sg24
Nsg25
Nsg26
S'DESIPRAMINE'
p3060
sg28
Nsg29
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p3061
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p3062
sa(dp3063
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p3064
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3065
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3066
sg24
Nsg25
Nsg26
S'DESIPRAMINE'
p3067
sg28
Nsg29
S'If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.| \r'
p3068
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p3069
sa(dp3070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3071
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3073
sg24
Nsg25
Nsg26
S'DESIPRAMINE'
p3074
sg28
Nsg29
S'If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.| \r'
p3075
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p3076
sa(dp3077
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p3078
sg5
S'http://bio2rdf.org/drugbank:DB01151'
p3079
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3080
sg24
Nsg25
Nsg26
S'DESIPRAMINE'
p3081
sg28
Nsg29
S'The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. | \r'
p3082
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NOREPINEPHRINE'
p3083
sa(dp3084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00518'
p3085
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3087
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p3088
sg28
Nsg29
S'Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| \r'
p3089
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALBENDAZOLE'
p3090
sa(dp3091
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3092
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3093
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3094
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p3095
sg28
Nsg29
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p3096
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p3097
sa(dp3098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3099
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3101
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p3102
sg28
Nsg29
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p3103
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p3104
sa(dp3105
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p3106
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3107
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3108
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p3109
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p3110
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p3111
sa(dp3112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3113
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3115
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p3116
sg28
Nsg29
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3117
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p3118
sa(dp3119
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p3120
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p3121
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3122
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p3123
sg28
Nsg29
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p3124
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p3125
sa(dp3126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3127
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p3128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3129
sg24
Nsg25
Nsg26
S'DEXBROMPHENIRAMINE'
p3130
sg28
Nsg29
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p3131
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p3132
sa(dp3133
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3134
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p3135
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3136
sg24
Nsg25
Nsg26
S'DEXBROMPHENIRAMINE'
p3137
sg28
Nsg29
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p3138
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p3139
sa(dp3140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01364'
p3141
sg5
S'http://bio2rdf.org/drugbank:DB00633'
p3142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3143
sg24
Nsg25
Nsg26
S'DEXMEDETOMIDINE'
p3144
sg28
Nsg29
S'In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. | At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. | We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.| \r'
p3145
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPHEDRINE'
p3146
sa(dp3147
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p3148
sg5
S'http://bio2rdf.org/drugbank:DB00514'
p3149
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3150
sg24
Nsg25
Nsg26
S'DEXTROMETHORPHAN'
p3151
sg28
Nsg29
S'Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| \r'
p3152
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p3153
sa(dp3154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3155
sg5
S'http://bio2rdf.org/drugbank:DB01209'
p3156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3157
sg24
Nsg25
Nsg26
S'DEZOCINE'
p3158
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3159
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p3160
sa(dp3161
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3162
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p3163
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3164
sg24
Nsg25
Nsg26
S'DIACETYLMORPHINE'
p3165
sg28
Nsg29
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p3166
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p3167
sa(dp3168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3169
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p3170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3171
sg24
Nsg25
Nsg26
S'DIACETYLMORPHINE'
p3172
sg28
Nsg29
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p3173
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p3174
sa(dp3175
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3176
sg5
S'http://bio2rdf.org/drugbank:DB01452'
p3177
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3178
sg24
Nsg25
Nsg26
S'DIACETYLMORPHINE'
p3179
sg28
Nsg29
S'Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| \r'
p3180
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valium'
p3181
sa(dp3182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3183
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p3184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3185
sg24
Nsg25
Nsg26
S'Diamox'
p3186
sg28
Nsg29
S'DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.| \r'
p3187
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p3188
sa(dp3189
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p3190
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p3191
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3192
sg24
Nsg25
Nsg26
S'Diamox'
p3193
sg28
Nsg29
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p3194
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p3195
sa(dp3196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p3197
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p3198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3199
sg24
Nsg25
Nsg26
S'Diamox'
p3200
sg28
Nsg29
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p3201
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p3202
sa(dp3203
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3204
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3205
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3206
sg24
Nsg25
Nsg26
S'DIAZEPAM'
p3207
sg28
Nsg29
S'Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| \r'
p3208
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p3209
sa(dp3210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p3211
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3213
sg24
Nsg25
Nsg26
S'DIAZEPAM'
p3214
sg28
Nsg29
S'Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. | \r'
p3215
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p3216
sa(dp3217
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p3218
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3219
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3220
sg24
Nsg25
Nsg26
S'DIAZEPAM'
p3221
sg28
Nsg29
S'Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. | \r'
p3222
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p3223
sa(dp3224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p3225
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p3226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3227
sg24
Nsg25
Nsg26
S'DIAZEPAM'
p3228
sg28
Nsg29
S'Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| \r'
p3229
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p3230
sa(dp3231
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p3232
sg5
S'http://bio2rdf.org/drugbank:DB01119'
p3233
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3234
sg24
Nsg25
Nsg26
S'DIAZOXIDE'
p3235
sg28
Nsg29
S'Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| \r'
p3236
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDRALAZINE'
p3237
sa(dp3238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3239
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3241
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3242
sg28
Nsg29
S'Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| \r'
p3243
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p3244
sa(dp3245
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3246
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3247
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3248
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3249
sg28
Nsg29
S'Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| \r'
p3250
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p3251
sa(dp3252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3253
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3255
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3256
sg28
Nsg29
S'Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| \r'
p3257
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p3258
sa(dp3259
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3260
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3261
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3262
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3263
sg28
Nsg29
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3264
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3265
sa(dp3266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3267
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3269
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3270
sg28
Nsg29
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3271
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3272
sa(dp3273
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3274
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3275
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3276
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3277
sg28
Nsg29
S'Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| \r'
p3278
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p3279
sa(dp3280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3281
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3283
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3284
sg28
Nsg29
S'Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| \r'
p3285
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p3286
sa(dp3287
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3288
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3289
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3290
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3291
sg28
Nsg29
S'In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| \r'
p3292
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p3293
sa(dp3294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p3295
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3297
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3298
sg28
Nsg29
S'In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| \r'
p3299
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p3300
sa(dp3301
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3302
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3303
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3304
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3305
sg28
Nsg29
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3306
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p3307
sa(dp3308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3309
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3311
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3312
sg28
Nsg29
S'Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| \r'
p3313
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p3314
sa(dp3315
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p3316
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3317
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3318
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3319
sg28
Nsg29
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p3320
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PREDNISOLONE'
p3321
sa(dp3322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00936'
p3323
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3325
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3326
sg28
Nsg29
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p3327
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SALICYLIC ACID'
p3328
sa(dp3329
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p3330
sg5
S'http://bio2rdf.org/drugbank:DB00586'
p3331
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3332
sg24
Nsg25
Nsg26
S'DICLOFENAC'
p3333
sg28
Nsg29
S'Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| \r'
p3334
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p3335
sa(dp3336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3337
sg5
S'http://bio2rdf.org/drugbank:DB00804'
p3338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3339
sg24
Nsg25
Nsg26
S'DICYCLOMINE'
p3340
sg28
Nsg29
S'Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| \r'
p3341
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p3342
sa(dp3343
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p3344
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p3345
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3346
sg24
Nsg25
Nsg26
S'DIDANOSINE'
p3347
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p3348
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p3349
sa(dp3350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p3351
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p3352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3353
sg24
Nsg25
Nsg26
S'DIDANOSINE'
p3354
sg28
Nsg29
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p3355
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p3356
sa(dp3357
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3358
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3359
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3360
sg24
Nsg25
Nsg26
S'Diflucan'
p3361
sg28
Nsg29
S'Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. | Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. | \r'
p3362
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p3363
sa(dp3364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3365
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3367
sg24
Nsg25
Nsg26
S'Diflucan'
p3368
sg28
Nsg29
S'Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. | Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. | \r'
p3369
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p3370
sa(dp3371
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p3372
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3373
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3374
sg24
Nsg25
Nsg26
S'Diflucan'
p3375
sg28
Nsg29
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3376
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLIPIZIDE'
p3377
sa(dp3378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p3379
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3381
sg24
Nsg25
Nsg26
S'Diflucan'
p3382
sg28
Nsg29
S'one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. | DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3383
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p3384
sa(dp3385
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p3386
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3387
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3388
sg24
Nsg25
Nsg26
S'Diflucan'
p3389
sg28
Nsg29
S'one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. | DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3390
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p3391
sa(dp3392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3393
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3395
sg24
Nsg25
Nsg26
S'Diflucan'
p3396
sg28
Nsg29
S'Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. | Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. | \r'
p3397
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p3398
sa(dp3399
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3400
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3401
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3402
sg24
Nsg25
Nsg26
S'Diflucan'
p3403
sg28
Nsg29
S'Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. | Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. | \r'
p3404
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p3405
sa(dp3406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3407
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3409
sg24
Nsg25
Nsg26
S'Diflucan'
p3410
sg28
Nsg29
S'Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. | \r'
p3411
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p3412
sa(dp3413
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3414
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3415
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3416
sg24
Nsg25
Nsg26
S'Diflucan'
p3417
sg28
Nsg29
S'Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. | Theophylline: DIFLUCAN increases the serum concentrations of theophylline. | \r'
p3418
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p3419
sa(dp3420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p3421
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3423
sg24
Nsg25
Nsg26
S'Diflucan'
p3424
sg28
Nsg29
S'Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. | Theophylline: DIFLUCAN increases the serum concentrations of theophylline. | \r'
p3425
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p3426
sa(dp3427
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p3428
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p3429
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3430
sg24
Nsg25
Nsg26
S'Diflucan'
p3431
sg28
Nsg29
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p3432
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p3433
sa(dp3434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3435
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3437
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3438
sg28
Nsg29
S'Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| \r'
p3439
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p3440
sa(dp3441
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3442
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3443
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3444
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3445
sg28
Nsg29
S'Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| \r'
p3446
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p3447
sa(dp3448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p3449
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3451
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3452
sg28
Nsg29
S'Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| \r'
p3453
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p3454
sa(dp3455
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3456
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3457
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3458
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3459
sg28
Nsg29
S'Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| \r'
p3460
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p3461
sa(dp3462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p3463
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3465
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3466
sg28
Nsg29
S'Diflunisal decreased the hyperuricemic effect of furosemide.| \r'
p3467
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p3468
sa(dp3469
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p3470
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3471
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3472
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3473
sg28
Nsg29
S'Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| \r'
p3474
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCHLOROTHIAZIDE'
p3475
sa(dp3476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p3477
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3479
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3480
sg28
Nsg29
S'Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| \r'
p3481
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCHLOROTHIAZIDE'
p3482
sa(dp3483
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p3484
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3485
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3486
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3487
sg28
Nsg29
S'Therefore, diflunisal and INDOCIN should not be used concomitantly.| \r'
p3488
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Indocin'
p3489
sa(dp3490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p3491
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3493
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3494
sg28
Nsg29
S'Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.| In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.| \r'
p3495
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p3496
sa(dp3497
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p3498
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3499
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3500
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3501
sg28
Nsg29
S'Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.| \r'
p3502
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p3503
sa(dp3504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p3505
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p3506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3507
sg24
Nsg25
Nsg26
S'DIFLUNISAL'
p3508
sg28
Nsg29
S'Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| \r'
p3509
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NAPROXEN'
p3510
sa(dp3511
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p3512
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3513
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3514
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3515
sg28
Nsg29
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p3516
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Adenocard'
p3517
sa(dp3518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p3519
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3521
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3522
sg28
Nsg29
S'In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.| \r'
p3523
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMINOSALICYLIC ACID'
p3524
sa(dp3525
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p3526
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3527
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3528
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3529
sg28
Nsg29
S'These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.| \r'
p3530
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p3531
sa(dp3532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p3533
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3535
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3536
sg28
Nsg29
S'When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| \r'
p3537
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Brevibloc'
p3538
sa(dp3539
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p3540
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3541
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3542
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3543
sg28
Nsg29
S'Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| \r'
p3544
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CONIVAPTAN'
p3545
sa(dp3546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p3547
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3549
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3550
sg28
Nsg29
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p3551
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coreg'
p3552
sa(dp3553
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p3554
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3555
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3556
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3557
sg28
Nsg29
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p3558
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coreg'
p3559
sa(dp3560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3561
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3563
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3564
sg28
Nsg29
S'Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.| \r'
p3565
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3566
sa(dp3567
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3568
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3569
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3570
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3571
sg28
Nsg29
S'In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p3572
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p3573
sa(dp3574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p3575
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3577
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3578
sg28
Nsg29
S'However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p3579
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Flolan'
p3580
sa(dp3581
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3582
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3583
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3584
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3585
sg28
Nsg29
S'It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| \r'
p3586
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p3587
sa(dp3588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p3589
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3591
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3592
sg28
Nsg29
S'Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | \r'
p3593
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p3594
sa(dp3595
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p3596
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3597
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3598
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3599
sg28
Nsg29
S'Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| \r'
p3600
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIFEDIPINE'
p3601
sa(dp3602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p3603
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3605
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3606
sg28
Nsg29
S'Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| \r'
p3607
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIFEDIPINE'
p3608
sa(dp3609
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00790'
p3610
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3611
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3612
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3613
sg28
Nsg29
S'Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. | \r'
p3614
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PERINDOPRIL'
p3615
sa(dp3616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01261'
p3617
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3619
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3620
sg28
Nsg29
S'Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | \r'
p3621
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SITAGLIPTIN PHOSPHATE'
p3622
sa(dp3623
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01261'
p3624
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3625
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3626
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3627
sg28
Nsg29
S'Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | \r'
p3628
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SITAGLIPTIN'
p3629
sa(dp3630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00795'
p3631
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3633
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3634
sg28
Nsg29
S'Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | \r'
p3635
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SULFASALAZINE'
p3636
sa(dp3637
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p3638
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p3639
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3640
sg24
Nsg25
Nsg26
S'DIGOXIN'
p3641
sg28
Nsg29
S'Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.| \r'
p3642
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vaprisol'
p3643
sa(dp3644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p3645
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3647
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3648
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p3649
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Axert'
p3650
sa(dp3651
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p3652
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3653
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3654
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3655
sg28
Nsg29
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p3656
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Frova'
p3657
sa(dp3658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p3659
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3661
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3662
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p3663
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NARATRIPTAN'
p3664
sa(dp3665
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p3666
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3667
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3668
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3669
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p3670
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p3671
sa(dp3672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p3673
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3675
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3676
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p3677
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p3678
sa(dp3679
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p3680
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3681
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3682
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3683
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p3684
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p3685
sa(dp3686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p3687
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p3688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3689
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p3690
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p3691
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p3692
sa(dp3693
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3694
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3695
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3696
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3697
sg28
Nsg29
S'Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.| \r'
p3698
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p3699
sa(dp3700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p3701
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3703
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3704
sg28
Nsg29
S'Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.| \r'
p3705
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p3706
sa(dp3707
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p3708
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3709
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3710
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3711
sg28
Nsg29
S'Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.| \r'
p3712
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p3713
sa(dp3714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3715
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3717
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3718
sg28
Nsg29
S'A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.| \r'
p3719
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p3720
sa(dp3721
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p3722
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3723
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3724
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3725
sg28
Nsg29
S'The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| \r'
p3726
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FENTANYL'
p3727
sa(dp3728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p3729
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3731
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3732
sg28
Nsg29
S'In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;| \r'
p3733
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOVASTATIN'
p3734
sa(dp3735
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3736
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3737
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3738
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3739
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| \r'
p3740
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p3741
sa(dp3742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3743
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3745
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3746
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| \r'
p3747
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p3748
sa(dp3749
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p3750
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3751
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3752
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3753
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p3754
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p3755
sa(dp3756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3757
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3759
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3760
sg28
Nsg29
S'Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.| \r'
p3761
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p3762
sa(dp3763
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00877'
p3764
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3765
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3766
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3767
sg28
Nsg29
S'CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. | Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.&#x0D;| \r'
p3768
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SIROLIMUS'
p3769
sa(dp3770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3771
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3773
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3774
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p3775
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p3776
sa(dp3777
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p3778
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3779
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3780
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3781
sg28
Nsg29
S'These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| \r'
p3782
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p3783
sa(dp3784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p3785
sg5
S'http://bio2rdf.org/drugbank:DB00343'
p3786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3787
sg24
Nsg25
Nsg26
S'DILTIAZEM'
p3788
sg28
Nsg29
S'These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| \r'
p3789
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p3790
sa(dp3791
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3792
sg5
S'http://bio2rdf.org/drugbank:DB00985'
p3793
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3794
sg24
Nsg25
Nsg26
S'DIMENHYDRINATE'
p3795
sg28
Nsg29
S'Dimenhydrinate may decrease emetic response to apomorphine.| \r'
p3796
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APOMORPHINE'
p3797
sa(dp3798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3799
sg5
S'http://bio2rdf.org/drugbank:DB01231'
p3800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3801
sg24
Nsg25
Nsg26
S'DIPHENIDOL'
p3802
sg28
Nsg29
S'apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.| \r'
p3803
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APOMORPHINE'
p3804
sa(dp3805
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p3806
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p3807
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3808
sg24
Nsg25
Nsg26
S'DIPHENOLIC ACID'
p3809
sg28
Nsg29
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p3810
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p3811
sa(dp3812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p3813
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p3814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3815
sg24
Nsg25
Nsg26
S'DIPHENOLIC ACID'
p3816
sg28
Nsg29
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p3817
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p3818
sa(dp3819
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00853'
p3820
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p3821
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3822
sg24
Nsg25
Nsg26
S'DIPHENOLIC ACID'
p3823
sg28
Nsg29
S'Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | \r'
p3824
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TEMOZOLOMIDE'
p3825
sa(dp3826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3827
sg5
S'http://bio2rdf.org/drugbank:DB01081'
p3828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3829
sg24
Nsg25
Nsg26
S'DIPHENOXYLATE'
p3830
sg28
Nsg29
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p3831
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3832
sa(dp3833
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p3834
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p3835
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3836
sg24
Nsg25
Nsg26
S'Diprivan'
p3837
sg28
Nsg29
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p3838
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FENTANYL'
p3839
sa(dp3840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p3841
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p3842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3843
sg24
Nsg25
Nsg26
S'Diprivan'
p3844
sg28
Nsg29
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p3845
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEPERIDINE'
p3846
sa(dp3847
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p3848
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p3849
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3850
sg24
Nsg25
Nsg26
S'Diprivan'
p3851
sg28
Nsg29
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p3852
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p3853
sa(dp3854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00009'
p3855
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3857
sg24
Nsg25
Nsg26
S'DIPYRIDAMOLE'
p3858
sg28
Nsg29
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.| \r'
p3859
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Activase'
p3860
sa(dp3861
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p3862
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3863
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3864
sg24
Nsg25
Nsg26
S'DIPYRIDAMOLE'
p3865
sg28
Nsg29
S'Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.| \r'
p3866
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ADENOSINE'
p3867
sa(dp3868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00015'
p3869
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3871
sg24
Nsg25
Nsg26
S'DIPYRIDAMOLE'
p3872
sg28
Nsg29
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| \r'
p3873
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Retavase'
p3874
sa(dp3875
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00031'
p3876
sg5
S'http://bio2rdf.org/drugbank:DB00975'
p3877
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3878
sg24
Nsg25
Nsg26
S'DIPYRIDAMOLE'
p3879
sg28
Nsg29
S'Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. | \r'
p3880
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TNKase'
p3881
sa(dp3882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3883
sg5
S'http://bio2rdf.org/drugbank:DB04817'
p3884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3885
sg24
Nsg25
Nsg26
S'DIPYRONE'
p3886
sg28
Nsg29
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3887
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p3888
sa(dp3889
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3890
sg5
S'http://bio2rdf.org/drugbank:DB00822'
p3891
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3892
sg24
Nsg25
Nsg26
S'DISULFIRAM'
p3893
sg28
Nsg29
S'SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.| DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.| \r'
p3894
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p3895
sa(dp3896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p3897
sg5
S'http://bio2rdf.org/drugbank:DB00822'
p3898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3899
sg24
Nsg25
Nsg26
S'DISULFIRAM'
p3900
sg28
Nsg29
S'SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.| DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.| \r'
p3901
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p3902
sa(dp3903
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00325'
p3904
sg5
S'http://bio2rdf.org/drugbank:DB00841'
p3905
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3906
sg24
Nsg25
Nsg26
S'Dobutamine'
p3907
sg28
Nsg29
S'Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.| \r'
p3908
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NITROPRUSSIDE'
p3909
sa(dp3910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p3911
sg5
S'http://bio2rdf.org/drugbank:DB00841'
p3912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3913
sg24
Nsg25
Nsg26
S'Dobutamine'
p3914
sg28
Nsg29
S'norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | \r'
p3915
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SODIUM BICARBONATE'
p3916
sa(dp3917
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p3918
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3919
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3920
sg24
Nsg25
Nsg26
S'DOCETAXEL'
p3921
sg28
Nsg29
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3922
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p3923
sa(dp3924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p3925
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3927
sg24
Nsg25
Nsg26
S'DOCETAXEL'
p3928
sg28
Nsg29
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3929
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p3930
sa(dp3931
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3932
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3933
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3934
sg24
Nsg25
Nsg26
S'DOCETAXEL'
p3935
sg28
Nsg29
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3936
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p3937
sa(dp3938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01268'
p3939
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3941
sg24
Nsg25
Nsg26
S'DOCETAXEL'
p3942
sg28
Nsg29
S'The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. | Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.| When cells were exposed to docetaxel followed by sunitinib, synergism was observed. | \r'
p3943
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUNITINIB'
p3944
sa(dp3945
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p3946
sg5
S'http://bio2rdf.org/drugbank:DB01248'
p3947
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3948
sg24
Nsg25
Nsg26
S'DOCETAXEL'
p3949
sg28
Nsg29
S'In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| \r'
p3950
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p3951
sa(dp3952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p3953
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p3954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3955
sg24
Nsg25
Nsg26
S'DOLASETRON'
p3956
sg28
Nsg29
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p3957
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p3958
sa(dp3959
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p3960
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p3961
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3962
sg24
Nsg25
Nsg26
S'DOLASETRON'
p3963
sg28
Nsg29
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p3964
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p3965
sa(dp3966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01158'
p3967
sg5
S'http://bio2rdf.org/drugbank:DB00988'
p3968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3969
sg24
Nsg25
Nsg26
S'DOPAMINE'
p3970
sg28
Nsg29
S'The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.| \r'
p3971
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Bretylium tosylate'
p3972
sa(dp3973
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p3974
sg5
S'http://bio2rdf.org/drugbank:DB00248'
p3975
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3976
sg24
Nsg25
Nsg26
S'Dostinex'
p3977
sg28
Nsg29
S'DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.| \r'
p3978
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p3979
sa(dp3980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00398'
p3981
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p3982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3983
sg24
Nsg25
Nsg26
S'DOXORUBICIN'
p3984
sg28
Nsg29
S'Caution is recommended when administering doxorubicin with NEXAVAR. | \r'
p3985
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nexavar'
p3986
sa(dp3987
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p3988
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p3989
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3990
sg24
Nsg25
Nsg26
S'DOXORUBICIN'
p3991
sg28
Nsg29
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p3992
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Proleukin'
p3993
sa(dp3994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3995
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p3996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3997
sg24
Nsg25
Nsg26
S'DOXORUBICIN'
p3998
sg28
Nsg29
S'Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.| \r'
p3999
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p4000
sa(dp4001
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00428'
p4002
sg5
S'http://bio2rdf.org/drugbank:DB00997'
p4003
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4004
sg24
Nsg25
Nsg26
S'DOXORUBICIN'
p4005
sg28
Nsg29
S'a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. | \r'
p4006
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zanosar'
p4007
sa(dp4008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p4009
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4011
sg24
Nsg25
Nsg26
S'DULOXETINE'
p4012
sg28
Nsg29
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p4013
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMITRIPTYLINE'
p4014
sa(dp4015
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p4016
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4017
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4018
sg24
Nsg25
Nsg26
S'DULOXETINE'
p4019
sg28
Nsg29
S'When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.| \r'
p4020
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DESIPRAMINE'
p4021
sa(dp4022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4023
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4025
sg24
Nsg25
Nsg26
S'DULOXETINE'
p4026
sg28
Nsg29
S'Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| \r'
p4027
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p4028
sa(dp4029
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p4030
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4031
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4032
sg24
Nsg25
Nsg26
S'DULOXETINE'
p4033
sg28
Nsg29
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p4034
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IMIPRAMINE'
p4035
sa(dp4036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00540'
p4037
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p4038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4039
sg24
Nsg25
Nsg26
S'DULOXETINE'
p4040
sg28
Nsg29
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p4041
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORTRIPTYLINE'
p4042
sa(dp4043
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4044
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p4045
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4046
sg24
Nsg25
Nsg26
S'Duragesic'
p4047
sg28
Nsg29
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p4048
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p4049
sa(dp4050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p4051
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p4052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4053
sg24
Nsg25
Nsg26
S'EFAVIRENZ'
p4054
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p4055
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p4056
sa(dp4057
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p4058
sg5
S'http://bio2rdf.org/drugbank:DB00023'
p4059
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4060
sg24
Nsg25
Nsg26
S'Elspar'
p4061
sg28
Nsg29
S'Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.| \r'
p4062
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p4063
sa(dp4064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p4065
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4067
sg24
Nsg25
Nsg26
S'Enablex'
p4068
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4069
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p4070
sa(dp4071
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4072
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4073
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4074
sg24
Nsg25
Nsg26
S'Enablex'
p4075
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4076
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4077
sa(dp4078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p4079
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4081
sg24
Nsg25
Nsg26
S'Enablex'
p4082
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4083
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p4084
sa(dp4085
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4086
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p4087
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4088
sg24
Nsg25
Nsg26
S'Enablex'
p4089
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p4090
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p4091
sa(dp4092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p4093
sg5
S'http://bio2rdf.org/drugbank:DB00584'
p4094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4095
sg24
Nsg25
Nsg26
S'ENALAPRIL'
p4096
sg28
Nsg29
S'It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| \r'
p4097
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p4098
sa(dp4099
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p4100
sg5
S'http://bio2rdf.org/drugbank:DB00584'
p4101
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4102
sg24
Nsg25
Nsg26
S'ENALAPRIL'
p4103
sg28
Nsg29
S'It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| \r'
p4104
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p4105
sa(dp4106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p4107
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4109
sg24
Nsg25
Nsg26
S'ENOXACIN'
p4110
sg28
Nsg29
S'Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| \r'
p4111
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BISMUTH SUBSALICYLATE'
p4112
sa(dp4113
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p4114
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4115
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4116
sg24
Nsg25
Nsg26
S'ENOXACIN'
p4117
sg28
Nsg29
S'In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.| \r'
p4118
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAFFEINE'
p4119
sa(dp4120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4121
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4123
sg24
Nsg25
Nsg26
S'ENOXACIN'
p4124
sg28
Nsg29
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p4125
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4126
sa(dp4127
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4128
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4129
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4130
sg24
Nsg25
Nsg26
S'ENOXACIN'
p4131
sg28
Nsg29
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p4132
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4133
sa(dp4134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00863'
p4135
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4137
sg24
Nsg25
Nsg26
S'ENOXACIN'
p4138
sg28
Nsg29
S'The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.| \r'
p4139
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RANITIDINE'
p4140
sa(dp4141
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4142
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p4143
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4144
sg24
Nsg25
Nsg26
S'ENOXACIN'
p4145
sg28
Nsg29
S'Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.| \r'
p4146
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p4147
sa(dp4148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p4149
sg5
S'http://bio2rdf.org/drugbank:DB04880'
p4150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4151
sg24
Nsg25
Nsg26
S'ENOXIMONE'
p4152
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p4153
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p4154
sa(dp4155
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p4156
sg5
S'http://bio2rdf.org/drugbank:DB00159'
p4157
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4158
sg24
Nsg25
Nsg26
S'EPA'
p4159
sg28
Nsg29
S'Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).| \r'
p4160
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p4161
sa(dp4162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00633'
p4163
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p4164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4165
sg24
Nsg25
Nsg26
S'EPHEDRINE'
p4166
sg28
Nsg29
S'Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#x0D;| \r'
p4167
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXMEDETOMIDINE'
p4168
sa(dp4169
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01403'
p4170
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p4171
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4172
sg24
Nsg25
Nsg26
S'EPHEDRINE'
p4173
sg28
Nsg29
S'Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | \r'
p4174
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVOMEPROMAZINE'
p4175
sa(dp4176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p4177
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p4178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4179
sg24
Nsg25
Nsg26
S'EPHEDRINE'
p4180
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p4181
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p4182
sa(dp4183
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p4184
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p4185
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4186
sg24
Nsg25
Nsg26
S'EPINEPHRINE'
p4187
sg28
Nsg29
S'Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| \r'
p4188
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p4189
sa(dp4190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01064'
p4191
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p4192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4193
sg24
Nsg25
Nsg26
S'EPINEPHRINE'
p4194
sg28
Nsg29
S'Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| \r'
p4195
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Isoproterenol'
p4196
sa(dp4197
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p4198
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4199
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4200
sg24
Nsg25
Nsg26
S'EPLERENONE'
p4201
sg28
Nsg29
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4202
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p4203
sa(dp4204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4205
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4207
sg24
Nsg25
Nsg26
S'EPLERENONE'
p4208
sg28
Nsg29
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4209
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p4210
sa(dp4211
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4212
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4213
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4214
sg24
Nsg25
Nsg26
S'EPLERENONE'
p4215
sg28
Nsg29
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4216
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p4217
sa(dp4218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4219
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4221
sg24
Nsg25
Nsg26
S'EPLERENONE'
p4222
sg28
Nsg29
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4223
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p4224
sa(dp4225
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p4226
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p4227
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4228
sg24
Nsg25
Nsg26
S'EPLERENONE'
p4229
sg28
Nsg29
S'Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| \r'
p4230
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p4231
sa(dp4232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4233
sg5
S'http://bio2rdf.org/drugbank:DB00848'
p4234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4235
sg24
Nsg25
Nsg26
S'Ergamisol'
p4236
sg28
Nsg29
S'ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.| \r'
p4237
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p4238
sa(dp4239
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p4240
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4241
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4242
sg24
Nsg25
Nsg26
S'Ergomar'
p4243
sg28
Nsg29
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p4244
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Triacetyloleandomycin'
p4245
sa(dp4246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p4247
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4249
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p4250
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p4251
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Axert'
p4252
sa(dp4253
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p4254
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4255
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4256
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p4257
sg28
Nsg29
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p4258
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Frova'
p4259
sa(dp4260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p4261
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4263
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p4264
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p4265
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NARATRIPTAN'
p4266
sa(dp4267
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p4268
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4269
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4270
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p4271
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p4272
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p4273
sa(dp4274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4275
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4277
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p4278
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p4279
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p4280
sa(dp4281
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4282
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p4283
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4284
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p4285
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p4286
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p4287
sa(dp4288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4289
sg5
S'http://bio2rdf.org/drugbank:DB00303'
p4290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4291
sg24
Nsg25
Nsg26
S'ERTAPENEM'
p4292
sg28
Nsg29
S'Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.| \r'
p4293
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p4294
sa(dp4295
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p4296
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4297
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4298
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4299
sg28
Nsg29
S'Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.| \r'
p4300
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alfenta'
p4301
sa(dp4302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00802'
p4303
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4305
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4306
sg28
Nsg29
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4307
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALFENTANIL'
p4308
sa(dp4309
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p4310
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4311
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4312
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4313
sg28
Nsg29
S'Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| \r'
p4314
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALMOTRIPTAN'
p4315
sa(dp4316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p4317
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4319
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4320
sg28
Nsg29
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| \r'
p4321
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p4322
sa(dp4323
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p4324
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4325
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4326
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4327
sg28
Nsg29
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| \r'
p4328
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p4329
sa(dp4330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p4331
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4333
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4334
sg28
Nsg29
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p4335
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p4336
sa(dp4337
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p4338
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4339
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4340
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4341
sg28
Nsg29
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| \r'
p4342
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BROMOCRIPTINE'
p4343
sa(dp4344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4345
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4347
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4348
sg28
Nsg29
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| \r'
p4349
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p4350
sa(dp4351
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01166'
p4352
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4353
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4354
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4355
sg28
Nsg29
S'Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.| \r'
p4356
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CILOSTAZOL'
p4357
sa(dp4358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4359
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4361
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4362
sg28
Nsg29
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4363
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p4364
sa(dp4365
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4366
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4367
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4368
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4369
sg28
Nsg29
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4370
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p4371
sa(dp4372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4373
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4375
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4376
sg28
Nsg29
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4377
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p4378
sa(dp4379
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p4380
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4381
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4382
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4383
sg28
Nsg29
S'Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| \r'
p4384
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p4385
sa(dp4386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4387
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4389
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4390
sg28
Nsg29
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4391
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p4392
sa(dp4393
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4394
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4395
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4396
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4397
sg28
Nsg29
S'Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p4398
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4399
sa(dp4400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p4401
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4403
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4404
sg28
Nsg29
S'Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| \r'
p4405
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIHYDROERGOTAMINE'
p4406
sa(dp4407
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p4408
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4409
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4410
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4411
sg28
Nsg29
S'Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| \r'
p4412
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERGOTAMINE'
p4413
sa(dp4414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p4415
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4417
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4418
sg28
Nsg29
S'The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| \r'
p4419
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FENTANYL'
p4420
sa(dp4421
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p4422
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4423
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4424
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4425
sg28
Nsg29
S'Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.| \r'
p4426
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LORATADINE'
p4427
sa(dp4428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p4429
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4431
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4432
sg28
Nsg29
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4433
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOVASTATIN'
p4434
sa(dp4435
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p4436
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4437
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4438
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4439
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p4440
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p4441
sa(dp4442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p4443
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4445
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4446
sg28
Nsg29
S'Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | \r'
p4447
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p4448
sa(dp4449
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4450
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4451
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4452
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4453
sg28
Nsg29
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4454
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p4455
sa(dp4456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p4457
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4459
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4460
sg28
Nsg29
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4461
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS ANHYDROUS'
p4462
sa(dp4463
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p4464
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4465
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4466
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4467
sg28
Nsg29
S'There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4468
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS'
p4469
sa(dp4470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4471
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4473
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4474
sg28
Nsg29
S'Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.| \r'
p4475
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p4476
sa(dp4477
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p4478
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4479
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4480
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4481
sg28
Nsg29
S'Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p4482
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p4483
sa(dp4484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p4485
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4487
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4488
sg28
Nsg29
S'Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| \r'
p4489
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p4490
sa(dp4491
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p4492
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4493
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4494
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4495
sg28
Nsg29
S'Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| \r'
p4496
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p4497
sa(dp4498
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p4499
sg5
S'http://bio2rdf.org/drugbank:DB00199'
p4500
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4501
sg24
Nsg25
Nsg26
S'ERYTHROMYCIN'
p4502
sg28
Nsg29
S'Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.| \r'
p4503
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p4504
sa(dp4505
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00215'
p4506
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4507
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4508
sg24
Nsg25
Nsg26
S'ESCITALOPRAM OXALATE'
p4509
sg28
Nsg29
S'Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| \r'
p4510
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celexa'
p4511
sa(dp4512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p4513
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4515
sg24
Nsg25
Nsg26
S'ESCITALOPRAM OXALATE'
p4516
sg28
Nsg29
S'However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.| \r'
p4517
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DESIPRAMINE'
p4518
sa(dp4519
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00215'
p4520
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4521
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4522
sg24
Nsg25
Nsg26
S'ESCITALOPRAM'
p4523
sg28
Nsg29
S'Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| \r'
p4524
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celexa'
p4525
sa(dp4526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p4527
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p4528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4529
sg24
Nsg25
Nsg26
S'ESCITALOPRAM'
p4530
sg28
Nsg29
S'However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.| \r'
p4531
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DESIPRAMINE'
p4532
sa(dp4533
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4534
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4535
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4536
sg24
Nsg25
Nsg26
S'ESOMEPRAZOLE'
p4537
sg28
Nsg29
S'Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.| \r'
p4538
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p4539
sa(dp4540
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4541
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4542
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4543
sg24
Nsg25
Nsg26
S'ESOMEPRAZOLE'
p4544
sg28
Nsg29
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p4545
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4546
sa(dp4547
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p4548
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4549
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4550
sg24
Nsg25
Nsg26
S'ESOMEPRAZOLE'
p4551
sg28
Nsg29
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p4552
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRON'
p4553
sa(dp4554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4555
sg5
S'http://bio2rdf.org/drugbank:DB00736'
p4556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4557
sg24
Nsg25
Nsg26
S'ESOMEPRAZOLE'
p4558
sg28
Nsg29
S'Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| \r'
p4559
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4560
sa(dp4561
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4562
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4563
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4564
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p4565
sg28
Nsg29
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4566
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p4567
sa(dp4568
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p4569
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4570
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4571
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p4572
sg28
Nsg29
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4573
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESTAZOLAM'
p4574
sa(dp4575
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4576
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4577
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4578
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p4579
sg28
Nsg29
S'Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| \r'
p4580
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4581
sa(dp4582
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4583
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4584
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4585
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p4586
sg28
Nsg29
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4587
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p4588
sa(dp4589
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4590
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p4591
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4592
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p4593
sg28
Nsg29
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p4594
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p4595
sa(dp4596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p4597
sg5
S'http://bio2rdf.org/drugbank:DB00783'
p4598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4599
sg24
Nsg25
Nsg26
S'ESTRADIOL'
p4600
sg28
Nsg29
S'Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). | Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). | \r'
p4601
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Noradrenaline'
p4602
sa(dp4603
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4604
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p4605
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4606
sg24
Nsg25
Nsg26
S'ESZOPICLONE'
p4607
sg28
Nsg29
S'CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.| \r'
p4608
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p4609
sa(dp4610
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4611
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p4612
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4613
sg24
Nsg25
Nsg26
S'ESZOPICLONE'
p4614
sg28
Nsg29
S'The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| \r'
p4615
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4616
sa(dp4617
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00334'
p4618
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p4619
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4620
sg24
Nsg25
Nsg26
S'ESZOPICLONE'
p4621
sg28
Nsg29
S'Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.| \r'
p4622
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'OLANZAPINE'
p4623
sa(dp4624
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p4625
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p4626
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4627
sg24
Nsg25
Nsg26
S'ETHAMBUTOL'
p4628
sg28
Nsg29
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p4629
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM HYDROXIDE'
p4630
sa(dp4631
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p4632
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p4633
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4634
sg24
Nsg25
Nsg26
S'ETHAMBUTOL'
p4635
sg28
Nsg29
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p4636
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM HYDROXIDE'
p4637
sa(dp4638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p4639
sg5
S'http://bio2rdf.org/drugbank:DB00977'
p4640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4641
sg24
Nsg25
Nsg26
S'ETHINYL ESTRADIOL'
p4642
sg28
Nsg29
S'Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.| \r'
p4643
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PREDNISOLONE'
p4644
sa(dp4645
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4646
sg5
S'http://bio2rdf.org/drugbank:DB00977'
p4647
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4648
sg24
Nsg25
Nsg26
S'ETHINYL ESTRADIOL'
p4649
sg28
Nsg29
S'Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.| \r'
p4650
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p4651
sa(dp4652
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00260'
p4653
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p4654
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4655
sg24
Nsg25
Nsg26
S'ETHIONAMIDE'
p4656
sg28
Nsg29
S'In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| \r'
p4657
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSERINE'
p4658
sa(dp4659
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p4660
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p4661
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4662
sg24
Nsg25
Nsg26
S'ETHOXZOLAMIDE'
p4663
sg28
Nsg29
S'Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.| \r'
p4664
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p4665
sa(dp4666
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p4667
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p4668
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4669
sg24
Nsg25
Nsg26
S'ETHOXZOLAMIDE'
p4670
sg28
Nsg29
S'Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| \r'
p4671
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p4672
sa(dp4673
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p4674
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p4675
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4676
sg24
Nsg25
Nsg26
S'ETHOXZOLAMIDE'
p4677
sg28
Nsg29
S'Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| \r'
p4678
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p4679
sa(dp4680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p4681
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p4682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4683
sg24
Nsg25
Nsg26
S'Etodolac'
p4684
sg28
Nsg29
S'Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| \r'
p4685
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p4686
sa(dp4687
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p4688
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4689
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4690
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4691
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4692
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p4693
sa(dp4694
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p4695
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4696
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4697
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4698
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4699
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ADENOSINE PHOSPHATE'
p4700
sa(dp4701
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p4702
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4703
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4704
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4705
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4706
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Agenerase'
p4707
sa(dp4708
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p4709
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4710
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4711
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4712
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4713
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p4714
sa(dp4715
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00126'
p4716
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4717
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4718
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4719
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4720
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASCORBIC ACID'
p4721
sa(dp4722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p4723
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4725
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4726
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4727
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATORVASTATIN'
p4728
sa(dp4729
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4730
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4731
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4732
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4733
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4734
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atromid-S'
p4735
sa(dp4736
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4737
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4738
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4739
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4740
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4741
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFIBRATE'
p4742
sa(dp4743
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p4744
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4745
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4746
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4747
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4748
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Crixivan'
p4749
sa(dp4750
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4751
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4752
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4753
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4754
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4755
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p4756
sa(dp4757
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p4758
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4759
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4760
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4761
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4762
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dilantin'
p4763
sa(dp4764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p4765
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4767
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4768
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4769
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Felbatol'
p4770
sa(dp4771
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4772
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4773
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4774
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4775
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4776
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fortovase'
p4777
sa(dp4778
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00400'
p4779
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4780
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4781
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4782
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4783
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Gris-PEG'
p4784
sa(dp4785
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p4786
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4787
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4788
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4789
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4790
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Invirase'
p4791
sa(dp4792
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p4793
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4794
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4795
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4796
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4797
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Kadian'
p4798
sa(dp4799
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p4800
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4801
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4802
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4803
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4804
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lipitor'
p4805
sa(dp4806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p4807
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4809
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4810
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4811
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p4812
sa(dp4813
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p4814
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4815
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4816
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4817
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4818
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MS Contin'
p4819
sa(dp4820
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4821
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4822
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4823
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4824
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4825
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Neoral '
p4826
sa(dp4827
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4828
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4829
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4830
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4831
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4832
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nizoral'
p4833
sa(dp4834
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4835
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4836
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4837
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4838
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4839
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Norvir'
p4840
sa(dp4841
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4842
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4843
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4844
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4845
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4846
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p4847
sa(dp4848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p4849
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4851
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4852
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4853
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p4854
sa(dp4855
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p4856
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4857
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4858
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4859
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4860
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PREDNISOLONE'
p4861
sa(dp4862
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p4863
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4864
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4865
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4866
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4867
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Prelone'
p4868
sa(dp4869
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4870
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4871
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4872
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4873
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4874
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifadin'
p4875
sa(dp4876
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4877
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4878
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4879
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4880
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4881
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p4882
sa(dp4883
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4884
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4885
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4886
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4887
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4888
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sandimmune '
p4889
sa(dp4890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p4891
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4893
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4894
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4895
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sporanox'
p4896
sa(dp4897
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p4898
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4899
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4900
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4901
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4902
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TEGretol'
p4903
sa(dp4904
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00759'
p4905
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4906
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4907
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4908
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4909
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TETRACYCLINE'
p4910
sa(dp4911
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4912
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4913
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4914
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4915
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4916
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Theo-Dur'
p4917
sa(dp4918
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4919
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4920
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4921
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4922
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4923
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p4924
sa(dp4925
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00273'
p4926
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4927
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4928
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4929
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4930
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Topamax'
p4931
sa(dp4932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p4933
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4935
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4936
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4937
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Trileptal'
p4938
sa(dp4939
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p4940
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4941
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4942
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4943
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4944
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tylenol'
p4945
sa(dp4946
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4947
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p4948
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4949
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p4950
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p4951
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p4952
sa(dp4953
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4954
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4955
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4956
sg24
Nsg25
Nsg26
S'Evista'
p4957
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4958
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFIBRATE'
p4959
sa(dp4960
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4961
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4962
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4963
sg24
Nsg25
Nsg26
S'Evista'
p4964
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4965
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p4966
sa(dp4967
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01119'
p4968
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4969
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4970
sg24
Nsg25
Nsg26
S'Evista'
p4971
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4972
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZOXIDE'
p4973
sa(dp4974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p4975
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4977
sg24
Nsg25
Nsg26
S'Evista'
p4978
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4979
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p4980
sa(dp4981
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p4982
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p4983
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4984
sg24
Nsg25
Nsg26
S'Evista'
p4985
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p4986
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NAPROXEN'
p4987
sa(dp4988
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p4989
sg5
S'http://bio2rdf.org/drugbank:DB01609'
p4990
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4991
sg24
Nsg25
Nsg26
S'Exjade'
p4992
sg28
Nsg29
S'Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.| \r'
p4993
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p4994
sa(dp4995
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p4996
sg5
S'http://bio2rdf.org/drugbank:DB00973'
p4997
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4998
sg24
Nsg25
Nsg26
S'EZETIMIBE'
p4999
sg28
Nsg29
S'Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. | Patients who take both ezetimibe and cyclosporine should be carefully monitored. | \r'
p5000
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p5001
sa(dp5002
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p5003
sg5
S'http://bio2rdf.org/drugbank:DB00973'
p5004
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5005
sg24
Nsg25
Nsg26
S'EZETIMIBE'
p5006
sg28
Nsg29
S'Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. | Patients who take both ezetimibe and cyclosporine should be carefully monitored. | \r'
p5007
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p5008
sa(dp5009
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06724'
p5010
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5011
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5012
sg24
Nsg25
Nsg26
S'Factive'
p5013
sg28
Nsg29
S'Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| \r'
p5014
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCIUM CARBONATE'
p5015
sa(dp5016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5017
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5019
sg24
Nsg25
Nsg26
S'Factive'
p5020
sg28
Nsg29
S'Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| \r'
p5021
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p5022
sa(dp5023
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p5024
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5025
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5026
sg24
Nsg25
Nsg26
S'Factive'
p5027
sg28
Nsg29
S'Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.| \r'
p5028
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p5029
sa(dp5030
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00396'
p5031
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p5032
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5033
sg24
Nsg25
Nsg26
S'Factive'
p5034
sg28
Nsg29
S'Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| \r'
p5035
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROGESTERONE'
p5036
sa(dp5037
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p5038
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p5039
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5040
sg24
Nsg25
Nsg26
S'FAMOTIDINE'
p5041
sg28
Nsg29
S'H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.| \r'
p5042
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFDITOREN PIVOXIL'
p5043
sa(dp5044
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p5045
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p5046
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5047
sg24
Nsg25
Nsg26
S'FAMOTIDINE'
p5048
sg28
Nsg29
S'H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.| \r'
p5049
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DASATINIB ANHYDROUS'
p5050
sa(dp5051
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p5052
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p5053
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5054
sg24
Nsg25
Nsg26
S'FAMOTIDINE'
p5055
sg28
Nsg29
S'H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.| \r'
p5056
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DASATINIB'
p5057
sa(dp5058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p5059
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5061
sg24
Nsg25
Nsg26
S'FELBAMATE'
p5062
sg28
Nsg29
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p5063
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p5064
sa(dp5065
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06730'
p5066
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5067
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5068
sg24
Nsg25
Nsg26
S'FELBAMATE'
p5069
sg28
Nsg29
S'Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.| \r'
p5070
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GESTODENE'
p5071
sa(dp5072
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5073
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5074
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5075
sg24
Nsg25
Nsg26
S'FELBAMATE'
p5076
sg28
Nsg29
S'Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.| \r'
p5077
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p5078
sa(dp5079
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5080
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5081
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5082
sg24
Nsg25
Nsg26
S'FELBAMATE'
p5083
sg28
Nsg29
S'In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.| Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.| \r'
p5084
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5085
sa(dp5086
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5087
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5088
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5089
sg24
Nsg25
Nsg26
S'FELBAMATE'
p5090
sg28
Nsg29
S'In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.| Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.| \r'
p5091
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5092
sa(dp5093
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p5094
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5095
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5096
sg24
Nsg25
Nsg26
S'FELBAMATE'
p5097
sg28
Nsg29
S'Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.| \r'
p5098
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p5099
sa(dp5100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p5101
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5103
sg24
Nsg25
Nsg26
S'Felbatol'
p5104
sg28
Nsg29
S'Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.| \r'
p5105
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p5106
sa(dp5107
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5108
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5109
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5110
sg24
Nsg25
Nsg26
S'Felbatol'
p5111
sg28
Nsg29
S'Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.| \r'
p5112
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5113
sa(dp5114
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p5115
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p5116
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5117
sg24
Nsg25
Nsg26
S'Felbatol'
p5118
sg28
Nsg29
S'Valproate: Felbatol  causes an increase in steady-state valproate concentrations.| \r'
p5119
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p5120
sa(dp5121
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5122
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p5123
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5124
sg24
Nsg25
Nsg26
S'Feldene'
p5125
sg28
Nsg29
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p5126
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p5127
sa(dp5128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p5129
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p5130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5131
sg24
Nsg25
Nsg26
S'Feldene'
p5132
sg28
Nsg29
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p5133
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p5134
sa(dp5135
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p5136
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p5137
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5138
sg24
Nsg25
Nsg26
S'Feldene'
p5139
sg28
Nsg29
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p5140
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p5141
sa(dp5142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p5143
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p5144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5145
sg24
Nsg25
Nsg26
S'Felodipine'
p5146
sg28
Nsg29
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p5147
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p5148
sa(dp5149
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5150
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p5151
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5152
sg24
Nsg25
Nsg26
S'Felodipine'
p5153
sg28
Nsg29
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p5154
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p5155
sa(dp5156
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5157
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p5158
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5159
sg24
Nsg25
Nsg26
S'Felodipine'
p5160
sg28
Nsg29
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p5161
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5162
sa(dp5163
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p5164
sg5
S'http://bio2rdf.org/drugbank:DB01006'
p5165
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5166
sg24
Nsg25
Nsg26
S'Femara'
p5167
sg28
Nsg29
S'(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.| \r'
p5168
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TAMOXIFEN'
p5169
sa(dp5170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p5171
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5173
sg24
Nsg25
Nsg26
S'FENOFIBRATE'
p5174
sg28
Nsg29
S'Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.| \r'
p5175
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATORVASTATIN'
p5176
sa(dp5177
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00973'
p5178
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5179
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5180
sg24
Nsg25
Nsg26
S'FENOFIBRATE'
p5181
sg28
Nsg29
S'Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | \r'
p5182
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EZETIMIBE'
p5183
sa(dp5184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00175'
p5185
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5187
sg24
Nsg25
Nsg26
S'FENOFIBRATE'
p5188
sg28
Nsg29
S'Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.| \r'
p5189
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAVASTATIN'
p5190
sa(dp5191
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p5192
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5193
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5194
sg24
Nsg25
Nsg26
S'FENOFIBRIC ACID'
p5195
sg28
Nsg29
S'Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.| \r'
p5196
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATORVASTATIN'
p5197
sa(dp5198
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00973'
p5199
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5200
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5201
sg24
Nsg25
Nsg26
S'FENOFIBRIC ACID'
p5202
sg28
Nsg29
S'Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | \r'
p5203
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EZETIMIBE'
p5204
sa(dp5205
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00175'
p5206
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p5207
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5208
sg24
Nsg25
Nsg26
S'FENOFIBRIC ACID'
p5209
sg28
Nsg29
S'Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.| \r'
p5210
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAVASTATIN'
p5211
sa(dp5212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5213
sg5
S'http://bio2rdf.org/drugbank:DB00573'
p5214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5215
sg24
Nsg25
Nsg26
S'Fenoprofen'
p5216
sg28
Nsg29
S'Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.| \r'
p5217
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p5218
sa(dp5219
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5220
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5221
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5222
sg24
Nsg25
Nsg26
S'FENTANYL'
p5223
sg28
Nsg29
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p5224
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p5225
sa(dp5226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p5227
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5229
sg24
Nsg25
Nsg26
S'FENTANYL'
p5230
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5231
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p5232
sa(dp5233
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5234
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5235
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5236
sg24
Nsg25
Nsg26
S'FENTANYL'
p5237
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5238
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5239
sa(dp5240
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p5241
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5242
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5243
sg24
Nsg25
Nsg26
S'FENTANYL'
p5244
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5245
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p5246
sa(dp5247
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p5248
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5249
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5250
sg24
Nsg25
Nsg26
S'FENTANYL'
p5251
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5252
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p5253
sa(dp5254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p5255
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5257
sg24
Nsg25
Nsg26
S'FENTANYL'
p5258
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p5259
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p5260
sa(dp5261
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p5262
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5263
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5264
sg24
Nsg25
Nsg26
S'FENTANYL'
p5265
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p5266
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p5267
sa(dp5268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p5269
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5271
sg24
Nsg25
Nsg26
S'FENTANYL'
p5272
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p5273
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p5274
sa(dp5275
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p5276
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p5277
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5278
sg24
Nsg25
Nsg26
S'FENTANYL'
p5279
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p5280
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p5281
sa(dp5282
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5283
sg5
S'http://bio2rdf.org/drugbank:DB00924'
p5284
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5285
sg24
Nsg25
Nsg26
S'Flexeril'
p5286
sg28
Nsg29
S'FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| \r'
p5287
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p5288
sa(dp5289
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5290
sg5
S'http://bio2rdf.org/drugbank:DB00706'
p5291
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5292
sg24
Nsg25
Nsg26
S'Flomax'
p5293
sg28
Nsg29
S'Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. | \r'
p5294
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p5295
sa(dp5296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p5297
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5299
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5300
sg28
Nsg29
S'Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. | \r'
p5301
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p5302
sa(dp5303
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p5304
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5305
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5306
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5307
sg28
Nsg29
S'Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| \r'
p5308
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CELECOXIB'
p5309
sa(dp5310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5311
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5313
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5314
sg28
Nsg29
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p5315
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5316
sa(dp5317
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5318
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5319
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5320
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5321
sg28
Nsg29
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p5322
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5323
sa(dp5324
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5325
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5326
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5327
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5328
sg28
Nsg29
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p5329
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5330
sa(dp5331
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p5332
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5333
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5334
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5335
sg28
Nsg29
S'While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | \r'
p5336
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p5337
sa(dp5338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p5339
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5341
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5342
sg28
Nsg29
S'The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.| \r'
p5343
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLIPIZIDE'
p5344
sa(dp5345
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00367'
p5346
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5347
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5348
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5349
sg28
Nsg29
S'Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | \r'
p5350
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVONORGESTREL'
p5351
sa(dp5352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00678'
p5353
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5355
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5356
sg28
Nsg29
S'Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.| \r'
p5357
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOSARTAN'
p5358
sa(dp5359
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p5360
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5361
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5362
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5363
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p5364
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p5365
sa(dp5366
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p5367
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5368
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5369
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5370
sg28
Nsg29
S'Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. | \r'
p5371
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p5372
sa(dp5373
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p5374
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5375
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5376
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5377
sg28
Nsg29
S'Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. | \r'
p5378
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS ANHYDROUS'
p5379
sa(dp5380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p5381
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p5382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5383
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p5384
sg28
Nsg29
S'Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. | \r'
p5385
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS'
p5386
sa(dp5387
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00552'
p5388
sg5
S'http://bio2rdf.org/drugbank:DB01073'
p5389
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5390
sg24
Nsg25
Nsg26
S'Fludara'
p5391
sg28
Nsg29
S'The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| \r'
p5392
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTOSTATIN'
p5393
sa(dp5394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p5395
sg5
S'http://bio2rdf.org/drugbank:DB01159'
p5396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5397
sg24
Nsg25
Nsg26
S'Fluothane'
p5398
sg28
Nsg29
S'FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| \r'
p5399
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TUBOCURARINE'
p5400
sa(dp5401
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5402
sg5
S'http://bio2rdf.org/drugbank:DB00875'
p5403
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5404
sg24
Nsg25
Nsg26
S'Flupenthixol'
p5405
sg28
Nsg29
S'Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants| \r'
p5406
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p5407
sa(dp5408
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p5409
sg5
S'http://bio2rdf.org/drugbank:DB00623'
p5410
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5411
sg24
Nsg25
Nsg26
S'FLUPHENAZINE'
p5412
sg28
Nsg29
S'There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.| \r'
p5413
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONIDINE'
p5414
sa(dp5415
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5416
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5417
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5418
sg24
Nsg25
Nsg26
S'Flurbiprofen'
p5419
sg28
Nsg29
S'Concurrent use of flurbiprofen and aspirin is therefore not recommended.| \r'
p5420
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p5421
sa(dp5422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5423
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5425
sg24
Nsg25
Nsg26
S'Flurbiprofen'
p5426
sg28
Nsg29
S'Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.| \r'
p5427
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p5428
sa(dp5429
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p5430
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5431
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5432
sg24
Nsg25
Nsg26
S'Flurbiprofen'
p5433
sg28
Nsg29
S'Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.| Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.| \r'
p5434
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p5435
sa(dp5436
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p5437
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p5438
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5439
sg24
Nsg25
Nsg26
S'Flurbiprofen'
p5440
sg28
Nsg29
S'Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.| Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.| \r'
p5441
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p5442
sa(dp5443
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p5444
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5445
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5446
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5447
sg28
Nsg29
S'Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.| \r'
p5448
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALOSETRON'
p5449
sa(dp5450
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p5451
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5452
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5453
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5454
sg28
Nsg29
S'Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| \r'
p5455
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p5456
sa(dp5457
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p5458
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5459
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5460
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5461
sg28
Nsg29
S'It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.| \r'
p5462
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p5463
sa(dp5464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p5465
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5467
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5468
sg28
Nsg29
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p5469
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p5470
sa(dp5471
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5472
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5473
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5474
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5475
sg28
Nsg29
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p5476
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5477
sa(dp5478
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p5479
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5480
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5481
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5482
sg28
Nsg29
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p5483
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p5484
sa(dp5485
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p5486
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5487
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5488
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5489
sg28
Nsg29
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p5490
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p5491
sa(dp5492
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p5493
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5494
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5495
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5496
sg28
Nsg29
S'Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. | \r'
p5497
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ROPIVACAINE'
p5498
sa(dp5499
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p5500
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5501
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5502
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5503
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p5504
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p5505
sa(dp5506
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p5507
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5508
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5509
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5510
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p5511
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p5512
sa(dp5513
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00857'
p5514
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5515
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5516
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5517
sg28
Nsg29
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p5518
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TERBINAFINE'
p5519
sa(dp5520
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p5521
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5522
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5523
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5524
sg28
Nsg29
S'Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.| RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. | \r'
p5525
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p5526
sa(dp5527
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p5528
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p5529
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5530
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p5531
sg28
Nsg29
S'Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| \r'
p5532
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Xanax'
p5533
sa(dp5534
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5535
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5536
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5537
sg24
Nsg25
Nsg26
S'FOLIC ACID'
p5538
sg28
Nsg29
S'Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| \r'
p5539
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p5540
sa(dp5541
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5542
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5543
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5544
sg24
Nsg25
Nsg26
S'FOLIC ACID'
p5545
sg28
Nsg29
S'Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| \r'
p5546
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5547
sa(dp5548
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p5549
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5550
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5551
sg24
Nsg25
Nsg26
S'FOLIC ACID'
p5552
sg28
Nsg29
S'Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| \r'
p5553
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p5554
sa(dp5555
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00795'
p5556
sg5
S'http://bio2rdf.org/drugbank:DB00158'
p5557
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5558
sg24
Nsg25
Nsg26
S'FOLIC ACID'
p5559
sg28
Nsg29
S'Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | \r'
p5560
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SULFASALAZINE'
p5561
sa(dp5562
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p5563
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5564
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5565
sg24
Nsg25
Nsg26
S'FOSCARNET'
p5566
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p5567
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p5568
sa(dp5569
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p5570
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5571
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5572
sg24
Nsg25
Nsg26
S'FOSCARNET'
p5573
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p5574
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p5575
sa(dp5576
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p5577
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5578
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5579
sg24
Nsg25
Nsg26
S'Foscavir'
p5580
sg28
Nsg29
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| \r'
p5581
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p5582
sa(dp5583
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5584
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5585
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5586
sg24
Nsg25
Nsg26
S'Foscavir'
p5587
sg28
Nsg29
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p5588
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p5589
sa(dp5590
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5591
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5592
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5593
sg24
Nsg25
Nsg26
S'Foscavir'
p5594
sg28
Nsg29
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p5595
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p5596
sa(dp5597
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5598
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p5599
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5600
sg24
Nsg25
Nsg26
S'Foscavir'
p5601
sg28
Nsg29
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p5602
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p5603
sa(dp5604
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5605
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5606
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5607
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5608
sg28
Nsg29
S'Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.| \r'
p5609
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p5610
sa(dp5611
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p5612
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5613
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5614
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5615
sg28
Nsg29
S'Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.| \r'
p5616
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHACRYNIC ACID'
p5617
sa(dp5618
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p5619
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5620
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5621
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5622
sg28
Nsg29
S'In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p5623
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Flolan'
p5624
sa(dp5625
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00524'
p5626
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5627
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5628
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5629
sg28
Nsg29
S'Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. | \r'
p5630
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Metolazone'
p5631
sa(dp5632
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p5633
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5634
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5635
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5636
sg28
Nsg29
S'Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. | \r'
p5637
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mobic'
p5638
sa(dp5639
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p5640
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5641
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5642
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5643
sg28
Nsg29
S'Furosemide may decrease arterial responsiveness to norepinephrine.| \r'
p5644
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NOREPINEPHRINE'
p5645
sa(dp5646
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p5647
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5648
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5649
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5650
sg28
Nsg29
S'Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| \r'
p5651
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p5652
sa(dp5653
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p5654
sg5
S'http://bio2rdf.org/drugbank:DB00695'
p5655
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5656
sg24
Nsg25
Nsg26
S'FUROSEMIDE'
p5657
sg28
Nsg29
S'Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| \r'
p5658
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TUBOCURARINE'
p5659
sa(dp5660
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5661
sg5
S'http://bio2rdf.org/drugbank:DB00996'
p5662
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5663
sg24
Nsg25
Nsg26
S'GABAPENTIN'
p5664
sg28
Nsg29
S'This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.| \r'
p5665
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p5666
sa(dp5667
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p5668
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p5669
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5670
sg24
Nsg25
Nsg26
S'GEMFIBROZIL'
p5671
sg28
Nsg29
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p5672
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p5673
sa(dp5674
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p5675
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p5676
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5677
sg24
Nsg25
Nsg26
S'GEMFIBROZIL'
p5678
sg28
Nsg29
S'Concomitant administration of gemfibrozil with Targretin capsules is not recommended.| \r'
p5679
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Targretin'
p5680
sa(dp5681
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p5682
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5683
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5684
sg24
Nsg25
Nsg26
S'Gleevec'
p5685
sg28
Nsg29
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| \r'
p5686
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p5687
sa(dp5688
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p5689
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5690
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5691
sg24
Nsg25
Nsg26
S'Gleevec'
p5692
sg28
Nsg29
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p5693
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p5694
sa(dp5695
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p5696
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5697
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5698
sg24
Nsg25
Nsg26
S'Gleevec'
p5699
sg28
Nsg29
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| \r'
p5700
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p5701
sa(dp5702
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5703
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5704
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5705
sg24
Nsg25
Nsg26
S'Gleevec'
p5706
sg28
Nsg29
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p5707
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5708
sa(dp5709
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5710
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5711
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5712
sg24
Nsg25
Nsg26
S'Gleevec'
p5713
sg28
Nsg29
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p5714
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5715
sa(dp5716
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p5717
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5718
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5719
sg24
Nsg25
Nsg26
S'Gleevec'
p5720
sg28
Nsg29
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p5721
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PIMOZIDE'
p5722
sa(dp5723
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p5724
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p5725
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5726
sg24
Nsg25
Nsg26
S'Gleevec'
p5727
sg28
Nsg29
S'Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.| \r'
p5728
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SIMVASTATIN'
p5729
sa(dp5730
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p5731
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5732
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5733
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5734
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5735
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p5736
sa(dp5737
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p5738
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5739
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5740
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5741
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5742
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BISMUTH SUBSALICYLATE'
p5743
sa(dp5744
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p5745
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5746
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5747
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5748
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5749
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Disalcid'
p5750
sa(dp5751
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01397'
p5752
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5753
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5754
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5755
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5756
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM SALICYLATE ANHYDROUS'
p5757
sa(dp5758
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01397'
p5759
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5760
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5761
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5762
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5763
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM SALICYLATE'
p5764
sa(dp5765
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p5766
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5767
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5768
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5769
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5770
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pepto-bismol'
p5771
sa(dp5772
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p5773
sg5
S'http://bio2rdf.org/drugbank:DB00222'
p5774
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5775
sg24
Nsg25
Nsg26
S'GLIMEPIRIDE'
p5776
sg28
Nsg29
S'Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| \r'
p5777
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SALSALATE'
p5778
sa(dp5779
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p5780
sg5
S'http://bio2rdf.org/drugbank:DB01067'
p5781
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5782
sg24
Nsg25
Nsg26
S'GLIPIZIDE'
p5783
sg28
Nsg29
S'The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| \r'
p5784
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p5785
sa(dp5786
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p5787
sg5
S'http://bio2rdf.org/drugbank:DB00130'
p5788
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5789
sg24
Nsg25
Nsg26
S'GLUTAMINE'
p5790
sg28
Nsg29
S'Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| \r'
p5791
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p5792
sa(dp5793
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p5794
sg5
S'http://bio2rdf.org/drugbank:DB00130'
p5795
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5796
sg24
Nsg25
Nsg26
S'GLUTAMINE'
p5797
sg28
Nsg29
S'Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.| \r'
p5798
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PACLITAXEL'
p5799
sa(dp5800
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p5801
sg5
S'http://bio2rdf.org/drugbank:DB01016'
p5802
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5803
sg24
Nsg25
Nsg26
S'GLYBURIDE'
p5804
sg28
Nsg29
S'A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.| \r'
p5805
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p5806
sa(dp5807
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p5808
sg5
S'http://bio2rdf.org/drugbank:DB01016'
p5809
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5810
sg24
Nsg25
Nsg26
S'GLYBURIDE'
p5811
sg28
Nsg29
S'Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.| \r'
p5812
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p5813
sa(dp5814
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00855'
p5815
sg5
S'http://bio2rdf.org/drugbank:DB00400'
p5816
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5817
sg24
Nsg25
Nsg26
S'GRISEOFULVIN'
p5818
sg28
Nsg29
S'It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.| \r'
p5819
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levulan Kerastick'
p5820
sa(dp5821
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00350'
p5822
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p5823
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5824
sg24
Nsg25
Nsg26
S'GUANETHIDINE'
p5825
sg28
Nsg29
S'If at all possible guanethidine should be discontinued well before minoxidil is begun. | \r'
p5826
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MINOXIDIL'
p5827
sa(dp5828
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p5829
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p5830
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5831
sg24
Nsg25
Nsg26
S'GUANETHIDINE'
p5832
sg28
Nsg29
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p5833
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zebeta'
p5834
sa(dp5835
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5836
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p5837
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5838
sg24
Nsg25
Nsg26
S'GUANFACINE'
p5839
sg28
Nsg29
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p5840
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p5841
sa(dp5842
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5843
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p5844
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5845
sg24
Nsg25
Nsg26
S'GUANFACINE'
p5846
sg28
Nsg29
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p5847
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5848
sa(dp5849
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5850
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5851
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5852
sg24
Nsg25
Nsg26
S'Haldol'
p5853
sg28
Nsg29
S'As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.| \r'
p5854
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p5855
sa(dp5856
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00988'
p5857
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5858
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5859
sg24
Nsg25
Nsg26
S'HALOPERIDOL'
p5860
sg28
Nsg29
S'Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.| \r'
p5861
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOPAMINE'
p5862
sa(dp5863
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB03575'
p5864
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5865
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5866
sg24
Nsg25
Nsg26
S'HALOPERIDOL'
p5867
sg28
Nsg29
S'Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. | \r'
p5868
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PCP'
p5869
sa(dp5870
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5871
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p5872
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5873
sg24
Nsg25
Nsg26
S'HALOPERIDOL'
p5874
sg28
Nsg29
S'In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.| \r'
p5875
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p5876
sa(dp5877
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p5878
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p5879
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5880
sg24
Nsg25
Nsg26
S'HCTZ'
p5881
sg28
Nsg29
S'In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.| \r'
p5882
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p5883
sa(dp5884
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p5885
sg5
S'http://bio2rdf.org/drugbank:DB00072'
p5886
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5887
sg24
Nsg25
Nsg26
S'Herceptin'
p5888
sg28
Nsg29
S'Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | \r'
p5889
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB DITOSYLATE'
p5890
sa(dp5891
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p5892
sg5
S'http://bio2rdf.org/drugbank:DB00072'
p5893
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5894
sg24
Nsg25
Nsg26
S'Herceptin'
p5895
sg28
Nsg29
S'Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | \r'
p5896
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB'
p5897
sa(dp5898
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p5899
sg5
S'http://bio2rdf.org/drugbank:DB00488'
p5900
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5901
sg24
Nsg25
Nsg26
S'Hexalen'
p5902
sg28
Nsg29
S'Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;| \r'
p5903
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CISPLATIN'
p5904
sa(dp5905
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00603'
p5906
sg5
S'http://bio2rdf.org/drugbank:DB00117'
p5907
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5908
sg24
Nsg25
Nsg26
S'HISTIDINE'
p5909
sg28
Nsg29
S'Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.| \r'
p5910
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEDROXYPROGESTERONE ACETATE'
p5911
sa(dp5912
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p5913
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5914
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5915
sg24
Nsg25
Nsg26
S'HIVID'
p5916
sg28
Nsg29
S'Concomitant use of HIVID with didanosine is not recommended.| \r'
p5917
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p5918
sa(dp5919
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p5920
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p5921
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5922
sg24
Nsg25
Nsg26
S'HYDROCHLOROTHIAZIDE'
p5923
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p5924
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p5925
sa(dp5926
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p5927
sg5
S'http://bio2rdf.org/drugbank:DB00956'
p5928
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5929
sg24
Nsg25
Nsg26
S'HYDROCODONE'
p5930
sg28
Nsg29
S'Hydrocodone increases gabapentin AUC values by 14%.| \r'
p5931
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GABAPENTIN'
p5932
sa(dp5933
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p5934
sg5
S'http://bio2rdf.org/drugbank:DB06720'
p5935
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5936
sg24
Nsg25
Nsg26
S'Imiglucerase'
p5937
sg28
Nsg29
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p5938
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zavesca'
p5939
sa(dp5940
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p5941
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p5942
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5943
sg24
Nsg25
Nsg26
S'IMIPRAMINE'
p5944
sg28
Nsg29
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p5945
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p5946
sa(dp5947
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p5948
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p5949
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5950
sg24
Nsg25
Nsg26
S'IMIPRAMINE'
p5951
sg28
Nsg29
S'The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.| \r'
p5952
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p5953
sa(dp5954
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p5955
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p5956
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5957
sg24
Nsg25
Nsg26
S'IMIPRAMINE'
p5958
sg28
Nsg29
S'The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.| \r'
p5959
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p5960
sa(dp5961
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p5962
sg5
S'http://bio2rdf.org/drugbank:DB01427'
p5963
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5964
sg24
Nsg25
Nsg26
S'INAMRINONE'
p5965
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p5966
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p5967
sa(dp5968
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p5969
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5970
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5971
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p5972
sg28
Nsg29
S'Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| \r'
p5973
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p5974
sa(dp5975
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5976
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5977
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5978
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p5979
sg28
Nsg29
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p5980
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5981
sa(dp5982
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p5983
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5984
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5985
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p5986
sg28
Nsg29
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | \r'
p5987
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p5988
sa(dp5989
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p5990
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5991
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5992
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p5993
sg28
Nsg29
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | \r'
p5994
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p5995
sa(dp5996
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p5997
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p5998
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5999
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6000
sg28
Nsg29
S'Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.| \r'
p6001
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p6002
sa(dp6003
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00351'
p6004
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6005
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6006
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6007
sg28
Nsg29
S'Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. | \r'
p6008
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEGESTROL ACETATE'
p6009
sa(dp6010
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p6011
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6012
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6013
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6014
sg28
Nsg29
S'Indinavir concentrations may be decreased in the presence of nevirapine.| \r'
p6015
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEVIRAPINE'
p6016
sa(dp6017
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p6018
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6019
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6020
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6021
sg28
Nsg29
S'Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| \r'
p6022
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p6023
sa(dp6024
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p6025
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6026
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6027
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6028
sg28
Nsg29
S'When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.| Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.| \r'
p6029
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sustiva'
p6030
sa(dp6031
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p6032
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6033
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6034
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6035
sg28
Nsg29
S'HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.| \r'
p6036
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p6037
sa(dp6038
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6039
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6040
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6041
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6042
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6043
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p6044
sa(dp6045
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6046
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6047
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6048
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6049
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6050
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p6051
sa(dp6052
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p6053
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6054
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6055
sg24
Nsg25
Nsg26
S'INDINAVIR ANHYDROUS'
p6056
sg28
Nsg29
S'Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.| \r'
p6057
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p6058
sa(dp6059
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p6060
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6061
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6062
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6063
sg28
Nsg29
S'Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| \r'
p6064
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p6065
sa(dp6066
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6067
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6068
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6069
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6070
sg28
Nsg29
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p6071
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p6072
sa(dp6073
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6074
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6075
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6076
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6077
sg28
Nsg29
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| \r'
p6078
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p6079
sa(dp6080
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6081
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6082
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6083
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6084
sg28
Nsg29
S'Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| \r'
p6085
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p6086
sa(dp6087
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p6088
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6089
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6090
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6091
sg28
Nsg29
S'Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.| \r'
p6092
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p6093
sa(dp6094
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00351'
p6095
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6096
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6097
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6098
sg28
Nsg29
S'Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. | \r'
p6099
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEGESTROL ACETATE'
p6100
sa(dp6101
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p6102
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6103
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6104
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6105
sg28
Nsg29
S'Indinavir concentrations may be decreased in the presence of nevirapine.| \r'
p6106
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEVIRAPINE'
p6107
sa(dp6108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p6109
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6110
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6111
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6112
sg28
Nsg29
S'Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| \r'
p6113
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p6114
sa(dp6115
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p6116
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6117
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6118
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6119
sg28
Nsg29
S'Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.| When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.| \r'
p6120
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sustiva'
p6121
sa(dp6122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p6123
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6125
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6126
sg28
Nsg29
S'HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.| \r'
p6127
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p6128
sa(dp6129
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6130
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6131
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6132
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6133
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6134
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p6135
sa(dp6136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6137
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6139
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6140
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p6141
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p6142
sa(dp6143
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p6144
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p6145
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6146
sg24
Nsg25
Nsg26
S'INDINAVIR'
p6147
sg28
Nsg29
S'Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.| \r'
p6148
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p6149
sa(dp6150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p6151
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6152
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6153
sg24
Nsg25
Nsg26
S'Indocin'
p6154
sg28
Nsg29
S'INDOCIN can reduce the antihypertensive effects of captopril and losartan.| \r'
p6155
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAPTOPRIL'
p6156
sa(dp6157
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p6158
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6159
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6160
sg24
Nsg25
Nsg26
S'Indocin'
p6161
sg28
Nsg29
S'In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.| \r'
p6162
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIFLUNISAL'
p6163
sa(dp6164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6165
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6167
sg24
Nsg25
Nsg26
S'Indocin'
p6168
sg28
Nsg29
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p6169
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p6170
sa(dp6171
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6172
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6173
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6174
sg24
Nsg25
Nsg26
S'Indocin'
p6175
sg28
Nsg29
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p6176
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p6177
sa(dp6178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6179
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6181
sg24
Nsg25
Nsg26
S'Indocin'
p6182
sg28
Nsg29
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6183
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p6184
sa(dp6185
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6186
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6187
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6188
sg24
Nsg25
Nsg26
S'Indocin'
p6189
sg28
Nsg29
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6190
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p6191
sa(dp6192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6193
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6194
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6195
sg24
Nsg25
Nsg26
S'Indocin'
p6196
sg28
Nsg29
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6197
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p6198
sa(dp6199
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6200
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6201
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6202
sg24
Nsg25
Nsg26
S'Indocin'
p6203
sg28
Nsg29
S'As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| \r'
p6204
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p6205
sa(dp6206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00678'
p6207
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6209
sg24
Nsg25
Nsg26
S'Indocin'
p6210
sg28
Nsg29
S'INDOCIN can reduce the antihypertensive effects of captopril and losartan.| \r'
p6211
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOSARTAN'
p6212
sa(dp6213
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p6214
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6215
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6216
sg24
Nsg25
Nsg26
S'Indocin'
p6217
sg28
Nsg29
S'INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.| Caution should be used if INDOCIN is administered simultaneously with methotrexate.| \r'
p6218
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p6219
sa(dp6220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p6221
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6223
sg24
Nsg25
Nsg26
S'Indocin'
p6224
sg28
Nsg29
S'INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.| Caution should be used if INDOCIN is administered simultaneously with methotrexate.| \r'
p6225
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p6226
sa(dp6227
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p6228
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6229
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6230
sg24
Nsg25
Nsg26
S'Indocin'
p6231
sg28
Nsg29
S'When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.| \r'
p6232
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p6233
sa(dp6234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p6235
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6236
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6237
sg24
Nsg25
Nsg26
S'Indocin'
p6238
sg28
Nsg29
S'INDOCIN and triamterene should not be administered together.| \r'
p6239
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAMTERENE'
p6240
sa(dp6241
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p6242
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6243
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6244
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6245
sg28
Nsg29
S'- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| - Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| \r'
p6246
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p6247
sa(dp6248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p6249
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6251
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6252
sg28
Nsg29
S'- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| - Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| \r'
p6253
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p6254
sa(dp6255
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p6256
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6257
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6258
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6259
sg28
Nsg29
S'Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.| \r'
p6260
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAPTOPRIL'
p6261
sa(dp6262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p6263
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6265
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6266
sg28
Nsg29
S'In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| \r'
p6267
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIFLUNISAL'
p6268
sa(dp6269
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p6270
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6271
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6272
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6273
sg28
Nsg29
S'In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| \r'
p6274
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIFLUNISAL'
p6275
sa(dp6276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6277
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6278
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6279
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6280
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p6281
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p6282
sa(dp6283
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p6284
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6285
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6286
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6287
sg28
Nsg29
S'Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| \r'
p6288
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p6289
sa(dp6290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p6291
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6293
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6294
sg28
Nsg29
S'Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| \r'
p6295
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p6296
sa(dp6297
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00594'
p6298
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6299
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6300
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6301
sg28
Nsg29
S'Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.| \r'
p6302
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Midamor'
p6303
sa(dp6304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p6305
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6307
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6308
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p6309
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p6310
sa(dp6311
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p6312
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p6313
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6314
sg24
Nsg25
Nsg26
S'INDOMETHACIN'
p6315
sg28
Nsg29
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p6316
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Proleukin'
p6317
sa(dp6318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6319
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6320
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6321
sg24
Nsg25
Nsg26
S'INH'
p6322
sg28
Nsg29
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p6323
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p6324
sa(dp6325
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00584'
p6326
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6327
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6328
sg24
Nsg25
Nsg26
S'INSPRA'
p6329
sg28
Nsg29
S'In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.| \r'
p6330
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENALAPRIL'
p6331
sa(dp6332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6333
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6335
sg24
Nsg25
Nsg26
S'INSPRA'
p6336
sg28
Nsg29
S'A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.| \r'
p6337
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p6338
sa(dp6339
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6340
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6341
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6342
sg24
Nsg25
Nsg26
S'INSPRA'
p6343
sg28
Nsg29
S'Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.| \r'
p6344
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p6345
sa(dp6346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6347
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p6348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6349
sg24
Nsg25
Nsg26
S'INSPRA'
p6350
sg28
Nsg29
S'Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.| \r'
p6351
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p6352
sa(dp6353
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6354
sg5
S'http://bio2rdf.org/drugbank:DB01267'
p6355
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6356
sg24
Nsg25
Nsg26
S'Invega'
p6357
sg28
Nsg29
S'Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. | \r'
p6358
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p6359
sa(dp6360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p6361
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p6362
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6363
sg24
Nsg25
Nsg26
S'Invirase'
p6364
sg28
Nsg29
S'Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| \r'
p6365
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p6366
sa(dp6367
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00389'
p6368
sg5
S'http://bio2rdf.org/drugbank:DB05382'
p6369
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6370
sg24
Nsg25
Nsg26
S'IODINE'
p6371
sg28
Nsg29
S'Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.| \r'
p6372
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBIMAZOLE'
p6373
sa(dp6374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6375
sg5
S'http://bio2rdf.org/drugbank:DB00964'
p6376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6377
sg24
Nsg25
Nsg26
S'Iopidine'
p6378
sg28
Nsg29
S'Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.| \r'
p6379
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p6380
sa(dp6381
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p6382
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p6383
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6384
sg24
Nsg25
Nsg26
S'IRBESARTAN'
p6385
sg28
Nsg29
S'Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| \r'
p6386
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALISKIREN'
p6387
sa(dp6388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00361'
p6389
sg5
S'http://bio2rdf.org/drugbank:DB00317'
p6390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6391
sg24
Nsg25
Nsg26
S'Iressa'
p6392
sg28
Nsg29
S'Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.| \r'
p6393
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VINORELBINE'
p6394
sa(dp6395
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00190'
p6396
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6397
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6398
sg24
Nsg25
Nsg26
S'IRON'
p6399
sg28
Nsg29
S'Iron salts may reduce the bioavailability of carbidopa and levodopa.| \r'
p6400
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBIDOPA'
p6401
sa(dp6402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p6403
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6404
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6405
sg24
Nsg25
Nsg26
S'IRON'
p6406
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p6407
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p6408
sa(dp6409
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p6410
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6411
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6412
sg24
Nsg25
Nsg26
S'IRON'
p6413
sg28
Nsg29
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p6414
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IBANDRONIC ACID'
p6415
sa(dp6416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p6417
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6419
sg24
Nsg25
Nsg26
S'IRON'
p6420
sg28
Nsg29
S'Iron salts may reduce the bioavailability of carbidopa and levodopa.| \r'
p6421
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVODOPA'
p6422
sa(dp6423
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p6424
sg5
S'http://bio2rdf.org/drugbank:DB01592'
p6425
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6426
sg24
Nsg25
Nsg26
S'IRON'
p6427
sg28
Nsg29
S'Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p6428
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p6429
sa(dp6430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p6431
sg5
S'http://bio2rdf.org/drugbank:DB01247'
p6432
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6433
sg24
Nsg25
Nsg26
S'ISOCARBOXAZID'
p6434
sg28
Nsg29
S'Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| \r'
p6435
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Antabuse'
p6436
sa(dp6437
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p6438
sg5
S'http://bio2rdf.org/drugbank:DB01247'
p6439
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6440
sg24
Nsg25
Nsg26
S'ISOCARBOXAZID'
p6441
sg28
Nsg29
S'Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| \r'
p6442
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DISULFIRAM'
p6443
sa(dp6444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p6445
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p6446
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6447
sg24
Nsg25
Nsg26
S'Isoflurane'
p6448
sg28
Nsg29
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p6449
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p6450
sa(dp6451
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p6452
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p6453
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6454
sg24
Nsg25
Nsg26
S'Isoflurane'
p6455
sg28
Nsg29
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p6456
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p6457
sa(dp6458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01135'
p6459
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p6460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6461
sg24
Nsg25
Nsg26
S'Isoflurane'
p6462
sg28
Nsg29
S'Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.| \r'
p6463
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nuromax'
p6464
sa(dp6465
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p6466
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6467
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6468
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6469
sg28
Nsg29
S'It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| \r'
p6470
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p6471
sa(dp6472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p6473
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6474
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6475
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6476
sg28
Nsg29
S'It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| \r'
p6477
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p6478
sa(dp6479
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p6480
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6481
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6482
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6483
sg28
Nsg29
S'Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| \r'
p6484
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p6485
sa(dp6486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p6487
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6488
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6489
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6490
sg28
Nsg29
S'Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;| \r'
p6491
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DISULFIRAM'
p6492
sa(dp6493
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6494
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6495
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6496
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6497
sg28
Nsg29
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p6498
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p6499
sa(dp6500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p6501
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6503
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6504
sg28
Nsg29
S'Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| \r'
p6505
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVODOPA'
p6506
sa(dp6507
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6508
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6509
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6510
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6511
sg28
Nsg29
S'Phenytoin: Isoniazid may increase serum levels of phenytoin.| \r'
p6512
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p6513
sa(dp6514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p6515
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6516
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6517
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6518
sg28
Nsg29
S'Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.| \r'
p6519
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p6520
sa(dp6521
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p6522
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p6523
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6524
sg24
Nsg25
Nsg26
S'ISONIAZID'
p6525
sg28
Nsg29
S'Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| \r'
p6526
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p6527
sa(dp6528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6529
sg5
S'http://bio2rdf.org/drugbank:DB01612'
p6530
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6531
sg24
Nsg25
Nsg26
S'ISOPENTYL NITRITE'
p6532
sg28
Nsg29
S'Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.| \r'
p6533
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p6534
sa(dp6535
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p6536
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p6537
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6538
sg24
Nsg25
Nsg26
S'Isopto Carbachol'
p6539
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p6540
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p6541
sa(dp6542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6543
sg5
S'http://bio2rdf.org/drugbank:DB01575'
p6544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6545
sg24
Nsg25
Nsg26
S'KAOLIN'
p6546
sg28
Nsg29
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p6547
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p6548
sa(dp6549
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p6550
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6551
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6552
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6553
sg28
Nsg29
S'Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| \r'
p6554
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALISKIREN'
p6555
sa(dp6556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p6557
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6558
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6559
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6560
sg28
Nsg29
S'Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.| \r'
p6561
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALOSETRON'
p6562
sa(dp6563
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p6564
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6565
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6566
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6567
sg28
Nsg29
S'When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p6568
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p6569
sa(dp6570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p6571
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6572
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6573
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6574
sg28
Nsg29
S'When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p6575
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p6576
sa(dp6577
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p6578
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6579
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6580
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6581
sg28
Nsg29
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p6582
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p6583
sa(dp6584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p6585
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6587
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6588
sg28
Nsg29
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p6589
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p6590
sa(dp6591
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p6592
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6593
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6594
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6595
sg28
Nsg29
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p6596
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p6597
sa(dp6598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01410'
p6599
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6600
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6601
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6602
sg28
Nsg29
S'Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.| \r'
p6603
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CICLESONIDE'
p6604
sa(dp6605
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01012'
p6606
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6607
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6608
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6609
sg28
Nsg29
S'Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| \r'
p6610
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CINACALCET'
p6611
sa(dp6612
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6613
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6614
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6615
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6616
sg28
Nsg29
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| \r'
p6617
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p6618
sa(dp6619
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6620
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6621
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6622
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6623
sg28
Nsg29
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| \r'
p6624
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p6625
sa(dp6626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p6627
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6629
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6630
sg28
Nsg29
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| \r'
p6631
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p6632
sa(dp6633
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p6634
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6635
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6636
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6637
sg28
Nsg29
S'When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.| \r'
p6638
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'COUMARIN'
p6639
sa(dp6640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p6641
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6642
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6643
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6644
sg28
Nsg29
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p6645
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p6646
sa(dp6647
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00530'
p6648
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6649
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6650
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6651
sg28
Nsg29
S'Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.| \r'
p6652
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERLOTINIB'
p6653
sa(dp6654
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00317'
p6655
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6656
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6657
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6658
sg28
Nsg29
S'Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.| \r'
p6659
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GEFITINIB'
p6660
sa(dp6661
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p6662
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6663
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p6664
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6665
sg28
Nsg29
S'Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| \r'
p6666
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p6667
sa(dp6668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p6669
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6671
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6672
sg28
Nsg29
S'Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| \r'
p6673
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB DITOSYLATE'
p6674
sa(dp6675
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p6676
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6677
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6678
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6679
sg28
Nsg29
S'Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| \r'
p6680
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB'
p6681
sa(dp6682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p6683
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6684
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6685
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6686
sg28
Nsg29
S'After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.| \r'
p6687
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LORATADINE'
p6688
sa(dp6689
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p6690
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6691
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6692
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6693
sg28
Nsg29
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | \r'
p6694
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p6695
sa(dp6696
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p6697
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6698
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6699
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6700
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p6701
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p6702
sa(dp6703
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p6704
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6705
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6706
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6707
sg28
Nsg29
S'Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | \r'
p6708
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p6709
sa(dp6710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00764'
p6711
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6713
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6714
sg28
Nsg29
S'However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.| \r'
p6715
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MOMETASONE FUROATE'
p6716
sa(dp6717
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00910'
p6718
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6719
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6720
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6721
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p6722
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PARICALCITOL'
p6723
sa(dp6724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6725
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6726
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6727
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6728
sg28
Nsg29
S'It is suggested to monitor both ketoconazole and phenytoin.| Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| \r'
p6729
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p6730
sa(dp6731
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6732
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6733
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6734
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6735
sg28
Nsg29
S'It is suggested to monitor both ketoconazole and phenytoin.| Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| \r'
p6736
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p6737
sa(dp6738
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01256'
p6739
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6740
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6741
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6742
sg28
Nsg29
S'Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. | \r'
p6743
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RETAPAMULIN'
p6744
sa(dp6745
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p6746
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6747
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6748
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6749
sg28
Nsg29
S'Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.| \r'
p6750
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ROPIVACAINE'
p6751
sa(dp6752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p6753
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6755
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6756
sg28
Nsg29
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p6757
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS ANHYDROUS'
p6758
sa(dp6759
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00864'
p6760
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6761
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6762
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6763
sg28
Nsg29
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p6764
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TACROLIMUS'
p6765
sa(dp6766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p6767
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6768
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6769
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6770
sg28
Nsg29
S'Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| \r'
p6771
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p6772
sa(dp6773
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01036'
p6774
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6775
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6776
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6777
sg28
Nsg29
S'CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). | \r'
p6778
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLTERODINE'
p6779
sa(dp6780
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p6781
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6782
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6783
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6784
sg28
Nsg29
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p6785
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIMETREXATE'
p6786
sa(dp6787
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p6788
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6789
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6790
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6791
sg28
Nsg29
S'Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.| \r'
p6792
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p6793
sa(dp6794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p6795
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6797
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6798
sg28
Nsg29
S'Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.| \r'
p6799
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p6800
sa(dp6801
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p6802
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6803
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6804
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6805
sg28
Nsg29
S'Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.| \r'
p6806
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p6807
sa(dp6808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p6809
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p6810
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6811
sg24
Nsg25
Nsg26
S'Ketoconazole'
p6812
sg28
Nsg29
S'Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| \r'
p6813
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALEPLON'
p6814
sa(dp6815
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p6816
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p6817
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6818
sg24
Nsg25
Nsg26
S'LAMIVUDINE'
p6819
sg28
Nsg29
S'Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| \r'
p6820
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p6821
sa(dp6822
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p6823
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p6824
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6825
sg24
Nsg25
Nsg26
S'LAMIVUDINE'
p6826
sg28
Nsg29
S'Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| \r'
p6827
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p6828
sa(dp6829
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p6830
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6831
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6832
sg24
Nsg25
Nsg26
S'Lansoprazole'
p6833
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6834
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ADENOSINE PHOSPHATE'
p6835
sa(dp6836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p6837
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6839
sg24
Nsg25
Nsg26
S'Lansoprazole'
p6840
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6841
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p6842
sa(dp6843
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p6844
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6845
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6846
sg24
Nsg25
Nsg26
S'Lansoprazole'
p6847
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6848
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p6849
sa(dp6850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p6851
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6852
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6853
sg24
Nsg25
Nsg26
S'Lansoprazole'
p6854
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6855
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRON'
p6856
sa(dp6857
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6858
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6859
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6860
sg24
Nsg25
Nsg26
S'Lansoprazole'
p6861
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p6862
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p6863
sa(dp6864
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p6865
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p6866
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6867
sg24
Nsg25
Nsg26
S'Lansoprazole'
p6868
sg28
Nsg29
S'When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.| \r'
p6869
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p6870
sa(dp6871
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p6872
sg5
S'http://bio2rdf.org/drugbank:DB01259'
p6873
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6874
sg24
Nsg25
Nsg26
S'LAPATINIB DITOSYLATE'
p6875
sg28
Nsg29
S'In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| \r'
p6876
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Herceptin'
p6877
sa(dp6878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p6879
sg5
S'http://bio2rdf.org/drugbank:DB01259'
p6880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6881
sg24
Nsg25
Nsg26
S'LAPATINIB'
p6882
sg28
Nsg29
S'In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| \r'
p6883
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Herceptin'
p6884
sa(dp6885
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6886
sg5
S'http://bio2rdf.org/drugbank:DB00020'
p6887
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6888
sg24
Nsg25
Nsg26
S'Leukine'
p6889
sg28
Nsg29
S'Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.| \r'
p6890
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p6891
sa(dp6892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6893
sg5
S'http://bio2rdf.org/drugbank:DB00020'
p6894
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6895
sg24
Nsg25
Nsg26
S'Leukine'
p6896
sg28
Nsg29
S'Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.| \r'
p6897
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p6898
sa(dp6899
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p6900
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6901
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6902
sg24
Nsg25
Nsg26
S'LEVOBUPIVACAINE'
p6903
sg28
Nsg29
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6904
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p6905
sa(dp6906
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p6907
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6908
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6909
sg24
Nsg25
Nsg26
S'LEVOBUPIVACAINE'
p6910
sg28
Nsg29
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6911
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p6912
sa(dp6913
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6914
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6915
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6916
sg24
Nsg25
Nsg26
S'LEVOBUPIVACAINE'
p6917
sg28
Nsg29
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6918
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p6919
sa(dp6920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p6921
sg5
S'http://bio2rdf.org/drugbank:DB01002'
p6922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6923
sg24
Nsg25
Nsg26
S'LEVOBUPIVACAINE'
p6924
sg28
Nsg29
S'Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| \r'
p6925
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p6926
sa(dp6927
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01113'
p6928
sg5
S'http://bio2rdf.org/drugbank:DB01235'
p6929
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6930
sg24
Nsg25
Nsg26
S'LEVODOPA'
p6931
sg28
Nsg29
S'In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| \r'
p6932
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAPAVERINE'
p6933
sa(dp6934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p6935
sg5
S'http://bio2rdf.org/drugbank:DB01235'
p6936
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6937
sg24
Nsg25
Nsg26
S'LEVODOPA'
p6938
sg28
Nsg29
S'In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| \r'
p6939
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p6940
sa(dp6941
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p6942
sg5
S'http://bio2rdf.org/drugbank:DB00854'
p6943
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6944
sg24
Nsg25
Nsg26
S'Levo-Dromoran'
p6945
sg28
Nsg29
S'Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| \r'
p6946
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p6947
sa(dp6948
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p6949
sg5
S'http://bio2rdf.org/drugbank:DB00451'
p6950
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6951
sg24
Nsg25
Nsg26
S'LEVOTHYROXINE'
p6952
sg28
Nsg29
S'In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.| \r'
p6953
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Estrogens'
p6954
sa(dp6955
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00915'
p6956
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p6957
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6958
sg24
Nsg25
Nsg26
S'Levsin'
p6959
sg28
Nsg29
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p6960
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMANTADINE'
p6961
sa(dp6962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p6963
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p6964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6965
sg24
Nsg25
Nsg26
S'Levsin'
p6966
sg28
Nsg29
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p6967
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p6968
sa(dp6969
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6970
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p6971
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6972
sg24
Nsg25
Nsg26
S'Lexapro'
p6973
sg28
Nsg29
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p6974
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p6975
sa(dp6976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p6977
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p6978
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p6979
sg24
Nsg25
Nsg26
S'Lexapro'
p6980
sg28
Nsg29
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p6981
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p6982
sa(dp6983
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p6984
sg5
S'http://bio2rdf.org/drugbank:DB01627'
p6985
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p6986
sg24
Nsg25
Nsg26
S'LINCOMYCIN'
p6987
sg28
Nsg29
S'Antagonism between lincomycin and erythromycin in vitro has been demonstrated.| \r'
p6988
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p6989
sa(dp6990
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00796'
p6991
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p6992
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p6993
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p6994
sg28
Nsg29
S'An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.| \r'
p6995
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atacand'
p6996
sa(dp6997
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p6998
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p6999
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7000
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7001
sg28
Nsg29
S'- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| \r'
p7002
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p7003
sa(dp7004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7005
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7007
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7008
sg28
Nsg29
S'Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| \r'
p7009
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celebrex'
p7010
sa(dp7011
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7012
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7013
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7014
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7015
sg28
Nsg29
S'Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| \r'
p7016
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celebrex'
p7017
sa(dp7018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00880'
p7019
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7020
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7021
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7022
sg28
Nsg29
S'Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide| \r'
p7023
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLOROTHIAZIDE'
p7024
sa(dp7025
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7026
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7027
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7028
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7029
sg28
Nsg29
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7030
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM OXALATE'
p7031
sa(dp7032
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7033
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7034
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7035
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7036
sg28
Nsg29
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7037
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM'
p7038
sa(dp7039
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00554'
p7040
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7041
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7042
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7043
sg28
Nsg29
S'It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.| \r'
p7044
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Feldene'
p7045
sa(dp7046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p7047
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7049
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7050
sg28
Nsg29
S'An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| \r'
p7051
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Haldol'
p7052
sa(dp7053
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p7054
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7055
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7056
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7057
sg28
Nsg29
S'Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.| \r'
p7058
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCHLOROTHIAZIDE'
p7059
sa(dp7060
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7061
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7062
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7063
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7064
sg28
Nsg29
S'In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. | \r'
p7065
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MELOXICAM'
p7066
sa(dp7067
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7068
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7069
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7070
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7071
sg28
Nsg29
S'Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. | \r'
p7072
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mobic'
p7073
sa(dp7074
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00019'
p7075
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7076
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7077
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7078
sg28
Nsg29
S'patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.| \r'
p7079
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Neulasta'
p7080
sa(dp7081
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00465'
p7082
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7083
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7084
sg24
Nsg25
Nsg26
S'LITHIUM CATION'
p7085
sg28
Nsg29
S'The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.| \r'
p7086
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Toradol'
p7087
sa(dp7088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00796'
p7089
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7091
sg24
Nsg25
Nsg26
S'LITHIUM'
p7092
sg28
Nsg29
S'An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.| \r'
p7093
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atacand'
p7094
sa(dp7095
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p7096
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7097
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7098
sg24
Nsg25
Nsg26
S'LITHIUM'
p7099
sg28
Nsg29
S'- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| \r'
p7100
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p7101
sa(dp7102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7103
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7105
sg24
Nsg25
Nsg26
S'LITHIUM'
p7106
sg28
Nsg29
S'Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| \r'
p7107
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celebrex'
p7108
sa(dp7109
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p7110
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7111
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7112
sg24
Nsg25
Nsg26
S'LITHIUM'
p7113
sg28
Nsg29
S'Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| \r'
p7114
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celebrex'
p7115
sa(dp7116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00880'
p7117
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7119
sg24
Nsg25
Nsg26
S'LITHIUM'
p7120
sg28
Nsg29
S'Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide| \r'
p7121
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLOROTHIAZIDE'
p7122
sa(dp7123
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7124
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7125
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7126
sg24
Nsg25
Nsg26
S'LITHIUM'
p7127
sg28
Nsg29
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7128
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM OXALATE'
p7129
sa(dp7130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p7131
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7133
sg24
Nsg25
Nsg26
S'LITHIUM'
p7134
sg28
Nsg29
S'Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| \r'
p7135
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM'
p7136
sa(dp7137
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00554'
p7138
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7139
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7140
sg24
Nsg25
Nsg26
S'LITHIUM'
p7141
sg28
Nsg29
S'It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.| \r'
p7142
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Feldene'
p7143
sa(dp7144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p7145
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7147
sg24
Nsg25
Nsg26
S'LITHIUM'
p7148
sg28
Nsg29
S'An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| \r'
p7149
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Haldol'
p7150
sa(dp7151
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00999'
p7152
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7153
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7154
sg24
Nsg25
Nsg26
S'LITHIUM'
p7155
sg28
Nsg29
S'Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.| \r'
p7156
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCHLOROTHIAZIDE'
p7157
sa(dp7158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7159
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7161
sg24
Nsg25
Nsg26
S'LITHIUM'
p7162
sg28
Nsg29
S'In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. | \r'
p7163
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MELOXICAM'
p7164
sa(dp7165
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p7166
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7167
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7168
sg24
Nsg25
Nsg26
S'LITHIUM'
p7169
sg28
Nsg29
S'Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. | \r'
p7170
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mobic'
p7171
sa(dp7172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00019'
p7173
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7175
sg24
Nsg25
Nsg26
S'LITHIUM'
p7176
sg28
Nsg29
S'patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.| \r'
p7177
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Neulasta'
p7178
sa(dp7179
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00465'
p7180
sg5
S'http://bio2rdf.org/drugbank:DB01356'
p7181
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7182
sg24
Nsg25
Nsg26
S'LITHIUM'
p7183
sg28
Nsg29
S'The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.| \r'
p7184
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Toradol'
p7185
sa(dp7186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7187
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7189
sg24
Nsg25
Nsg26
S'Lodine'
p7190
sg28
Nsg29
S'Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p7191
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p7192
sa(dp7193
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7194
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7195
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7196
sg24
Nsg25
Nsg26
S'Lodine'
p7197
sg28
Nsg29
S'Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p7198
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p7199
sa(dp7200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p7201
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7203
sg24
Nsg25
Nsg26
S'Lodine'
p7204
sg28
Nsg29
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p7205
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p7206
sa(dp7207
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p7208
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7209
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7210
sg24
Nsg25
Nsg26
S'Lodine'
p7211
sg28
Nsg29
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p7212
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p7213
sa(dp7214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p7215
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7217
sg24
Nsg25
Nsg26
S'Lodine'
p7218
sg28
Nsg29
S'Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.| \r'
p7219
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p7220
sa(dp7221
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p7222
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p7223
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7224
sg24
Nsg25
Nsg26
S'Lodine'
p7225
sg28
Nsg29
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p7226
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p7227
sa(dp7228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p7229
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p7230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7231
sg24
Nsg25
Nsg26
S'LOPINAVIR'
p7232
sg28
Nsg29
S'A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.| \r'
p7233
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEVIRAPINE'
p7234
sa(dp7235
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p7236
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p7237
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7238
sg24
Nsg25
Nsg26
S'LOPINAVIR'
p7239
sg28
Nsg29
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p7240
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sustiva'
p7241
sa(dp7242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p7243
sg5
S'http://bio2rdf.org/drugbank:DB00447'
p7244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7245
sg24
Nsg25
Nsg26
S'LORACARBEF ANHYDROUS'
p7246
sg28
Nsg29
S'Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| \r'
p7247
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p7248
sa(dp7249
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p7250
sg5
S'http://bio2rdf.org/drugbank:DB00447'
p7251
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7252
sg24
Nsg25
Nsg26
S'LORACARBEF'
p7253
sg28
Nsg29
S'Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| \r'
p7254
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p7255
sa(dp7256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p7257
sg5
S'http://bio2rdf.org/drugbank:DB00678'
p7258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7259
sg24
Nsg25
Nsg26
S'LOSARTAN'
p7260
sg28
Nsg29
S'As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin| \r'
p7261
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p7262
sa(dp7263
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p7264
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p7265
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7266
sg24
Nsg25
Nsg26
S'LOVASTATIN'
p7267
sg28
Nsg29
S'Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;| \r'
p7268
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p7269
sa(dp7270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01592'
p7271
sg5
S'http://bio2rdf.org/drugbank:DB00256'
p7272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7273
sg24
Nsg25
Nsg26
S'LYMECYCLINE'
p7274
sg28
Nsg29
S'The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.| \r'
p7275
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRON'
p7276
sa(dp7277
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01593'
p7278
sg5
S'http://bio2rdf.org/drugbank:DB00256'
p7279
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7280
sg24
Nsg25
Nsg26
S'LYMECYCLINE'
p7281
sg28
Nsg29
S'The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.| \r'
p7282
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZINC'
p7283
sa(dp7284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p7285
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7287
sg24
Nsg25
Nsg26
S'MAGNESIUM CATION'
p7288
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p7289
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p7290
sa(dp7291
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p7292
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7293
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7294
sg24
Nsg25
Nsg26
S'MAGNESIUM CATION'
p7295
sg28
Nsg29
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p7296
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IBANDRONIC ACID'
p7297
sa(dp7298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p7299
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7301
sg24
Nsg25
Nsg26
S'MAGNESIUM CATION'
p7302
sg28
Nsg29
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p7303
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Skelid'
p7304
sa(dp7305
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p7306
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7307
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7308
sg24
Nsg25
Nsg26
S'MAGNESIUM CATION'
p7309
sg28
Nsg29
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p7310
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p7311
sa(dp7312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p7313
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7315
sg24
Nsg25
Nsg26
S'MAGNESIUM'
p7316
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p7317
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p7318
sa(dp7319
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00710'
p7320
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7321
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7322
sg24
Nsg25
Nsg26
S'MAGNESIUM'
p7323
sg28
Nsg29
S'Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| \r'
p7324
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IBANDRONIC ACID'
p7325
sa(dp7326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p7327
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7329
sg24
Nsg25
Nsg26
S'MAGNESIUM'
p7330
sg28
Nsg29
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p7331
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Skelid'
p7332
sa(dp7333
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p7334
sg5
S'http://bio2rdf.org/drugbank:DB01378'
p7335
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7336
sg24
Nsg25
Nsg26
S'MAGNESIUM'
p7337
sg28
Nsg29
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p7338
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p7339
sa(dp7340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p7341
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7343
sg24
Nsg25
Nsg26
S'Mazindol'
p7344
sg28
Nsg29
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p7345
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p7346
sa(dp7347
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p7348
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7349
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7350
sg24
Nsg25
Nsg26
S'Mazindol'
p7351
sg28
Nsg29
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p7352
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ismelin'
p7353
sa(dp7354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p7355
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7357
sg24
Nsg25
Nsg26
S'Mazindol'
p7358
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7359
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISOCARBOXAZID'
p7360
sa(dp7361
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p7362
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7363
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7364
sg24
Nsg25
Nsg26
S'Mazindol'
p7365
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7366
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Marplan'
p7367
sa(dp7368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p7369
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7371
sg24
Nsg25
Nsg26
S'Mazindol'
p7372
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7373
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nardil'
p7374
sa(dp7375
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p7376
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7377
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7378
sg24
Nsg25
Nsg26
S'Mazindol'
p7379
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7380
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Parnate'
p7381
sa(dp7382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p7383
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7385
sg24
Nsg25
Nsg26
S'Mazindol'
p7386
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7387
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENELZINE'
p7388
sa(dp7389
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p7390
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p7391
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7392
sg24
Nsg25
Nsg26
S'Mazindol'
p7393
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p7394
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tranylcypromine'
p7395
sa(dp7396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p7397
sg5
S'http://bio2rdf.org/drugbank:DB00351'
p7398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7399
sg24
Nsg25
Nsg26
S'MEGESTROL ACETATE'
p7400
sg28
Nsg29
S'A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. | \r'
p7401
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p7402
sa(dp7403
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p7404
sg5
S'http://bio2rdf.org/drugbank:DB00351'
p7405
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7406
sg24
Nsg25
Nsg26
S'MEGESTROL ACETATE'
p7407
sg28
Nsg29
S'A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. | \r'
p7408
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p7409
sa(dp7410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7411
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p7412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7413
sg24
Nsg25
Nsg26
S'MELATONIN'
p7414
sg28
Nsg29
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p7415
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p7416
sa(dp7417
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p7418
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p7419
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7420
sg24
Nsg25
Nsg26
S'MELATONIN'
p7421
sg28
Nsg29
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p7422
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p7423
sa(dp7424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7425
sg5
S'http://bio2rdf.org/drugbank:DB00814'
p7426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7427
sg24
Nsg25
Nsg26
S'MELOXICAM'
p7428
sg28
Nsg29
S'however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. | \r'
p7429
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p7430
sa(dp7431
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7432
sg5
S'http://bio2rdf.org/drugbank:DB00454'
p7433
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7434
sg24
Nsg25
Nsg26
S'MEPERIDINE'
p7435
sg28
Nsg29
S'Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). | \r'
p7436
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p7437
sa(dp7438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00352'
p7439
sg5
S'http://bio2rdf.org/drugbank:DB01033'
p7440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7441
sg24
Nsg25
Nsg26
S'MERCAPTOPURINE'
p7442
sg28
Nsg29
S'There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | \r'
p7443
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tabloid'
p7444
sa(dp7445
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7446
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7447
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7448
sg24
Nsg25
Nsg26
S'MEROPENEM ANHYDROUS'
p7449
sg28
Nsg29
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7450
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIPHENOLIC ACID'
p7451
sa(dp7452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7453
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7455
sg24
Nsg25
Nsg26
S'MEROPENEM ANHYDROUS'
p7456
sg28
Nsg29
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7457
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALPROIC ACID'
p7458
sa(dp7459
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7460
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7461
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7462
sg24
Nsg25
Nsg26
S'MEROPENEM'
p7463
sg28
Nsg29
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7464
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIPHENOLIC ACID'
p7465
sa(dp7466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p7467
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p7468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7469
sg24
Nsg25
Nsg26
S'MEROPENEM'
p7470
sg28
Nsg29
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p7471
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALPROIC ACID'
p7472
sa(dp7473
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p7474
sg5
S'http://bio2rdf.org/drugbank:DB00331'
p7475
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7476
sg24
Nsg25
Nsg26
S'METFORMIN'
p7477
sg28
Nsg29
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p7478
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p7479
sa(dp7480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01626'
p7481
sg5
S'http://bio2rdf.org/drugbank:DB01577'
p7482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7483
sg24
Nsg25
Nsg26
S'METHAMPHETAMINE'
p7484
sg28
Nsg29
S'Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. | \r'
p7485
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PARGYLINE'
p7486
sa(dp7487
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7488
sg5
S'http://bio2rdf.org/drugbank:DB00134'
p7489
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7490
sg24
Nsg25
Nsg26
S'METHIONINE'
p7491
sg28
Nsg29
S'Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| \r'
p7492
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p7493
sa(dp7494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p7495
sg5
S'http://bio2rdf.org/drugbank:DB00134'
p7496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7497
sg24
Nsg25
Nsg26
S'METHIONINE'
p7498
sg28
Nsg29
S'Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| \r'
p7499
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p7500
sa(dp7501
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p7502
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7503
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7504
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7505
sg28
Nsg29
S'Consequently, the combination of methotrexate with acitretin is also contraindicated.| \r'
p7506
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACITRETIN'
p7507
sa(dp7508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p7509
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7511
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7512
sg28
Nsg29
S'Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| \r'
p7513
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p7514
sa(dp7515
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p7516
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7517
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7518
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7519
sg28
Nsg29
S'Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| \r'
p7520
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p7521
sa(dp7522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00023'
p7523
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7525
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7526
sg28
Nsg29
S'These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.| \r'
p7527
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Elspar'
p7528
sa(dp7529
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00926'
p7530
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7531
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7532
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7533
sg28
Nsg29
S'Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.| \r'
p7534
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETRETINATE'
p7535
sa(dp7536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00130'
p7537
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7539
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7540
sg28
Nsg29
S'In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.| Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.| \r'
p7541
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLUTAMINE'
p7542
sa(dp7543
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00041'
p7544
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7545
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7546
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7547
sg28
Nsg29
S'Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| \r'
p7548
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Proleukin'
p7549
sa(dp7550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p7551
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7553
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7554
sg28
Nsg29
S'At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).| \r'
p7555
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ROFECOXIB'
p7556
sa(dp7557
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p7558
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7559
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7560
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7561
sg28
Nsg29
S'- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate| \r'
p7562
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SULFAPYRIDINE'
p7563
sa(dp7564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p7565
sg5
S'http://bio2rdf.org/drugbank:DB00563'
p7566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7567
sg24
Nsg25
Nsg26
S'METHOTREXATE'
p7568
sg28
Nsg29
S'An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.| \r'
p7569
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TENIPOSIDE'
p7570
sa(dp7571
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7572
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p7573
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7574
sg24
Nsg25
Nsg26
S'METHYLDOPA'
p7575
sg28
Nsg29
S'When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. | \r'
p7576
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p7577
sa(dp7578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7579
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p7580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7581
sg24
Nsg25
Nsg26
S'METHYLDOPA'
p7582
sg28
Nsg29
S'When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. | \r'
p7583
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p7584
sa(dp7585
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p7586
sg5
S'http://bio2rdf.org/drugbank:DB00968'
p7587
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7588
sg24
Nsg25
Nsg26
S'METHYLDOPA'
p7589
sg28
Nsg29
S'- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood| \r'
p7590
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SULFAPYRIDINE'
p7591
sa(dp7592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p7593
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p7594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7595
sg24
Nsg25
Nsg26
S'METHYLPREDNISOLONE'
p7596
sg28
Nsg29
S'The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| \r'
p7597
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p7598
sa(dp7599
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p7600
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p7601
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7602
sg24
Nsg25
Nsg26
S'METHYLPREDNISOLONE'
p7603
sg28
Nsg29
S'Methylprednisolone may increase the clearance of chronic high dose aspirin. | \r'
p7604
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p7605
sa(dp7606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p7607
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7609
sg24
Nsg25
Nsg26
S'METHYSERGIDE'
p7610
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p7611
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Axert'
p7612
sa(dp7613
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p7614
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7615
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7616
sg24
Nsg25
Nsg26
S'METHYSERGIDE'
p7617
sg28
Nsg29
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p7618
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Frova'
p7619
sa(dp7620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p7621
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7623
sg24
Nsg25
Nsg26
S'METHYSERGIDE'
p7624
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p7625
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NARATRIPTAN'
p7626
sa(dp7627
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p7628
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7629
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7630
sg24
Nsg25
Nsg26
S'METHYSERGIDE'
p7631
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p7632
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p7633
sa(dp7634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p7635
sg5
S'http://bio2rdf.org/drugbank:DB00247'
p7636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7637
sg24
Nsg25
Nsg26
S'METHYSERGIDE'
p7638
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p7639
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p7640
sa(dp7641
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7642
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7643
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7644
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7645
sg28
Nsg29
S'Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | \r'
p7646
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p7647
sa(dp7648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7649
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7651
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7652
sg28
Nsg29
S'Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. | \r'
p7653
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p7654
sa(dp7655
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p7656
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7657
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7658
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7659
sg28
Nsg29
S'Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| \r'
p7660
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Apokyn'
p7661
sa(dp7662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p7663
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7665
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7666
sg28
Nsg29
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p7667
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p7668
sa(dp7669
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p7670
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7671
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7672
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7673
sg28
Nsg29
S'Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.| \r'
p7674
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVODOPA'
p7675
sa(dp7676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01186'
p7677
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7679
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7680
sg28
Nsg29
S'Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); | \r'
p7681
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Permax'
p7682
sa(dp7683
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p7684
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p7685
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7686
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p7687
sg28
Nsg29
S'Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. | \r'
p7688
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mirapex'
p7689
sa(dp7690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p7691
sg5
S'http://bio2rdf.org/drugbank:DB00524'
p7692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7693
sg24
Nsg25
Nsg26
S'Metolazone'
p7694
sg28
Nsg29
S'Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. | \r'
p7695
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NOREPINEPHRINE'
p7696
sa(dp7697
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7698
sg5
S'http://bio2rdf.org/drugbank:DB01011'
p7699
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7700
sg24
Nsg25
Nsg26
S'Metopirone'
p7701
sg28
Nsg29
S'Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| \r'
p7702
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p7703
sa(dp7704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p7705
sg5
S'http://bio2rdf.org/drugbank:DB01011'
p7706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7707
sg24
Nsg25
Nsg26
S'Metopirone'
p7708
sg28
Nsg29
S'Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| \r'
p7709
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p7710
sa(dp7711
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p7712
sg5
S'http://bio2rdf.org/drugbank:DB01011'
p7713
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7714
sg24
Nsg25
Nsg26
S'Metopirone'
p7715
sg28
Nsg29
S'The metabolism of Metopirone is accelerated by phenytoin; | \r'
p7716
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p7717
sa(dp7718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p7719
sg5
S'http://bio2rdf.org/drugbank:DB00916'
p7720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7721
sg24
Nsg25
Nsg26
S'METRONIDAZOLE'
p7722
sg28
Nsg29
S'Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. | \r'
p7723
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'COUMARIN'
p7724
sa(dp7725
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p7726
sg5
S'http://bio2rdf.org/drugbank:DB00379'
p7727
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7728
sg24
Nsg25
Nsg26
S'Mexitil'
p7729
sg28
Nsg29
S'This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. | \r'
p7730
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p7731
sa(dp7732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p7733
sg5
S'http://bio2rdf.org/drugbank:DB00379'
p7734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7735
sg24
Nsg25
Nsg26
S'Mexitil'
p7736
sg28
Nsg29
S'This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. | \r'
p7737
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p7738
sa(dp7739
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p7740
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7741
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7742
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7743
sg28
Nsg29
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p7744
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p7745
sa(dp7746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p7747
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7749
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7750
sg28
Nsg29
S'Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). | \r'
p7751
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p7752
sa(dp7753
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p7754
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7755
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7756
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7757
sg28
Nsg29
S'The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| \r'
p7758
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p7759
sa(dp7760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p7761
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7763
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7764
sg28
Nsg29
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p7765
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p7766
sa(dp7767
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p7768
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7769
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7770
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7771
sg28
Nsg29
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p7772
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p7773
sa(dp7774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p7775
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7777
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7778
sg28
Nsg29
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p7779
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p7780
sa(dp7781
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p7782
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7783
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7784
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7785
sg28
Nsg29
S'Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.| \r'
p7786
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p7787
sa(dp7788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p7789
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p7790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7791
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p7792
sg28
Nsg29
S'Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.| \r'
p7793
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p7794
sa(dp7795
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p7796
sg5
S'http://bio2rdf.org/drugbank:DB00235'
p7797
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7798
sg24
Nsg25
Nsg26
S'MILRINONE'
p7799
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p7800
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p7801
sa(dp7802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00828'
p7803
sg5
S'http://bio2rdf.org/drugbank:DB01017'
p7804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7805
sg24
Nsg25
Nsg26
S'MINOCYCLINE'
p7806
sg28
Nsg29
S'The combination of minocycline and fosfomycin can be synergistic against MRSA. | \r'
p7807
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FOSFOMYCIN'
p7808
sa(dp7809
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p7810
sg5
S'http://bio2rdf.org/drugbank:DB00350'
p7811
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7812
sg24
Nsg25
Nsg26
S'MINOXIDIL'
p7813
sg28
Nsg29
S'Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. | \r'
p7814
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p7815
sa(dp7816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00626'
p7817
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7819
sg24
Nsg25
Nsg26
S'Mivacron'
p7820
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7821
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BACITRACIN A'
p7822
sa(dp7823
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01190'
p7824
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7825
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7826
sg24
Nsg25
Nsg26
S'Mivacron'
p7827
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7828
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLINDAMYCIN'
p7829
sa(dp7830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p7831
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7833
sg24
Nsg25
Nsg26
S'Mivacron'
p7834
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7835
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Colistin'
p7836
sa(dp7837
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01627'
p7838
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7839
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7840
sg24
Nsg25
Nsg26
S'Mivacron'
p7841
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7842
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LINCOMYCIN'
p7843
sa(dp7844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7845
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7847
sg24
Nsg25
Nsg26
S'Mivacron'
p7848
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7849
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p7850
sa(dp7851
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p7852
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7853
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7854
sg24
Nsg25
Nsg26
S'Mivacron'
p7855
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7856
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p7857
sa(dp7858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7859
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7861
sg24
Nsg25
Nsg26
S'Mivacron'
p7862
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7863
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p7864
sa(dp7865
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7866
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7867
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7868
sg24
Nsg25
Nsg26
S'Mivacron'
p7869
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7870
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p7871
sa(dp7872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p7873
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7875
sg24
Nsg25
Nsg26
S'Mivacron'
p7876
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7877
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p7878
sa(dp7879
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p7880
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p7881
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p7882
sg24
Nsg25
Nsg26
S'Mivacron'
p7883
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p7884
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p7885
sa(dp7886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p7887
sg5
S'http://bio2rdf.org/drugbank:DB01171'
p7888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7889
sg24
Nsg25
Nsg26
S'MOCLOBEMIDE'
p7890
sg28
Nsg29
S'Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| \r'
p7891
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALMOTRIPTAN'
p7892
sa(dp7893
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p7894
sg5
S'http://bio2rdf.org/drugbank:DB00828'
p7895
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7896
sg24
Nsg25
Nsg26
S'Monurol'
p7897
sg28
Nsg29
S'Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| \r'
p7898
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p7899
sa(dp7900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06274'
p7901
sg5
S'http://bio2rdf.org/drugbank:DB00295'
p7902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7903
sg24
Nsg25
Nsg26
S'MORPHINE'
p7904
sg28
Nsg29
S'Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). | \r'
p7905
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ADL 8-2698'
p7906
sa(dp7907
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7908
sg5
S'http://bio2rdf.org/drugbank:DB00295'
p7909
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7910
sg24
Nsg25
Nsg26
S'MORPHINE'
p7911
sg28
Nsg29
S'Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. | \r'
p7912
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p7913
sa(dp7914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p7915
sg5
S'http://bio2rdf.org/drugbank:DB00295'
p7916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7917
sg24
Nsg25
Nsg26
S'MORPHINE'
p7918
sg28
Nsg29
S'Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.| \r'
p7919
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Neurontin'
p7920
sa(dp7921
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p7922
sg5
S'http://bio2rdf.org/drugbank:DB00218'
p7923
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7924
sg24
Nsg25
Nsg26
S'MOXIFLOXACIN'
p7925
sg28
Nsg29
S'Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. | \r'
p7926
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p7927
sa(dp7928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p7929
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7931
sg24
Nsg25
Nsg26
S'Myfortic'
p7932
sg28
Nsg29
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p7933
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p7934
sa(dp7935
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p7936
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7937
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7938
sg24
Nsg25
Nsg26
S'Myfortic'
p7939
sg28
Nsg29
S'Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. | \r'
p7940
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AZATHIOPRINE'
p7941
sa(dp7942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7943
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7945
sg24
Nsg25
Nsg26
S'Myfortic'
p7946
sg28
Nsg29
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p7947
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p7948
sa(dp7949
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p7950
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7951
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p7952
sg24
Nsg25
Nsg26
S'Myfortic'
p7953
sg28
Nsg29
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p7954
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p7955
sa(dp7956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00688'
p7957
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p7958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7959
sg24
Nsg25
Nsg26
S'Myfortic'
p7960
sg28
Nsg29
S'Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. | \r'
p7961
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MYCOPHENOLATE MOFETIL'
p7962
sa(dp7963
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7964
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7965
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7966
sg24
Nsg25
Nsg26
S'Nabilone'
p7967
sg28
Nsg29
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| \r'
p7968
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p7969
sa(dp7970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p7971
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7973
sg24
Nsg25
Nsg26
S'Nabilone'
p7974
sg28
Nsg29
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| \r'
p7975
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p7976
sa(dp7977
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00318'
p7978
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7979
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7980
sg24
Nsg25
Nsg26
S'Nabilone'
p7981
sg28
Nsg29
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p7982
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CODEINE'
p7983
sa(dp7984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p7985
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p7986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p7987
sg24
Nsg25
Nsg26
S'Nabilone'
p7988
sg28
Nsg29
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p7989
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p7990
sa(dp7991
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p7992
sg5
S'http://bio2rdf.org/drugbank:DB00844'
p7993
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p7994
sg24
Nsg25
Nsg26
S'NALBUPHINE'
p7995
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p7996
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p7997
sa(dp7998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01042'
p7999
sg5
S'http://bio2rdf.org/drugbank:DB00779'
p8000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8001
sg24
Nsg25
Nsg26
S'NALIDIXIC ACID'
p8002
sg28
Nsg29
S'DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  | \r'
p8003
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MELPHALAN'
p8004
sa(dp8005
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p8006
sg5
S'http://bio2rdf.org/drugbank:DB01183'
p8007
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8008
sg24
Nsg25
Nsg26
S'NALOXONE'
p8009
sg28
Nsg29
S'Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. | the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. | On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). | \r'
p8010
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p8011
sa(dp8012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00659'
p8013
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p8014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8015
sg24
Nsg25
Nsg26
S'NALTREXONE'
p8016
sg28
Nsg29
S'Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| \r'
p8017
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACAMPROSATE'
p8018
sa(dp8019
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8020
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p8021
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8022
sg24
Nsg25
Nsg26
S'NAPROXEN'
p8023
sg28
Nsg29
S'Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| \r'
p8024
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p8025
sa(dp8026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p8027
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p8028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8029
sg24
Nsg25
Nsg26
S'NAPROXEN'
p8030
sg28
Nsg29
S'Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| Caution should be used if naproxen is administered concomitantly with methotrexate.| \r'
p8031
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p8032
sa(dp8033
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p8034
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p8035
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8036
sg24
Nsg25
Nsg26
S'NAPROXEN'
p8037
sg28
Nsg29
S'Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| Caution should be used if naproxen is administered concomitantly with methotrexate.| \r'
p8038
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p8039
sa(dp8040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p8041
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p8042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8043
sg24
Nsg25
Nsg26
S'NEFAZODONE'
p8044
sg28
Nsg29
S'Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p8045
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p8046
sa(dp8047
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p8048
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p8049
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8050
sg24
Nsg25
Nsg26
S'NELFINAVIR'
p8051
sg28
Nsg29
S'Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| \r'
p8052
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p8053
sa(dp8054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p8055
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p8056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8057
sg24
Nsg25
Nsg26
S'NELFINAVIR'
p8058
sg28
Nsg29
S'therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.| \r'
p8059
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p8060
sa(dp8061
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p8062
sg5
S'http://bio2rdf.org/drugbank:DB05251'
p8063
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8064
sg24
Nsg25
Nsg26
S'NELFINAVIR'
p8065
sg28
Nsg29
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p8066
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p8067
sa(dp8068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p8069
sg5
S'http://bio2rdf.org/drugbank:DB00955'
p8070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8071
sg24
Nsg25
Nsg26
S'NETILMICIN'
p8072
sg28
Nsg29
S'Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| \r'
p8073
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHACRYNIC ACID'
p8074
sa(dp8075
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p8076
sg5
S'http://bio2rdf.org/drugbank:DB00955'
p8077
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8078
sg24
Nsg25
Nsg26
S'NETILMICIN'
p8079
sg28
Nsg29
S'Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| \r'
p8080
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p8081
sa(dp8082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p8083
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p8084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8085
sg24
Nsg25
Nsg26
S'NEVIRAPINE'
p8086
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p8087
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p8088
sa(dp8089
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p8090
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p8091
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8092
sg24
Nsg25
Nsg26
S'NEVIRAPINE'
p8093
sg28
Nsg29
S'Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.| \r'
p8094
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p8095
sa(dp8096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p8097
sg5
S'http://bio2rdf.org/drugbank:DB00238'
p8098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8099
sg24
Nsg25
Nsg26
S'NEVIRAPINE'
p8100
sg28
Nsg29
S'Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.| \r'
p8101
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p8102
sa(dp8103
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p8104
sg5
S'http://bio2rdf.org/drugbank:DB00398'
p8105
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8106
sg24
Nsg25
Nsg26
S'Nexavar'
p8107
sg28
Nsg29
S'Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. | \r'
p8108
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p8109
sa(dp8110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00762'
p8111
sg5
S'http://bio2rdf.org/drugbank:DB00398'
p8112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8113
sg24
Nsg25
Nsg26
S'Nexavar'
p8114
sg28
Nsg29
S'Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). | \r'
p8115
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IRINOTECAN'
p8116
sa(dp8117
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p8118
sg5
S'http://bio2rdf.org/drugbank:DB00184'
p8119
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8120
sg24
Nsg25
Nsg26
S'NICOTINE'
p8121
sg28
Nsg29
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p8122
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p8123
sa(dp8124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p8125
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8127
sg24
Nsg25
Nsg26
S'NIFEDIPINE'
p8128
sg28
Nsg29
S'If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.| \r'
p8129
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p8130
sa(dp8131
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p8132
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8133
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8134
sg24
Nsg25
Nsg26
S'NIFEDIPINE'
p8135
sg28
Nsg29
S'Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. | \r'
p8136
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mycamine'
p8137
sa(dp8138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p8139
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8141
sg24
Nsg25
Nsg26
S'NIFEDIPINE'
p8142
sg28
Nsg29
S'Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. | \r'
p8143
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mycamine'
p8144
sa(dp8145
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p8146
sg5
S'http://bio2rdf.org/drugbank:DB01115'
p8147
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8148
sg24
Nsg25
Nsg26
S'NIFEDIPINE'
p8149
sg28
Nsg29
S'In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.| \r'
p8150
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p8151
sa(dp8152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00626'
p8153
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8155
sg24
Nsg25
Nsg26
S'Nimbex'
p8156
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8157
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BACITRACIN A'
p8158
sa(dp8159
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01190'
p8160
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8161
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8162
sg24
Nsg25
Nsg26
S'Nimbex'
p8163
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8164
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLINDAMYCIN'
p8165
sa(dp8166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p8167
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8169
sg24
Nsg25
Nsg26
S'Nimbex'
p8170
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8171
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Colistin'
p8172
sa(dp8173
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01627'
p8174
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8175
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8176
sg24
Nsg25
Nsg26
S'Nimbex'
p8177
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8178
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LINCOMYCIN'
p8179
sa(dp8180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8181
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8183
sg24
Nsg25
Nsg26
S'Nimbex'
p8184
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8185
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p8186
sa(dp8187
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8188
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8189
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8190
sg24
Nsg25
Nsg26
S'Nimbex'
p8191
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8192
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p8193
sa(dp8194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8195
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8197
sg24
Nsg25
Nsg26
S'Nimbex'
p8198
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8199
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p8200
sa(dp8201
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8202
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8203
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8204
sg24
Nsg25
Nsg26
S'Nimbex'
p8205
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8206
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p8207
sa(dp8208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p8209
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8211
sg24
Nsg25
Nsg26
S'Nimbex'
p8212
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8213
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p8214
sa(dp8215
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p8216
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8217
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8218
sg24
Nsg25
Nsg26
S'Nimbex'
p8219
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8220
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p8221
sa(dp8222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p8223
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p8224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8225
sg24
Nsg25
Nsg26
S'Nimbex'
p8226
sg28
Nsg29
S'Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.| The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.| \r'
p8227
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p8228
sa(dp8229
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00779'
p8230
sg5
S'http://bio2rdf.org/drugbank:DB00698'
p8231
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8232
sg24
Nsg25
Nsg26
S'NITROFURANTOIN'
p8233
sg28
Nsg29
S'Nitrofurantoin interferes with the therapeutic action of nalidixic acid.| \r'
p8234
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NALIDIXIC ACID'
p8235
sa(dp8236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p8237
sg5
S'http://bio2rdf.org/drugbank:DB00698'
p8238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8239
sg24
Nsg25
Nsg26
S'NITROFURANTOIN'
p8240
sg28
Nsg29
S'The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.| \r'
p8241
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p8242
sa(dp8243
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01197'
p8244
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p8245
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8246
sg24
Nsg25
Nsg26
S'NITROGLYCERIN'
p8247
sg28
Nsg29
S'therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.| \r'
p8248
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAPTOPRIL'
p8249
sa(dp8250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00435'
p8251
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p8252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8253
sg24
Nsg25
Nsg26
S'NITROGLYCERIN'
p8254
sg28
Nsg29
S'Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| \r'
p8255
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INOmax'
p8256
sa(dp8257
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p8258
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p8259
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8260
sg24
Nsg25
Nsg26
S'Nizoral'
p8261
sg28
Nsg29
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p8262
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p8263
sa(dp8264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p8265
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p8266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8267
sg24
Nsg25
Nsg26
S'Nizoral'
p8268
sg28
Nsg29
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p8269
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p8270
sa(dp8271
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01158'
p8272
sg5
S'http://bio2rdf.org/drugbank:DB00368'
p8273
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8274
sg24
Nsg25
Nsg26
S'NOREPINEPHRINE'
p8275
sg28
Nsg29
S'The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.| \r'
p8276
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Bretylium tosylate'
p8277
sa(dp8278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p8279
sg5
S'http://bio2rdf.org/drugbank:DB00368'
p8280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p8281
sg24
Nsg25
Nsg26
S'NOREPINEPHRINE'
p8282
sg28
Nsg29
S'norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | \r'
p8283
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SODIUM BICARBONATE'
p8284
sa(dp8285
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p8286
sg5
S'http://bio2rdf.org/drugbank:DB00717'
p8287
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8288
sg24
Nsg25
Nsg26
S'NORETHINDRONE'
p8289
sg28
Nsg29
S'The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| \r'
p8290
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GABAPENTIN'
p8291
sa(dp8292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p8293
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p8294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8295
sg24
Nsg25
Nsg26
S'NORFLOXACIN'
p8296
sg28
Nsg29
S'The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.| \r'
p8297
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p8298
sa(dp8299
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p8300
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p8301
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8302
sg24
Nsg25
Nsg26
S'NORFLOXACIN'
p8303
sg28
Nsg29
S'There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.| \r'
p8304
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p8305
sa(dp8306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p8307
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p8308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8309
sg24
Nsg25
Nsg26
S'NORFLOXACIN'
p8310
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p8311
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p8312
sa(dp8313
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p8314
sg5
S'http://bio2rdf.org/drugbank:DB00280'
p8315
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8316
sg24
Nsg25
Nsg26
S'Norpace'
p8317
sg28
Nsg29
S'Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.| \r'
p8318
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p8319
sa(dp8320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00626'
p8321
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8323
sg24
Nsg25
Nsg26
S'Nuromax'
p8324
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8325
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BACITRACIN A'
p8326
sa(dp8327
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p8328
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8329
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8330
sg24
Nsg25
Nsg26
S'Nuromax'
p8331
sg28
Nsg29
S'As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.| \r'
p8332
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p8333
sa(dp8334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01190'
p8335
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8337
sg24
Nsg25
Nsg26
S'Nuromax'
p8338
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8339
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLINDAMYCIN'
p8340
sa(dp8341
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p8342
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8343
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8344
sg24
Nsg25
Nsg26
S'Nuromax'
p8345
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8346
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Colistin'
p8347
sa(dp8348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01627'
p8349
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8351
sg24
Nsg25
Nsg26
S'Nuromax'
p8352
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8353
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LINCOMYCIN'
p8354
sa(dp8355
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8356
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8357
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8358
sg24
Nsg25
Nsg26
S'Nuromax'
p8359
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8360
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p8361
sa(dp8362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p8363
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8365
sg24
Nsg25
Nsg26
S'Nuromax'
p8366
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8367
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p8368
sa(dp8369
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8370
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8371
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8372
sg24
Nsg25
Nsg26
S'Nuromax'
p8373
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8374
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p8375
sa(dp8376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p8377
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8379
sg24
Nsg25
Nsg26
S'Nuromax'
p8380
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8381
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p8382
sa(dp8383
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p8384
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8385
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8386
sg24
Nsg25
Nsg26
S'Nuromax'
p8387
sg28
Nsg29
S'As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.| \r'
p8388
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p8389
sa(dp8390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p8391
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8393
sg24
Nsg25
Nsg26
S'Nuromax'
p8394
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8395
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p8396
sa(dp8397
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p8398
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p8399
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8400
sg24
Nsg25
Nsg26
S'Nuromax'
p8401
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p8402
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p8403
sa(dp8404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00450'
p8405
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p8406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8407
sg24
Nsg25
Nsg26
S'OUABAIN'
p8408
sg28
Nsg29
S'Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.| \r'
p8409
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DROPERIDOL'
p8410
sa(dp8411
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00692'
p8412
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p8413
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8414
sg24
Nsg25
Nsg26
S'OUABAIN'
p8415
sg28
Nsg29
S'When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. | \r'
p8416
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENTOLAMINE'
p8417
sa(dp8418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00818'
p8419
sg5
S'http://bio2rdf.org/drugbank:DB01192'
p8420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8421
sg24
Nsg25
Nsg26
S'OXYMORPHONE'
p8422
sg28
Nsg29
S'It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. | \r'
p8423
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROPOFOL'
p8424
sa(dp8425
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8426
sg5
S'http://bio2rdf.org/drugbank:DB03585'
p8427
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8428
sg24
Nsg25
Nsg26
S'Oxyphenbutazone'
p8429
sg28
Nsg29
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p8430
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p8431
sa(dp8432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p8433
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p8434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8435
sg24
Nsg25
Nsg26
S'PACLITAXEL'
p8436
sg28
Nsg29
S'Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.| \r'
p8437
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p8438
sa(dp8439
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p8440
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p8441
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8442
sg24
Nsg25
Nsg26
S'PACLITAXEL'
p8443
sg28
Nsg29
S'Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.| \r'
p8444
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Herceptin'
p8445
sa(dp8446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00721'
p8447
sg5
S'http://bio2rdf.org/drugbank:DB00345'
p8448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8449
sg24
Nsg25
Nsg26
S'PAH'
p8450
sg28
Nsg29
S'Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.| \r'
p8451
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINE'
p8452
sa(dp8453
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p8454
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p8455
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8456
sg24
Nsg25
Nsg26
S'para-aminosalicylic acid'
p8457
sg28
Nsg29
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p8458
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p8459
sa(dp8460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p8461
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8463
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8464
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8465
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p8466
sa(dp8467
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p8468
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8469
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8470
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8471
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8472
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p8473
sa(dp8474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p8475
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8477
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8478
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8479
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p8480
sa(dp8481
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p8482
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8483
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8484
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8485
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8486
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p8487
sa(dp8488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p8489
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8491
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8492
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8493
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p8494
sa(dp8495
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p8496
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8497
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8498
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8499
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8500
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p8501
sa(dp8502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p8503
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8505
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8506
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8507
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p8508
sa(dp8509
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p8510
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8511
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8512
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8513
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8514
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p8515
sa(dp8516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8517
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8519
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8520
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8521
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p8522
sa(dp8523
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8524
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8525
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8526
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8527
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8528
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p8529
sa(dp8530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p8531
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8533
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8534
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8535
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TELITHROMYCIN'
p8536
sa(dp8537
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p8538
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p8539
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8540
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p8541
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p8542
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VORICONAZOLE'
p8543
sa(dp8544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p8545
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8547
sg24
Nsg25
Nsg26
S'PAROXETINE'
p8548
sg28
Nsg29
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p8549
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p8550
sa(dp8551
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p8552
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8553
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8554
sg24
Nsg25
Nsg26
S'PAROXETINE'
p8555
sg28
Nsg29
S'In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| \r'
p8556
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATOMOXETINE'
p8557
sa(dp8558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p8559
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8561
sg24
Nsg25
Nsg26
S'PAROXETINE'
p8562
sg28
Nsg29
S'Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| \r'
p8563
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p8564
sa(dp8565
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p8566
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8567
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8568
sg24
Nsg25
Nsg26
S'PAROXETINE'
p8569
sg28
Nsg29
S'Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| \r'
p8570
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DULOXETINE'
p8571
sa(dp8572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p8573
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8575
sg24
Nsg25
Nsg26
S'PAROXETINE'
p8576
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p8577
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p8578
sa(dp8579
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p8580
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p8581
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8582
sg24
Nsg25
Nsg26
S'PAROXETINE'
p8583
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p8584
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p8585
sa(dp8586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p8587
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p8588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8589
sg24
Nsg25
Nsg26
S'Peganone'
p8590
sg28
Nsg29
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p8591
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENACEMIDE'
p8592
sa(dp8593
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p8594
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p8595
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8596
sg24
Nsg25
Nsg26
S'Peganone'
p8597
sg28
Nsg29
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p8598
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Phenurone'
p8599
sa(dp8600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p8601
sg5
S'http://bio2rdf.org/drugbank:DB00008'
p8602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8603
sg24
Nsg25
Nsg26
S'Pegasys'
p8604
sg28
Nsg29
S'Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.| \r'
p8605
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p8606
sa(dp8607
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p8608
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p8609
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8610
sg24
Nsg25
Nsg26
S'PENTAMIDINE'
p8611
sg28
Nsg29
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p8612
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p8613
sa(dp8614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p8615
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p8616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8617
sg24
Nsg25
Nsg26
S'PENTAMIDINE'
p8618
sg28
Nsg29
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p8619
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p8620
sa(dp8621
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p8622
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p8623
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8624
sg24
Nsg25
Nsg26
S'PENTAZOCINE, (-)-'
p8625
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p8626
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p8627
sa(dp8628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00792'
p8629
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p8630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8631
sg24
Nsg25
Nsg26
S'PENTAZOCINE, (-)-'
p8632
sg28
Nsg29
S'Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. | \r'
p8633
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIPELENNAMINE'
p8634
sa(dp8635
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p8636
sg5
S'http://bio2rdf.org/drugbank:DB00514'
p8637
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8638
sg24
Nsg25
Nsg26
S'PHENARSAZINE CHLORIDE'
p8639
sg28
Nsg29
S'Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| \r'
p8640
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p8641
sa(dp8642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p8643
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8645
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8646
sg28
Nsg29
S'Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p8647
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p8648
sa(dp8649
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8650
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8651
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8652
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8653
sg28
Nsg29
S'Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| \r'
p8654
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p8655
sa(dp8656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p8657
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8659
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8660
sg28
Nsg29
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p8661
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p8662
sa(dp8663
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p8664
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8665
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8666
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8667
sg28
Nsg29
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p8668
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCITRIOL'
p8669
sa(dp8670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p8671
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8673
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8674
sg28
Nsg29
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p8675
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONAZEPAM'
p8676
sa(dp8677
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00586'
p8678
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8679
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8680
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8681
sg28
Nsg29
S'Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.| \r'
p8682
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DICLOFENAC'
p8683
sa(dp8684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p8685
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8687
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8688
sg28
Nsg29
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p8689
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p8690
sa(dp8691
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p8692
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8693
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8694
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8695
sg28
Nsg29
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p8696
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p8697
sa(dp8698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p8699
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8701
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8702
sg28
Nsg29
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p8703
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EXEMESTANE'
p8704
sa(dp8705
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p8706
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8707
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8708
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8709
sg28
Nsg29
S'Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.| \r'
p8710
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FELBAMATE'
p8711
sa(dp8712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p8713
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8715
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8716
sg28
Nsg29
S'Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| \r'
p8717
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fenoprofen'
p8718
sa(dp8719
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p8720
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8721
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8722
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8723
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p8724
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p8725
sa(dp8726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p8727
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8729
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8730
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p8731
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p8732
sa(dp8733
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p8734
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8735
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8736
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8737
sg28
Nsg29
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p8738
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p8739
sa(dp8740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p8741
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8743
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8744
sg28
Nsg29
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p8745
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p8746
sa(dp8747
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p8748
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8749
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8750
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8751
sg28
Nsg29
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p8752
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MONTELUKAST'
p8753
sa(dp8754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p8755
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p8757
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8758
sg28
Nsg29
S'When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| \r'
p8759
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nalfon'
p8760
sa(dp8761
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8762
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8763
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8764
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8765
sg28
Nsg29
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p8766
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p8767
sa(dp8768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p8769
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8771
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8772
sg28
Nsg29
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p8773
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p8774
sa(dp8775
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p8776
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p8777
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8778
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p8779
sg28
Nsg29
S'The increase of phenobarbital level, however, is small (15%) when given with Trileptal.| \r'
p8780
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Trileptal'
p8781
sa(dp8782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01037'
p8783
sg5
S'http://bio2rdf.org/drugbank:DB00120'
p8784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8785
sg24
Nsg25
Nsg26
S'PHENYLALANINE'
p8786
sg28
Nsg29
S'Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.| \r'
p8787
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SELEGILINE'
p8788
sa(dp8789
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8790
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p8791
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8792
sg24
Nsg25
Nsg26
S'PHENYLBUTAZONE'
p8793
sg28
Nsg29
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p8794
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p8795
sa(dp8796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p8797
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p8798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8799
sg24
Nsg25
Nsg26
S'PHENYLBUTAZONE'
p8800
sg28
Nsg29
S'Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| \r'
p8801
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Etodolac'
p8802
sa(dp8803
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p8804
sg5
S'http://bio2rdf.org/drugbank:DB00388'
p8805
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8806
sg24
Nsg25
Nsg26
S'PHENYLEPHRINE'
p8807
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p8808
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p8809
sa(dp8810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p8811
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8813
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8814
sg28
Nsg29
S'- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8815
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p8816
sa(dp8817
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p8818
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8819
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8820
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8821
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8822
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p8823
sa(dp8824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p8825
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8827
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8828
sg28
Nsg29
S'Phenytoin: Serum phenytoin levels may be increased by aspirin.| \r'
p8829
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p8830
sa(dp8831
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p8832
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8833
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8834
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8835
sg28
Nsg29
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p8836
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p8837
sa(dp8838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p8839
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8841
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8842
sg28
Nsg29
S'Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.| \r'
p8843
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUSULFAN'
p8844
sa(dp8845
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p8846
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8847
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8848
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8849
sg28
Nsg29
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p8850
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCITRIOL'
p8851
sa(dp8852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p8853
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8855
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8856
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p8857
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p8858
sa(dp8859
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p8860
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8861
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8862
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8863
sg28
Nsg29
S'- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| \r'
p8864
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p8865
sa(dp8866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p8867
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8869
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8870
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8871
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p8872
sa(dp8873
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p8874
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8875
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8876
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8877
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8878
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p8879
sa(dp8880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p8881
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8883
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8884
sg28
Nsg29
S'Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.| \r'
p8885
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p8886
sa(dp8887
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p8888
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8889
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8890
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8891
sg28
Nsg29
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p8892
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONAZEPAM'
p8893
sa(dp8894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p8895
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8897
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8898
sg28
Nsg29
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p8899
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p8900
sa(dp8901
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p8902
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8903
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8904
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8905
sg28
Nsg29
S'Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8906
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'COUMARIN'
p8907
sa(dp8908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p8909
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8911
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8912
sg28
Nsg29
S'Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8913
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'COUMARIN'
p8914
sa(dp8915
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p8916
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8917
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8918
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8919
sg28
Nsg29
S'Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.| \r'
p8920
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p8921
sa(dp8922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p8923
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8925
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8926
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8927
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p8928
sa(dp8929
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p8930
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8931
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8932
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8933
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8934
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DICUMAROL'
p8935
sa(dp8936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01396'
p8937
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8939
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8940
sg28
Nsg29
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8941
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGITOXIN'
p8942
sa(dp8943
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p8944
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8945
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8946
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8947
sg28
Nsg29
S'Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p8948
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIPHENOLIC ACID'
p8949
sa(dp8950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p8951
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8953
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8954
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p8955
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DISULFIRAM'
p8956
sa(dp8957
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p8958
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8959
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8960
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8961
sg28
Nsg29
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8962
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXYCYCLINE'
p8963
sa(dp8964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00254'
p8965
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8967
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8968
sg28
Nsg29
S'Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8969
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXYCYCLINE'
p8970
sa(dp8971
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p8972
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8973
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p8974
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8975
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8976
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Estrogens'
p8977
sa(dp8978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p8979
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8981
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8982
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p8983
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Estrogens'
p8984
sa(dp8985
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p8986
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8987
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8988
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8989
sg28
Nsg29
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p8990
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p8991
sa(dp8992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p8993
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p8994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p8995
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p8996
sg28
Nsg29
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p8997
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EXEMESTANE'
p8998
sa(dp8999
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p9000
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9001
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9002
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9003
sg28
Nsg29
S'Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| \r'
p9004
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FELBAMATE'
p9005
sa(dp9006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p9007
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9009
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9010
sg28
Nsg29
S'Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| \r'
p9011
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Felbatol'
p9012
sa(dp9013
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p9014
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9015
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9016
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9017
sg28
Nsg29
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p9018
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p9019
sa(dp9020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p9021
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9023
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9024
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9025
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p9026
sa(dp9027
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p9028
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9029
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9030
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9031
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p9032
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p9033
sa(dp9034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p9035
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9037
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9038
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p9039
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p9040
sa(dp9041
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p9042
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9043
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9044
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9045
sg28
Nsg29
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p9046
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p9047
sa(dp9048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p9049
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9051
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9052
sg28
Nsg29
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p9053
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p9054
sa(dp9055
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p9056
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9057
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9058
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9059
sg28
Nsg29
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p9060
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p9061
sa(dp9062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p9063
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9065
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9066
sg28
Nsg29
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. | \r'
p9067
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mivacron'
p9068
sa(dp9069
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p9070
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9071
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9072
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9073
sg28
Nsg29
S'While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.| \r'
p9074
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p9075
sa(dp9076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00280'
p9077
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9079
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9080
sg28
Nsg29
S'If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.| \r'
p9081
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Norpace'
p9082
sa(dp9083
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p9084
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9085
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9086
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9087
sg28
Nsg29
S'- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.| Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9088
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p9089
sa(dp9090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p9091
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9093
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9094
sg28
Nsg29
S'- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.| Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9095
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p9096
sa(dp9097
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p9098
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9099
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9100
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9101
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9102
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p9103
sa(dp9104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01224'
p9105
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9107
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9108
sg28
Nsg29
S'This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. | \r'
p9109
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUETIAPINE FUMARATE'
p9110
sa(dp9111
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01224'
p9112
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9113
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9114
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9115
sg28
Nsg29
S'This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. | \r'
p9116
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUETIAPINE'
p9117
sa(dp9118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p9119
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9121
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9122
sg28
Nsg29
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p9123
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p9124
sa(dp9125
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00206'
p9126
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9127
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9128
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9129
sg28
Nsg29
S'- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| \r'
p9130
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RESERPINE'
p9131
sa(dp9132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p9133
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9135
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9136
sg28
Nsg29
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| \r'
p9137
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p9138
sa(dp9139
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9140
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9141
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9142
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9143
sg28
Nsg29
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p9144
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p9145
sa(dp9146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9147
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9149
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9150
sg28
Nsg29
S'Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| \r'
p9151
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p9152
sa(dp9153
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00401'
p9154
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9155
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9156
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9157
sg28
Nsg29
S'Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.| \r'
p9158
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sular'
p9159
sa(dp9160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00891'
p9161
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9163
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9164
sg28
Nsg29
S'- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin| \r'
p9165
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SULFAPYRIDINE'
p9166
sa(dp9167
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p9168
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9169
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9170
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9171
sg28
Nsg29
S'- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.| \r'
p9172
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p9173
sa(dp9174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p9175
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9177
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9178
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9179
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p9180
sa(dp9181
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00656'
p9182
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9183
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9184
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9185
sg28
Nsg29
S'The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| \r'
p9186
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRAZODONE'
p9187
sa(dp9188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p9189
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9191
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9192
sg28
Nsg29
S'1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.| \r'
p9193
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Trileptal'
p9194
sa(dp9195
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p9196
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9197
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9198
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9199
sg28
Nsg29
S'Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9200
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p9201
sa(dp9202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p9203
sg5
S'http://bio2rdf.org/drugbank:DB00252'
p9204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9205
sg24
Nsg25
Nsg26
S'PHENYTOIN'
p9206
sg28
Nsg29
S'Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| \r'
p9207
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALPROIC ACID'
p9208
sa(dp9209
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p9210
sg5
S'http://bio2rdf.org/drugbank:DB01057'
p9211
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9212
sg24
Nsg25
Nsg26
S'Phospholine Iodide'
p9213
sg28
Nsg29
S'Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| \r'
p9214
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p9215
sa(dp9216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p9217
sg5
S'http://bio2rdf.org/drugbank:DB00981'
p9218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9219
sg24
Nsg25
Nsg26
S'PHYSOSTIGMINE'
p9220
sg28
Nsg29
S"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. | \r"
p9221
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p9222
sa(dp9223
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9224
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p9225
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9226
sg24
Nsg25
Nsg26
S'PIMOZIDE'
p9227
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9228
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p9229
sa(dp9230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9231
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p9232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9233
sg24
Nsg25
Nsg26
S'PIMOZIDE'
p9234
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9235
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p9236
sa(dp9237
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p9238
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p9239
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9240
sg24
Nsg25
Nsg26
S'PIMOZIDE'
p9241
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p9242
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p9243
sa(dp9244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p9245
sg5
S'http://bio2rdf.org/drugbank:DB00319'
p9246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9247
sg24
Nsg25
Nsg26
S'PIPERACILLIN ANHYDROUS'
p9248
sg28
Nsg29
S'Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| \r'
p9249
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VECURONIUM'
p9250
sa(dp9251
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p9252
sg5
S'http://bio2rdf.org/drugbank:DB00319'
p9253
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9254
sg24
Nsg25
Nsg26
S'PIPERACILLIN'
p9255
sg28
Nsg29
S'In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| \r'
p9256
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VECURONIUM'
p9257
sa(dp9258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p9259
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p9260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9261
sg24
Nsg25
Nsg26
S'Pletal'
p9262
sg28
Nsg29
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p9263
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p9264
sa(dp9265
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p9266
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p9267
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9268
sg24
Nsg25
Nsg26
S'Pletal'
p9269
sg28
Nsg29
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p9270
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p9271
sa(dp9272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p9273
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p9274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9275
sg24
Nsg25
Nsg26
S'Ponstel'
p9276
sg28
Nsg29
S'Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p9277
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p9278
sa(dp9279
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p9280
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p9281
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9282
sg24
Nsg25
Nsg26
S'Ponstel'
p9283
sg28
Nsg29
S'During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.| \r'
p9284
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p9285
sa(dp9286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p9287
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p9288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9289
sg24
Nsg25
Nsg26
S'Posicor'
p9290
sg28
Nsg29
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p9291
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p9292
sa(dp9293
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p9294
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p9295
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9296
sg24
Nsg25
Nsg26
S'Posicor'
p9297
sg28
Nsg29
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p9298
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p9299
sa(dp9300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p9301
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p9302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9303
sg24
Nsg25
Nsg26
S'Posicor'
p9304
sg28
Nsg29
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p9305
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p9306
sa(dp9307
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p9308
sg5
S'http://bio2rdf.org/drugbank:DB00733'
p9309
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9310
sg24
Nsg25
Nsg26
S'PRALIDOXIME'
p9311
sg28
Nsg29
S'When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p9312
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atropine'
p9313
sa(dp9314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p9315
sg5
S'http://bio2rdf.org/drugbank:DB00457'
p9316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9317
sg24
Nsg25
Nsg26
S'PRAZOSIN'
p9318
sg28
Nsg29
S'ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. | \r'
p9319
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p9320
sa(dp9321
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00594'
p9322
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9323
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9324
sg24
Nsg25
Nsg26
S'Prinivil'
p9325
sg28
Nsg29
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9326
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMILORIDE'
p9327
sa(dp9328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p9329
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9331
sg24
Nsg25
Nsg26
S'Prinivil'
p9332
sg28
Nsg29
S'It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| \r'
p9333
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p9334
sa(dp9335
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p9336
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9337
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9338
sg24
Nsg25
Nsg26
S'Prinivil'
p9339
sg28
Nsg29
S'It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| \r'
p9340
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p9341
sa(dp9342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01345'
p9343
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9345
sg24
Nsg25
Nsg26
S'Prinivil'
p9346
sg28
Nsg29
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9347
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'POTASSIUM'
p9348
sa(dp9349
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00421'
p9350
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9351
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9352
sg24
Nsg25
Nsg26
S'Prinivil'
p9353
sg28
Nsg29
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9354
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SPIRONOLACTONE'
p9355
sa(dp9356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p9357
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p9358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9359
sg24
Nsg25
Nsg26
S'Prinivil'
p9360
sg28
Nsg29
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p9361
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAMTERENE'
p9362
sa(dp9363
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p9364
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9365
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9366
sg24
Nsg25
Nsg26
S'PROBENECID'
p9367
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9368
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p9369
sa(dp9370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00787'
p9371
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9373
sg24
Nsg25
Nsg26
S'PROBENECID'
p9374
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| \r'
p9375
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACYCLOVIR'
p9376
sa(dp9377
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p9378
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9379
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9380
sg24
Nsg25
Nsg26
S'PROBENECID'
p9381
sg28
Nsg29
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p9382
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ADENOSINE PHOSPHATE'
p9383
sa(dp9384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00642'
p9385
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9387
sg24
Nsg25
Nsg26
S'PROBENECID'
p9388
sg28
Nsg29
S'Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. | \r'
p9389
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alimta'
p9390
sa(dp9391
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p9392
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9393
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9394
sg24
Nsg25
Nsg26
S'PROBENECID'
p9395
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9396
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMINOSALICYLIC ACID'
p9397
sa(dp9398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p9399
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9401
sg24
Nsg25
Nsg26
S'PROBENECID'
p9402
sg28
Nsg29
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p9403
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p9404
sa(dp9405
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p9406
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9407
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9408
sg24
Nsg25
Nsg26
S'PROBENECID'
p9409
sg28
Nsg29
S'Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9410
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p9411
sa(dp9412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p9413
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9415
sg24
Nsg25
Nsg26
S'PROBENECID'
p9416
sg28
Nsg29
S'Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9417
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p9418
sa(dp9419
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p9420
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9421
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9422
sg24
Nsg25
Nsg26
S'PROBENECID'
p9423
sg28
Nsg29
S'Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9424
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BUMETANIDE'
p9425
sa(dp9426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00535'
p9427
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9429
sg24
Nsg25
Nsg26
S'PROBENECID'
p9430
sg28
Nsg29
S'Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| \r'
p9431
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFDINIR'
p9432
sa(dp9433
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p9434
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9435
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9436
sg24
Nsg25
Nsg26
S'PROBENECID'
p9437
sg28
Nsg29
S'Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.| \r'
p9438
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFDITOREN PIVOXIL'
p9439
sa(dp9440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01150'
p9441
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9443
sg24
Nsg25
Nsg26
S'PROBENECID'
p9444
sg28
Nsg29
S'Concomitant administration of probenecid doubled the AUC for cefprozil.| \r'
p9445
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFPROZIL ANHYDROUS, (E)-'
p9446
sa(dp9447
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p9448
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9449
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9450
sg24
Nsg25
Nsg26
S'PROBENECID'
p9451
sg28
Nsg29
S'Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| \r'
p9452
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p9453
sa(dp9454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p9455
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9457
sg24
Nsg25
Nsg26
S'PROBENECID'
p9458
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9459
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFIBRATE'
p9460
sa(dp9461
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01147'
p9462
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9463
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9464
sg24
Nsg25
Nsg26
S'PROBENECID'
p9465
sg28
Nsg29
S'This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.| \r'
p9466
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOXACILLIN'
p9467
sa(dp9468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p9469
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9471
sg24
Nsg25
Nsg26
S'PROBENECID'
p9472
sg28
Nsg29
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p9473
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERTAPENEM'
p9474
sa(dp9475
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p9476
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9477
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9478
sg24
Nsg25
Nsg26
S'PROBENECID'
p9479
sg28
Nsg29
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p9480
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERTAPENEM'
p9481
sa(dp9482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00927'
p9483
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9485
sg24
Nsg25
Nsg26
S'PROBENECID'
p9486
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9487
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FAMOTIDINE'
p9488
sa(dp9489
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p9490
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9491
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9492
sg24
Nsg25
Nsg26
S'PROBENECID'
p9493
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9494
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p9495
sa(dp9496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9497
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9499
sg24
Nsg25
Nsg26
S'PROBENECID'
p9500
sg28
Nsg29
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p9501
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEROPENEM ANHYDROUS'
p9502
sa(dp9503
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9504
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9505
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9506
sg24
Nsg25
Nsg26
S'PROBENECID'
p9507
sg28
Nsg29
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p9508
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEROPENEM ANHYDROUS'
p9509
sa(dp9510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9511
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9513
sg24
Nsg25
Nsg26
S'PROBENECID'
p9514
sg28
Nsg29
S'Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | Therefore, the coadministration of probenecid with meropenem is not recommended. | \r'
p9515
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEROPENEM'
p9516
sa(dp9517
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p9518
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9519
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9520
sg24
Nsg25
Nsg26
S'PROBENECID'
p9521
sg28
Nsg29
S'Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | Therefore, the coadministration of probenecid with meropenem is not recommended. | \r'
p9522
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEROPENEM'
p9523
sa(dp9524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p9525
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9527
sg24
Nsg25
Nsg26
S'PROBENECID'
p9528
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9529
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p9530
sa(dp9531
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p9532
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9533
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9534
sg24
Nsg25
Nsg26
S'PROBENECID'
p9535
sg28
Nsg29
S'Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| \r'
p9536
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NAPROXEN'
p9537
sa(dp9538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00698'
p9539
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9541
sg24
Nsg25
Nsg26
S'PROBENECID'
p9542
sg28
Nsg29
S'Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.| \r'
p9543
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NITROFURANTOIN'
p9544
sa(dp9545
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p9546
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9547
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9548
sg24
Nsg25
Nsg26
S'PROBENECID'
p9549
sg28
Nsg29
S'Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| \r'
p9550
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p9551
sa(dp9552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p9553
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9555
sg24
Nsg25
Nsg26
S'PROBENECID'
p9556
sg28
Nsg29
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p9557
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAH'
p9558
sa(dp9559
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p9560
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9561
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9562
sg24
Nsg25
Nsg26
S'PROBENECID'
p9563
sg28
Nsg29
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p9564
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAH'
p9565
sa(dp9566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00299'
p9567
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9569
sg24
Nsg25
Nsg26
S'PROBENECID'
p9570
sg28
Nsg29
S'Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| \r'
p9571
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENCICLOVIR'
p9572
sa(dp9573
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00319'
p9574
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9575
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9576
sg24
Nsg25
Nsg26
S'PROBENECID'
p9577
sg28
Nsg29
S'Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.| \r'
p9578
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pipracil'
p9579
sa(dp9580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00140'
p9581
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9583
sg24
Nsg25
Nsg26
S'PROBENECID'
p9584
sg28
Nsg29
S'Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; | \r'
p9585
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIBOFLAVIN'
p9586
sa(dp9587
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p9588
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9589
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9590
sg24
Nsg25
Nsg26
S'PROBENECID'
p9591
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9592
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p9593
sa(dp9594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p9595
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9597
sg24
Nsg25
Nsg26
S'PROBENECID'
p9598
sg28
Nsg29
S'Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| \r'
p9599
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p9600
sa(dp9601
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p9602
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p9603
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9604
sg24
Nsg25
Nsg26
S'PROBENECID'
p9605
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p9606
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZIDOVUDINE'
p9607
sa(dp9608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00762'
p9609
sg5
S'http://bio2rdf.org/drugbank:DB00433'
p9610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9611
sg24
Nsg25
Nsg26
S'PROCHLORPERAZINE'
p9612
sg28
Nsg29
S'The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).| \r'
p9613
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Camptosar'
p9614
sa(dp9615
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00851'
p9616
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p9617
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9618
sg24
Nsg25
Nsg26
S'Proleukin'
p9619
sg28
Nsg29
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p9620
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DACARBAZINE'
p9621
sa(dp9622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p9623
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p9624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9625
sg24
Nsg25
Nsg26
S'Proleukin'
p9626
sg28
Nsg29
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p9627
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TAMOXIFEN'
p9628
sa(dp9629
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p9630
sg5
S'http://bio2rdf.org/drugbank:DB00782'
p9631
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9632
sg24
Nsg25
Nsg26
S'PROPANTHELINE'
p9633
sg28
Nsg29
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p9634
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p9635
sa(dp9636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p9637
sg5
S'http://bio2rdf.org/drugbank:DB00647'
p9638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9639
sg24
Nsg25
Nsg26
S'PROPOXYPHENE'
p9640
sg28
Nsg29
S'The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. | \r'
p9641
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p9642
sa(dp9643
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p9644
sg5
S'http://bio2rdf.org/drugbank:DB00647'
p9645
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9646
sg24
Nsg25
Nsg26
S'PROPOXYPHENE'
p9647
sg28
Nsg29
S'Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.| \r'
p9648
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p9649
sa(dp9650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01575'
p9651
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p9652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9653
sg24
Nsg25
Nsg26
S'PSEUDOEPHEDRINE'
p9654
sg28
Nsg29
S'Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.| \r'
p9655
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'KAOLIN'
p9656
sa(dp9657
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p9658
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p9659
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9660
sg24
Nsg25
Nsg26
S'PSEUDOEPHEDRINE'
p9661
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p9662
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p9663
sa(dp9664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00352'
p9665
sg5
S'http://bio2rdf.org/drugbank:DB01033'
p9666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9667
sg24
Nsg25
Nsg26
S'Purinethol'
p9668
sg28
Nsg29
S'There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | \r'
p9669
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tabloid'
p9670
sa(dp9671
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p9672
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p9673
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9674
sg24
Nsg25
Nsg26
S'PYRIDOXINE'
p9675
sg28
Nsg29
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p9676
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CISPLATIN'
p9677
sa(dp9678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p9679
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p9680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9681
sg24
Nsg25
Nsg26
S'PYRIDOXINE'
p9682
sg28
Nsg29
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p9683
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Hexalen'
p9684
sa(dp9685
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p9686
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9687
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9688
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9689
sg28
Nsg29
S'Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p9690
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p9691
sa(dp9692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p9693
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9695
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9696
sg28
Nsg29
S'Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p9697
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p9698
sa(dp9699
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p9700
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9701
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9702
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9703
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p9704
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p9705
sa(dp9706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p9707
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9709
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9710
sg28
Nsg29
S'Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).| \r'
p9711
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIFEDIPINE'
p9712
sa(dp9713
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p9714
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9715
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9716
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9717
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p9718
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p9719
sa(dp9720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9721
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9723
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9724
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9725
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p9726
sa(dp9727
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9728
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9729
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9730
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9731
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9732
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p9733
sa(dp9734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p9735
sg5
S'http://bio2rdf.org/drugbank:DB00908'
p9736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9737
sg24
Nsg25
Nsg26
S'QUINIDINE'
p9738
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p9739
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p9740
sa(dp9741
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p9742
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9743
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9744
sg24
Nsg25
Nsg26
S'QUININE'
p9745
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p9746
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p9747
sa(dp9748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9749
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9751
sg24
Nsg25
Nsg26
S'QUININE'
p9752
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9753
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p9754
sa(dp9755
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p9756
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9757
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9758
sg24
Nsg25
Nsg26
S'QUININE'
p9759
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p9760
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p9761
sa(dp9762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p9763
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p9764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9765
sg24
Nsg25
Nsg26
S'QUININE'
p9766
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p9767
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p9768
sa(dp9769
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00630'
p9770
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9771
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9772
sg24
Nsg25
Nsg26
S'RANITIDINE'
p9773
sg28
Nsg29
S'Intravenous ranitidine was shown to double the bioavailability of oral alendronate.| \r'
p9774
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALENDRONIC ACID'
p9775
sa(dp9776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01415'
p9777
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9779
sg24
Nsg25
Nsg26
S'RANITIDINE'
p9780
sg28
Nsg29
S'however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.| \r'
p9781
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFTIBUTEN'
p9782
sa(dp9783
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p9784
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9785
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9786
sg24
Nsg25
Nsg26
S'RANITIDINE'
p9787
sg28
Nsg29
S'The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| \r'
p9788
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p9789
sa(dp9790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00317'
p9791
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9793
sg24
Nsg25
Nsg26
S'RANITIDINE'
p9794
sg28
Nsg29
S'Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.| \r'
p9795
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Iressa'
p9796
sa(dp9797
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p9798
sg5
S'http://bio2rdf.org/drugbank:DB00863'
p9799
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9800
sg24
Nsg25
Nsg26
S'RANITIDINE'
p9801
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p9802
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p9803
sa(dp9804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p9805
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p9806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9807
sg24
Nsg25
Nsg26
S'Remeron'
p9808
sg28
Nsg29
S'However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. | \r'
p9809
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p9810
sa(dp9811
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p9812
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p9813
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9814
sg24
Nsg25
Nsg26
S'Remeron'
p9815
sg28
Nsg29
S'However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. | \r'
p9816
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p9817
sa(dp9818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p9819
sg5
S'http://bio2rdf.org/drugbank:DB00206'
p9820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9821
sg24
Nsg25
Nsg26
S'RESERPINE'
p9822
sg28
Nsg29
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p9823
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zebeta'
p9824
sa(dp9825
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p9826
sg5
S'http://bio2rdf.org/drugbank:DB00162'
p9827
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9828
sg24
Nsg25
Nsg26
S'RETINOL'
p9829
sg28
Nsg29
S'Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| \r'
p9830
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACITRETIN'
p9831
sa(dp9832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p9833
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p9834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9835
sg24
Nsg25
Nsg26
S'Revia'
p9836
sg28
Nsg29
S'The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.| \r'
p9837
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DISULFIRAM'
p9838
sa(dp9839
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p9840
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p9841
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9842
sg24
Nsg25
Nsg26
S'RIBAVIRIN'
p9843
sg28
Nsg29
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p9844
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p9845
sa(dp9846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p9847
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p9848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9849
sg24
Nsg25
Nsg26
S'RIBAVIRIN'
p9850
sg28
Nsg29
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p9851
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZIDOVUDINE'
p9852
sa(dp9853
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p9854
sg5
S'http://bio2rdf.org/drugbank:DB00140'
p9855
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p9856
sg24
Nsg25
Nsg26
S'RIBOFLAVIN'
p9857
sg28
Nsg29
S'requirements for riboflavin may be increased in patients receiving probenecid.| \r'
p9858
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p9859
sa(dp9860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p9861
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9863
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p9864
sg28
Nsg29
S'Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| \r'
p9865
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Crixivan'
p9866
sa(dp9867
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p9868
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9869
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9870
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p9871
sg28
Nsg29
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p9872
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p9873
sa(dp9874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p9875
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9877
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p9878
sg28
Nsg29
S'Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. | \r'
p9879
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p9880
sa(dp9881
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p9882
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9883
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9884
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p9885
sg28
Nsg29
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p9886
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p9887
sa(dp9888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p9889
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p9890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9891
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p9892
sg28
Nsg29
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p9893
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p9894
sa(dp9895
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p9896
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9897
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9898
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9899
sg28
Nsg29
S'Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. | Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. | \r'
p9900
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p9901
sa(dp9902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p9903
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9905
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9906
sg28
Nsg29
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p9907
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p9908
sa(dp9909
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p9910
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9911
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9912
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9913
sg28
Nsg29
S'Patients on rifampin should receive 70 mg of CANCIDAS daily.| \r'
p9914
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p9915
sa(dp9916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p9917
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9919
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9920
sg28
Nsg29
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p9921
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p9922
sa(dp9923
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p9924
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9925
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9926
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9927
sg28
Nsg29
S'Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. | \r'
p9928
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Diflucan'
p9929
sa(dp9930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p9931
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9933
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9934
sg28
Nsg29
S'Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| \r'
p9935
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p9936
sa(dp9937
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p9938
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9939
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9940
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9941
sg28
Nsg29
S'Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.| \r'
p9942
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p9943
sa(dp9944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p9945
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9947
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9948
sg28
Nsg29
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p9949
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p9950
sa(dp9951
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00530'
p9952
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9953
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9954
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9955
sg28
Nsg29
S'Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.| \r'
p9956
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERLOTINIB'
p9957
sa(dp9958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p9959
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9961
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9962
sg28
Nsg29
S'Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| \r'
p9963
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p9964
sa(dp9965
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p9966
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9967
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9968
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9969
sg28
Nsg29
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p9970
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EXEMESTANE'
p9971
sa(dp9972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p9973
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9975
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9976
sg28
Nsg29
S'Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| \r'
p9977
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Gleevec'
p9978
sa(dp9979
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p9980
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9981
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p9982
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9983
sg28
Nsg29
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p9984
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p9985
sa(dp9986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p9987
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9989
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9990
sg28
Nsg29
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p9991
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p9992
sa(dp9993
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p9994
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p9995
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p9996
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p9997
sg28
Nsg29
S'Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| \r'
p9998
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p9999
sa(dp10000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00678'
p10001
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10003
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10004
sg28
Nsg29
S'Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.| \r'
p10005
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LOSARTAN'
p10006
sa(dp10007
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p10008
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10009
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10010
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10011
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p10012
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p10013
sa(dp10014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p10015
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10017
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10018
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p10019
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p10020
sa(dp10021
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p10022
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10023
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10024
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10025
sg28
Nsg29
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p10026
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p10027
sa(dp10028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p10029
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10031
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10032
sg28
Nsg29
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p10033
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p10034
sa(dp10035
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p10036
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10037
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10038
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10039
sg28
Nsg29
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p10040
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MONTELUKAST'
p10041
sa(dp10042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p10043
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10045
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10046
sg28
Nsg29
S'Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| \r'
p10047
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORETHINDRONE'
p10048
sa(dp10049
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10050
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10051
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10052
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10053
sg28
Nsg29
S'Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.| \r'
p10054
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p10055
sa(dp10056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p10057
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10059
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10060
sg28
Nsg29
S'Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.| \r'
p10061
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALEPLON'
p10062
sa(dp10063
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p10064
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p10065
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10066
sg24
Nsg25
Nsg26
S'RIFAMPIN'
p10067
sg28
Nsg29
S'Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| \r'
p10068
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zebeta'
p10069
sa(dp10070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p10071
sg5
S'http://bio2rdf.org/drugbank:DB00734'
p10072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10073
sg24
Nsg25
Nsg26
S'RISPERIDONE'
p10074
sg28
Nsg29
S'Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| \r'
p10075
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVODOPA'
p10076
sa(dp10077
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01242'
p10078
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10079
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10080
sg24
Nsg25
Nsg26
S'Ritalin'
p10081
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10082
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOMIPRAMINE'
p10083
sa(dp10084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01151'
p10085
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10087
sg24
Nsg25
Nsg26
S'Ritalin'
p10088
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10089
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DESIPRAMINE'
p10090
sa(dp10091
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p10092
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10093
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10094
sg24
Nsg25
Nsg26
S'Ritalin'
p10095
sg28
Nsg29
S'Ritalin may decrease the hypotensive effect of guanethidine. | \r'
p10096
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p10097
sa(dp10098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p10099
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10101
sg24
Nsg25
Nsg26
S'Ritalin'
p10102
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10103
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IMIPRAMINE'
p10104
sa(dp10105
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p10106
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10107
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10108
sg24
Nsg25
Nsg26
S'Ritalin'
p10109
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10110
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p10111
sa(dp10112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p10113
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10115
sg24
Nsg25
Nsg26
S'Ritalin'
p10116
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10117
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p10118
sa(dp10119
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p10120
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p10121
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10122
sg24
Nsg25
Nsg26
S'Ritalin'
p10123
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p10124
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p10125
sa(dp10126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p10127
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10129
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10130
sg28
Nsg29
S'Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| \r'
p10131
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALMOTRIPTAN'
p10132
sa(dp10133
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p10134
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10135
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10136
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10137
sg28
Nsg29
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p10138
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p10139
sa(dp10140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p10141
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10143
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10144
sg28
Nsg29
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p10145
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p10146
sa(dp10147
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00238'
p10148
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10149
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10150
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10151
sg28
Nsg29
S'A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.| \r'
p10152
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEVIRAPINE'
p10153
sa(dp10154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p10155
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10157
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10158
sg28
Nsg29
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p10159
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sustiva'
p10160
sa(dp10161
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p10162
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10163
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10164
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10165
sg28
Nsg29
S'Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.| Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.| \r'
p10166
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p10167
sa(dp10168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10169
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p10170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10171
sg24
Nsg25
Nsg26
S'RITONAVIR'
p10172
sg28
Nsg29
S'Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.| \r'
p10173
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p10174
sa(dp10175
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00761'
p10176
sg5
S'http://bio2rdf.org/drugbank:DB00986'
p10177
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10178
sg24
Nsg25
Nsg26
S'Robinul'
p10179
sg28
Nsg29
S'Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| \r'
p10180
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'POTASSIUM CHLORIDE'
p10181
sa(dp10182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p10183
sg5
S'http://bio2rdf.org/drugbank:DB00296'
p10184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10185
sg24
Nsg25
Nsg26
S'ROPIVACAINE'
p10186
sg28
Nsg29
S'In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. | \r'
p10187
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p10188
sa(dp10189
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p10190
sg5
S'http://bio2rdf.org/drugbank:DB00778'
p10191
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10192
sg24
Nsg25
Nsg26
S'ROXITHROMYCIN'
p10193
sg28
Nsg29
S'Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. | \r'
p10194
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p10195
sa(dp10196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p10197
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10199
sg24
Nsg25
Nsg26
S'Sanctura'
p10200
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10201
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p10202
sa(dp10203
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p10204
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10205
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10206
sg24
Nsg25
Nsg26
S'Sanctura'
p10207
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10208
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p10209
sa(dp10210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p10211
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10213
sg24
Nsg25
Nsg26
S'Sanctura'
p10214
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10215
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p10216
sa(dp10217
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01337'
p10218
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10219
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10220
sg24
Nsg25
Nsg26
S'Sanctura'
p10221
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10222
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PANCURONIUM'
p10223
sa(dp10224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p10225
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10227
sg24
Nsg25
Nsg26
S'Sanctura'
p10228
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10229
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROCAINAMIDE'
p10230
sa(dp10231
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00300'
p10232
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10233
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10234
sg24
Nsg25
Nsg26
S'Sanctura'
p10235
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10236
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TENOFOVIR'
p10237
sa(dp10238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p10239
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p10240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10241
sg24
Nsg25
Nsg26
S'Sanctura'
p10242
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p10243
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VANCOMYCIN'
p10244
sa(dp10245
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p10246
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10247
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10248
sg24
Nsg25
Nsg26
S'SAQUINAVIR MESYLATE'
p10249
sg28
Nsg29
S'Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| \r'
p10250
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p10251
sa(dp10252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10253
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10255
sg24
Nsg25
Nsg26
S'SAQUINAVIR MESYLATE'
p10256
sg28
Nsg29
S'Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.| \r'
p10257
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p10258
sa(dp10259
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p10260
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10261
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10262
sg24
Nsg25
Nsg26
S'SAQUINAVIR'
p10263
sg28
Nsg29
S'Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| \r'
p10264
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p10265
sa(dp10266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p10267
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p10268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10269
sg24
Nsg25
Nsg26
S'SAQUINAVIR'
p10270
sg28
Nsg29
S'Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.| \r'
p10271
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p10272
sa(dp10273
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p10274
sg5
S'http://bio2rdf.org/drugbank:DB00747'
p10275
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10276
sg24
Nsg25
Nsg26
S'SCOPOLAMINE'
p10277
sg28
Nsg29
S'Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. | \r'
p10278
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p10279
sa(dp10280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01364'
p10281
sg5
S'http://bio2rdf.org/drugbank:DB01037'
p10282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10283
sg24
Nsg25
Nsg26
S'SELEGILINE'
p10284
sg28
Nsg29
S'One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).| \r'
p10285
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPHEDRINE'
p10286
sa(dp10287
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p10288
sg5
S'http://bio2rdf.org/drugbank:DB01037'
p10289
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10290
sg24
Nsg25
Nsg26
S'SELEGILINE'
p10291
sg28
Nsg29
S'The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. | \r'
p10292
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEPERIDINE'
p10293
sa(dp10294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p10295
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p10296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10297
sg24
Nsg25
Nsg26
S'Sensipar'
p10298
sg28
Nsg29
S'Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| \r'
p10299
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p10300
sa(dp10301
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10302
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p10303
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10304
sg24
Nsg25
Nsg26
S'Sensipar'
p10305
sg28
Nsg29
S'Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| \r'
p10306
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p10307
sa(dp10308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10309
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p10310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10311
sg24
Nsg25
Nsg26
S'SERTRALINE'
p10312
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p10313
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p10314
sa(dp10315
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10316
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p10317
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10318
sg24
Nsg25
Nsg26
S'SERTRALINE'
p10319
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p10320
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p10321
sa(dp10322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10323
sg5
S'http://bio2rdf.org/drugbank:DB00203'
p10324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10325
sg24
Nsg25
Nsg26
S'SILDENAFIL'
p10326
sg28
Nsg29
S'Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| \r'
p10327
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p10328
sa(dp10329
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10330
sg5
S'http://bio2rdf.org/drugbank:DB00203'
p10331
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10332
sg24
Nsg25
Nsg26
S'SILDENAFIL'
p10333
sg28
Nsg29
S'Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| \r'
p10334
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p10335
sa(dp10336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00993'
p10337
sg5
S'http://bio2rdf.org/drugbank:DB00074'
p10338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10339
sg24
Nsg25
Nsg26
S'Simulect'
p10340
sg28
Nsg29
S'Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.| \r'
p10341
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AZATHIOPRINE'
p10342
sa(dp10343
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00688'
p10344
sg5
S'http://bio2rdf.org/drugbank:DB00074'
p10345
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10346
sg24
Nsg25
Nsg26
S'Simulect'
p10347
sg28
Nsg29
S'Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.| \r'
p10348
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MYCOPHENOLATE MOFETIL'
p10349
sa(dp10350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10351
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p10352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10353
sg24
Nsg25
Nsg26
S'SIMVASTATIN'
p10354
sg28
Nsg29
S'Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.&#x0D;| \r'
p10355
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p10356
sa(dp10357
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p10358
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10359
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10360
sg24
Nsg25
Nsg26
S'SIROLIMUS'
p10361
sg28
Nsg29
S'RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. | Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.| Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. | \r'
p10362
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p10363
sa(dp10364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p10365
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10367
sg24
Nsg25
Nsg26
S'SIROLIMUS'
p10368
sg28
Nsg29
S'RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. | Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.| Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. | \r'
p10369
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p10370
sa(dp10371
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p10372
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10373
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10374
sg24
Nsg25
Nsg26
S'SIROLIMUS'
p10375
sg28
Nsg29
S'Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. | Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | \r'
p10376
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mycamine'
p10377
sa(dp10378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01141'
p10379
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10381
sg24
Nsg25
Nsg26
S'SIROLIMUS'
p10382
sg28
Nsg29
S'Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. | Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | \r'
p10383
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mycamine'
p10384
sa(dp10385
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p10386
sg5
S'http://bio2rdf.org/drugbank:DB00877'
p10387
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10388
sg24
Nsg25
Nsg26
S'SIROLIMUS'
p10389
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p10390
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p10391
sa(dp10392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p10393
sg5
S'http://bio2rdf.org/drugbank:DB00660'
p10394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10395
sg24
Nsg25
Nsg26
S'Skelaxin'
p10396
sg28
Nsg29
S'SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.| \r'
p10397
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p10398
sa(dp10399
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01373'
p10400
sg5
S'http://bio2rdf.org/drugbank:DB01133'
p10401
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10402
sg24
Nsg25
Nsg26
S'Skelid'
p10403
sg28
Nsg29
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p10404
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCIUM'
p10405
sa(dp10406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p10407
sg5
S'http://bio2rdf.org/drugbank:DB01133'
p10408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10409
sg24
Nsg25
Nsg26
S'Skelid'
p10410
sg28
Nsg29
S'The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. | \r'
p10411
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDOMETHACIN'
p10412
sa(dp10413
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p10414
sg5
S'http://bio2rdf.org/drugbank:DB01398'
p10415
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10416
sg24
Nsg25
Nsg26
S'SODIUM SALICYLATE'
p10417
sg28
Nsg29
S'In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | \r'
p10418
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TENIPOSIDE'
p10419
sa(dp10420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p10421
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p10422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10423
sg24
Nsg25
Nsg26
S'Sonata'
p10424
sg28
Nsg29
S'CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.| \r'
p10425
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p10426
sa(dp10427
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p10428
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p10429
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10430
sg24
Nsg25
Nsg26
S'Sonata'
p10431
sg28
Nsg29
S'Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| \r'
p10432
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p10433
sa(dp10434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p10435
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p10436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10437
sg24
Nsg25
Nsg26
S'Sonata'
p10438
sg28
Nsg29
S'Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.| \r'
p10439
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IMIPRAMINE'
p10440
sa(dp10441
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p10442
sg5
S'http://bio2rdf.org/drugbank:DB00421'
p10443
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10444
sg24
Nsg25
Nsg26
S'SPIRONOLACTONE'
p10445
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p10446
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p10447
sa(dp10448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p10449
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10451
sg24
Nsg25
Nsg26
S'Sprycel'
p10452
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10453
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p10454
sa(dp10455
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10456
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10457
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10458
sg24
Nsg25
Nsg26
S'Sprycel'
p10459
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10460
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p10461
sa(dp10462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p10463
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10465
sg24
Nsg25
Nsg26
S'Sprycel'
p10466
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10467
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p10468
sa(dp10469
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10470
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10471
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10472
sg24
Nsg25
Nsg26
S'Sprycel'
p10473
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10474
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p10475
sa(dp10476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10477
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10479
sg24
Nsg25
Nsg26
S'Sprycel'
p10480
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10481
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p10482
sa(dp10483
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10484
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10485
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10486
sg24
Nsg25
Nsg26
S'Sprycel'
p10487
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10488
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p10489
sa(dp10490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p10491
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10493
sg24
Nsg25
Nsg26
S'Sprycel'
p10494
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10495
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p10496
sa(dp10497
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p10498
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10499
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10500
sg24
Nsg25
Nsg26
S'Sprycel'
p10501
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10502
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p10503
sa(dp10504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p10505
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10507
sg24
Nsg25
Nsg26
S'Sprycel'
p10508
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10509
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p10510
sa(dp10511
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10512
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10513
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10514
sg24
Nsg25
Nsg26
S'Sprycel'
p10515
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10516
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p10517
sa(dp10518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10519
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10521
sg24
Nsg25
Nsg26
S'Sprycel'
p10522
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10523
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p10524
sa(dp10525
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p10526
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p10527
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10528
sg24
Nsg25
Nsg26
S'Sprycel'
p10529
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p10530
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TELITHROMYCIN'
p10531
sa(dp10532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10533
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10535
sg24
Nsg25
Nsg26
S'Stadol NS'
p10536
sg28
Nsg29
S'However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| \r'
p10537
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p10538
sa(dp10539
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10540
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10541
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10542
sg24
Nsg25
Nsg26
S'Stadol NS'
p10543
sg28
Nsg29
S'However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| \r'
p10544
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN SUCCINATE'
p10545
sa(dp10546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10547
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10549
sg24
Nsg25
Nsg26
S'Stadol NS'
p10550
sg28
Nsg29
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p10551
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p10552
sa(dp10553
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p10554
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p10555
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10556
sg24
Nsg25
Nsg26
S'Stadol NS'
p10557
sg28
Nsg29
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p10558
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p10559
sa(dp10560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p10561
sg5
S'http://bio2rdf.org/drugbank:DB00731'
p10562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10563
sg24
Nsg25
Nsg26
S'Starlix'
p10564
sg28
Nsg29
S'Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.| \r'
p10565
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p10566
sa(dp10567
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p10568
sg5
S'http://bio2rdf.org/drugbank:DB00649'
p10569
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10570
sg24
Nsg25
Nsg26
S'STAVUDINE'
p10571
sg28
Nsg29
S'In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | \r'
p10572
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p10573
sa(dp10574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00811'
p10575
sg5
S'http://bio2rdf.org/drugbank:DB00649'
p10576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10577
sg24
Nsg25
Nsg26
S'STAVUDINE'
p10578
sg28
Nsg29
S'In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | \r'
p10579
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIBAVIRIN'
p10580
sa(dp10581
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01001'
p10582
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p10583
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10584
sg24
Nsg25
Nsg26
S'Strattera'
p10585
sg28
Nsg29
S'Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| \r'
p10586
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Albuterol'
p10587
sa(dp10588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p10589
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p10590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10591
sg24
Nsg25
Nsg26
S'Strattera'
p10592
sg28
Nsg29
S'Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| \r'
p10593
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p10594
sa(dp10595
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p10596
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p10597
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10598
sg24
Nsg25
Nsg26
S'Strattera'
p10599
sg28
Nsg29
S'Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| \r'
p10600
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p10601
sa(dp10602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00997'
p10603
sg5
S'http://bio2rdf.org/drugbank:DB00428'
p10604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10605
sg24
Nsg25
Nsg26
S'STREPTOZOCIN'
p10606
sg28
Nsg29
S'Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; | \r'
p10607
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOXORUBICIN'
p10608
sa(dp10609
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10610
sg5
S'http://bio2rdf.org/drugbank:DB00428'
p10611
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10612
sg24
Nsg25
Nsg26
S'STREPTOZOCIN'
p10613
sg28
Nsg29
S'The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    | \r'
p10614
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p10615
sa(dp10616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p10617
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10619
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p10620
sg28
Nsg29
S'The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| \r'
p10621
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Brevibloc'
p10622
sa(dp10623
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p10624
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10625
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10626
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p10627
sg28
Nsg29
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p10628
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coly-Mycin M'
p10629
sa(dp10630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p10631
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10633
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p10634
sg28
Nsg29
S'Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. | \r'
p10635
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mivacron'
p10636
sa(dp10637
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p10638
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p10639
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10640
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p10641
sg28
Nsg29
S'Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.| \r'
p10642
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p10643
sa(dp10644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10645
sg5
S'http://bio2rdf.org/drugbank:DB00401'
p10646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10647
sg24
Nsg25
Nsg26
S'Sular'
p10648
sg28
Nsg29
S'Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.| \r'
p10649
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p10650
sa(dp10651
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p10652
sg5
S'http://bio2rdf.org/drugbank:DB00576'
p10653
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10654
sg24
Nsg25
Nsg26
S'SULFAMETHIZOLE'
p10655
sg28
Nsg29
S'In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | \r'
p10656
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TENIPOSIDE'
p10657
sa(dp10658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p10659
sg5
S'http://bio2rdf.org/drugbank:DB00576'
p10660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10661
sg24
Nsg25
Nsg26
S'SULFAMETHIZOLE'
p10662
sg28
Nsg29
S'Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p10663
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p10664
sa(dp10665
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10666
sg5
S'http://bio2rdf.org/drugbank:DB01015'
p10667
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10668
sg24
Nsg25
Nsg26
S'SULFAMETHOXAZOLE'
p10669
sg28
Nsg29
S'At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. | Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. | \r'
p10670
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p10671
sa(dp10672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p10673
sg5
S'http://bio2rdf.org/drugbank:DB00891'
p10674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p10675
sg24
Nsg25
Nsg26
S'SULFAPYRIDINE'
p10676
sg28
Nsg29
S'Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| \r'
p10677
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p10678
sa(dp10679
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p10680
sg5
S'http://bio2rdf.org/drugbank:DB00891'
p10681
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p10682
sg24
Nsg25
Nsg26
S'SULFAPYRIDINE'
p10683
sg28
Nsg29
S'Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| \r'
p10684
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tylenol'
p10685
sa(dp10686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p10687
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p10688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10689
sg24
Nsg25
Nsg26
S'SULFASALAZINE'
p10690
sg28
Nsg29
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p10691
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p10692
sa(dp10693
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00005'
p10694
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p10695
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10696
sg24
Nsg25
Nsg26
S'SULFASALAZINE'
p10697
sg28
Nsg29
S'Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.| \r'
p10698
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Enbrel'
p10699
sa(dp10700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p10701
sg5
S'http://bio2rdf.org/drugbank:DB01145'
p10702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10703
sg24
Nsg25
Nsg26
S'SULFOXONE'
p10704
sg28
Nsg29
S'Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p10705
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p10706
sa(dp10707
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10708
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10709
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10710
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10711
sg28
Nsg29
S'Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| \r'
p10712
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'D.H.E. 45'
p10713
sa(dp10714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10715
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10717
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10718
sg28
Nsg29
S'Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| \r'
p10719
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'D.H.E. 45'
p10720
sa(dp10721
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10722
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10723
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10724
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10725
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10726
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM OXALATE'
p10727
sa(dp10728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10729
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10731
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10732
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10733
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM'
p10734
sa(dp10735
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p10736
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10737
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10738
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10739
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10740
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p10741
sa(dp10742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p10743
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10745
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10746
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10747
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p10748
sa(dp10749
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p10750
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10751
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10752
sg24
Nsg25
Nsg26
S'SUMATRIPTAN SUCCINATE'
p10753
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10754
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p10755
sa(dp10756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10757
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10759
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10760
sg28
Nsg29
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p10761
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'D.H.E. 45'
p10762
sa(dp10763
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p10764
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10765
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10766
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10767
sg28
Nsg29
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p10768
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'D.H.E. 45'
p10769
sa(dp10770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10771
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10773
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10774
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10775
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM OXALATE'
p10776
sa(dp10777
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p10778
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10779
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10780
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10781
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10782
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM'
p10783
sa(dp10784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p10785
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10787
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10788
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10789
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p10790
sa(dp10791
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p10792
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10793
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10794
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10795
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10796
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p10797
sa(dp10798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p10799
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p10800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10801
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p10802
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p10803
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p10804
sa(dp10805
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01248'
p10806
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10807
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10808
sg24
Nsg25
Nsg26
S'SUNITINIB'
p10809
sg28
Nsg29
S'Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.| Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. | \r'
p10810
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOCETAXEL'
p10811
sa(dp10812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01248'
p10813
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p10815
sg24
Nsg25
Nsg26
S'SUNITINIB'
p10816
sg28
Nsg29
S'Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.| Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. | \r'
p10817
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOCETAXEL'
p10818
sa(dp10819
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10820
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p10821
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p10822
sg24
Nsg25
Nsg26
S'Sustiva'
p10823
sg28
Nsg29
S'In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.| \r'
p10824
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p10825
sa(dp10826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10827
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p10828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10829
sg24
Nsg25
Nsg26
S'Sustiva'
p10830
sg28
Nsg29
S'SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.| \r'
p10831
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p10832
sa(dp10833
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p10834
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p10835
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10836
sg24
Nsg25
Nsg26
S'Sustiva'
p10837
sg28
Nsg29
S'Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.| \r'
p10838
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p10839
sa(dp10840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p10841
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10843
sg24
Nsg25
Nsg26
S'Sutent'
p10844
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10845
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p10846
sa(dp10847
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p10848
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10849
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10850
sg24
Nsg25
Nsg26
S'Sutent'
p10851
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10852
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p10853
sa(dp10854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p10855
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10857
sg24
Nsg25
Nsg26
S'Sutent'
p10858
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10859
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p10860
sa(dp10861
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p10862
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10863
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10864
sg24
Nsg25
Nsg26
S'Sutent'
p10865
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10866
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p10867
sa(dp10868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10869
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10871
sg24
Nsg25
Nsg26
S'Sutent'
p10872
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10873
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p10874
sa(dp10875
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p10876
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10877
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10878
sg24
Nsg25
Nsg26
S'Sutent'
p10879
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10880
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p10881
sa(dp10882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p10883
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10885
sg24
Nsg25
Nsg26
S'Sutent'
p10886
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10887
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p10888
sa(dp10889
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p10890
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10891
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10892
sg24
Nsg25
Nsg26
S'Sutent'
p10893
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10894
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p10895
sa(dp10896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p10897
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10899
sg24
Nsg25
Nsg26
S'Sutent'
p10900
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10901
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p10902
sa(dp10903
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p10904
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10905
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10906
sg24
Nsg25
Nsg26
S'Sutent'
p10907
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10908
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p10909
sa(dp10910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p10911
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10913
sg24
Nsg25
Nsg26
S'Sutent'
p10914
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10915
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p10916
sa(dp10917
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p10918
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10919
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10920
sg24
Nsg25
Nsg26
S'Sutent'
p10921
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10922
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p10923
sa(dp10924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p10925
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10927
sg24
Nsg25
Nsg26
S'Sutent'
p10928
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p10929
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p10930
sa(dp10931
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p10932
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10933
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10934
sg24
Nsg25
Nsg26
S'Sutent'
p10935
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10936
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p10937
sa(dp10938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10939
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10941
sg24
Nsg25
Nsg26
S'Sutent'
p10942
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10943
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p10944
sa(dp10945
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p10946
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10947
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10948
sg24
Nsg25
Nsg26
S'Sutent'
p10949
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10950
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p10951
sa(dp10952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p10953
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p10954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10955
sg24
Nsg25
Nsg26
S'Sutent'
p10956
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p10957
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TELITHROMYCIN'
p10958
sa(dp10959
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p10960
sg5
S'http://bio2rdf.org/drugbank:DB01278'
p10961
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10962
sg24
Nsg25
Nsg26
S'Symlin'
p10963
sg28
Nsg29
S'Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). | \r'
p10964
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atropine'
p10965
sa(dp10966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10967
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10969
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p10970
sg28
Nsg29
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10971
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN ANHYDROUS'
p10972
sa(dp10973
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10974
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10975
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10976
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p10977
sg28
Nsg29
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10978
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN ANHYDROUS'
p10979
sa(dp10980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10981
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10983
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p10984
sg28
Nsg29
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10985
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN'
p10986
sa(dp10987
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p10988
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10989
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p10990
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p10991
sg28
Nsg29
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p10992
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN'
p10993
sa(dp10994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p10995
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p10996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p10997
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p10998
sg28
Nsg29
S'Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. | \r'
p10999
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p11000
sa(dp11001
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11002
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11003
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11004
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p11005
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11006
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p11007
sa(dp11008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11009
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11011
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p11012
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11013
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p11014
sa(dp11015
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p11016
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11017
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11018
sg24
Nsg25
Nsg26
S'TACROLIMUS ANHYDROUS'
p11019
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p11020
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p11021
sa(dp11022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11023
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11025
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11026
sg28
Nsg29
S'Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| Caution should be exercised if tacrolimus and bosentan are used together.| \r'
p11027
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN ANHYDROUS'
p11028
sa(dp11029
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11030
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11031
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11032
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11033
sg28
Nsg29
S'Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| Caution should be exercised if tacrolimus and bosentan are used together.| \r'
p11034
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN ANHYDROUS'
p11035
sa(dp11036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11037
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11039
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11040
sg28
Nsg29
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p11041
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN'
p11042
sa(dp11043
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00559'
p11044
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11045
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11046
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11047
sg28
Nsg29
S'Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| \r'
p11048
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BOSENTAN'
p11049
sa(dp11050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p11051
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11053
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11054
sg28
Nsg29
S'Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. | \r'
p11055
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p11056
sa(dp11057
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11058
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11059
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11060
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11061
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11062
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p11063
sa(dp11064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11065
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11067
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11068
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11069
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p11070
sa(dp11071
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p11072
sg5
S'http://bio2rdf.org/drugbank:DB00864'
p11073
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11074
sg24
Nsg25
Nsg26
S'TACROLIMUS'
p11075
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p11076
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p11077
sa(dp11078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11079
sg5
S'http://bio2rdf.org/drugbank:DB00820'
p11080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11081
sg24
Nsg25
Nsg26
S'TADALAFIL'
p11082
sg28
Nsg29
S'Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| \r'
p11083
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p11084
sa(dp11085
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11086
sg5
S'http://bio2rdf.org/drugbank:DB00820'
p11087
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11088
sg24
Nsg25
Nsg26
S'TADALAFIL'
p11089
sg28
Nsg29
S'Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| \r'
p11090
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p11091
sa(dp11092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p11093
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11095
sg24
Nsg25
Nsg26
S'Tagamet'
p11096
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11097
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p11098
sa(dp11099
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p11100
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11101
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11102
sg24
Nsg25
Nsg26
S'Tagamet'
p11103
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11104
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p11105
sa(dp11106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05291'
p11107
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11109
sg24
Nsg25
Nsg26
S'Tagamet'
p11110
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11111
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LIDOCAINE'
p11112
sa(dp11113
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p11114
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11115
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11116
sg24
Nsg25
Nsg26
S'Tagamet'
p11117
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11118
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METRONIDAZOLE'
p11119
sa(dp11120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01115'
p11121
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11123
sg24
Nsg25
Nsg26
S'Tagamet'
p11124
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11125
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NIFEDIPINE'
p11126
sa(dp11127
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11128
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11129
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11130
sg24
Nsg25
Nsg26
S'Tagamet'
p11131
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p11132
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11133
sa(dp11134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11135
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11137
sg24
Nsg25
Nsg26
S'Tagamet'
p11138
sg28
Nsg29
S'However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| \r'
p11139
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Theo-Dur'
p11140
sa(dp11141
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11142
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p11143
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11144
sg24
Nsg25
Nsg26
S'Tagamet'
p11145
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| \r'
p11146
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p11147
sa(dp11148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p11149
sg5
S'http://bio2rdf.org/drugbank:DB01195'
p11150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11151
sg24
Nsg25
Nsg26
S'Tambocor'
p11152
sg28
Nsg29
S'During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| \r'
p11153
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p11154
sa(dp11155
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01217'
p11156
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p11157
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11158
sg24
Nsg25
Nsg26
S'TAMOXIFEN'
p11159
sg28
Nsg29
S'Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| \r'
p11160
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANASTROZOLE'
p11161
sa(dp11162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p11163
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p11164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11165
sg24
Nsg25
Nsg26
S'TAMOXIFEN'
p11166
sg28
Nsg29
S'It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. | \r'
p11167
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p11168
sa(dp11169
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p11170
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11171
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11172
sg24
Nsg25
Nsg26
S'Tarceva'
p11173
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11174
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p11175
sa(dp11176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p11177
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11179
sg24
Nsg25
Nsg26
S'Tarceva'
p11180
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11181
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLARITHROMYCIN'
p11182
sa(dp11183
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11184
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11185
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11186
sg24
Nsg25
Nsg26
S'Tarceva'
p11187
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11188
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p11189
sa(dp11190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11191
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11193
sg24
Nsg25
Nsg26
S'Tarceva'
p11194
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11195
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p11196
sa(dp11197
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11198
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11199
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11200
sg24
Nsg25
Nsg26
S'Tarceva'
p11201
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11202
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p11203
sa(dp11204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p11205
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11207
sg24
Nsg25
Nsg26
S'Tarceva'
p11208
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11209
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p11210
sa(dp11211
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB05251'
p11212
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11213
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11214
sg24
Nsg25
Nsg26
S'Tarceva'
p11215
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11216
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p11217
sa(dp11218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p11219
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11221
sg24
Nsg25
Nsg26
S'Tarceva'
p11222
sg28
Nsg29
S'If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.| \r'
p11223
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p11224
sa(dp11225
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p11226
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11227
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11228
sg24
Nsg25
Nsg26
S'Tarceva'
p11229
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11230
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p11231
sa(dp11232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11233
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11235
sg24
Nsg25
Nsg26
S'Tarceva'
p11236
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11237
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p11238
sa(dp11239
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11240
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11241
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11242
sg24
Nsg25
Nsg26
S'Tarceva'
p11243
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11244
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p11245
sa(dp11246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p11247
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11249
sg24
Nsg25
Nsg26
S'Tarceva'
p11250
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11251
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tao'
p11252
sa(dp11253
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p11254
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11255
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11256
sg24
Nsg25
Nsg26
S'Tarceva'
p11257
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11258
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TELITHROMYCIN'
p11259
sa(dp11260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p11261
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11263
sg24
Nsg25
Nsg26
S'Tarceva'
p11264
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11265
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p11266
sa(dp11267
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p11268
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p11269
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11270
sg24
Nsg25
Nsg26
S'Tarceva'
p11271
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p11272
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VORICONAZOLE'
p11273
sa(dp11274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p11275
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p11276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11277
sg24
Nsg25
Nsg26
S'Targretin'
p11278
sg28
Nsg29
S'Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p11279
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GEMFIBROZIL'
p11280
sa(dp11281
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p11282
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p11283
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11284
sg24
Nsg25
Nsg26
S'Taxol'
p11285
sg28
Nsg29
S'In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).| Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.| \r'
p11286
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CISPLATIN'
p11287
sa(dp11288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00515'
p11289
sg5
S'http://bio2rdf.org/drugbank:DB01229'
p11290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11291
sg24
Nsg25
Nsg26
S'Taxol'
p11292
sg28
Nsg29
S'In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).| Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.| \r'
p11293
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CISPLATIN'
p11294
sa(dp11295
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01229'
p11296
sg5
S'http://bio2rdf.org/drugbank:DB00444'
p11297
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11298
sg24
Nsg25
Nsg26
S'TENIPOSIDE'
p11299
sg28
Nsg29
S'Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.| \r'
p11300
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Taxol'
p11301
sa(dp11302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00201'
p11303
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11305
sg24
Nsg25
Nsg26
S'TERBINAFINE'
p11306
sg28
Nsg29
S'Terbinafine decreases the clearance of caffeine by 19%. | \r'
p11307
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CAFFEINE'
p11308
sa(dp11309
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p11310
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11311
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11312
sg24
Nsg25
Nsg26
S'TERBINAFINE'
p11313
sg28
Nsg29
S'Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | \r'
p11314
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p11315
sa(dp11316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p11317
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11319
sg24
Nsg25
Nsg26
S'TERBINAFINE'
p11320
sg28
Nsg29
S'Terbinafine increases the clearance of cyclosporine by 15%. | \r'
p11321
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p11322
sa(dp11323
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p11324
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p11325
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11326
sg24
Nsg25
Nsg26
S'TERBINAFINE'
p11327
sg28
Nsg29
S'Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | \r'
p11328
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p11329
sa(dp11330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p11331
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11333
sg24
Nsg25
Nsg26
S'TETRACYCLINE'
p11334
sg28
Nsg29
S'Absorption of tetracycline is impaired by bismuth subsalicylate.| \r'
p11335
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BISMUTH SUBSALICYLATE'
p11336
sa(dp11337
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p11338
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11339
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11340
sg24
Nsg25
Nsg26
S'TETRACYCLINE'
p11341
sg28
Nsg29
S'Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| \r'
p11342
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p11343
sa(dp11344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p11345
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11347
sg24
Nsg25
Nsg26
S'TETRACYCLINE'
p11348
sg28
Nsg29
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. | \r'
p11349
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOXYFLURANE'
p11350
sa(dp11351
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p11352
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11353
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11354
sg24
Nsg25
Nsg26
S'TETRACYCLINE'
p11355
sg28
Nsg29
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| \r'
p11356
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Penthrane'
p11357
sa(dp11358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01028'
p11359
sg5
S'http://bio2rdf.org/drugbank:DB00759'
p11360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11361
sg24
Nsg25
Nsg26
S'TETRACYCLINE'
p11362
sg28
Nsg29
S'The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. | \r'
p11363
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOXYFLURANE'
p11364
sa(dp11365
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p11366
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11367
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11368
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11369
sg28
Nsg29
S'Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; | \r'
p11370
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACETAMINOPHEN'
p11371
sa(dp11372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p11373
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11375
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11376
sg28
Nsg29
S'Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.| \r'
p11377
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p11378
sa(dp11379
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p11380
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11381
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11382
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11383
sg28
Nsg29
S'In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.| \r'
p11384
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p11385
sa(dp11386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00448'
p11387
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11389
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11390
sg28
Nsg29
S'Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.| \r'
p11391
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lansoprazole'
p11392
sa(dp11393
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p11394
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11395
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11396
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11397
sg28
Nsg29
S'This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | \r'
p11398
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p11399
sa(dp11400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00008'
p11401
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11403
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11404
sg28
Nsg29
S'Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.| \r'
p11405
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pegasys'
p11406
sa(dp11407
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11408
sg5
S'http://bio2rdf.org/drugbank:DB00277'
p11409
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11410
sg24
Nsg25
Nsg26
S'THEOPHYLLINE'
p11411
sg28
Nsg29
S'Enhanced theophylline clearance secondary to phenytoin therapy.&#x0D;| This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. | \r'
p11412
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11413
sa(dp11414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11415
sg5
S'http://bio2rdf.org/drugbank:DB00730'
p11416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11417
sg24
Nsg25
Nsg26
S'THIABENDAZOLE'
p11418
sg28
Nsg29
S'Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. | \r'
p11419
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p11420
sa(dp11421
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p11422
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p11423
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p11424
sg24
Nsg25
Nsg26
S'THIAMINE ION'
p11425
sg28
Nsg29
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p11426
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p11427
sa(dp11428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p11429
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p11430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p11431
sg24
Nsg25
Nsg26
S'THIAMINE'
p11432
sg28
Nsg29
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p11433
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p11434
sa(dp11435
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p11436
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11437
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11438
sg24
Nsg25
Nsg26
S'TIAGABINE'
p11439
sg28
Nsg29
S'Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.| \r'
p11440
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p11441
sa(dp11442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p11443
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11445
sg24
Nsg25
Nsg26
S'TIAGABINE'
p11446
sg28
Nsg29
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p11447
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p11448
sa(dp11449
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11450
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11451
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11452
sg24
Nsg25
Nsg26
S'TIAGABINE'
p11453
sg28
Nsg29
S'Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.| \r'
p11454
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11455
sa(dp11456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p11457
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11459
sg24
Nsg25
Nsg26
S'TIAGABINE'
p11460
sg28
Nsg29
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p11461
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p11462
sa(dp11463
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p11464
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p11465
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11466
sg24
Nsg25
Nsg26
S'TIAGABINE'
p11467
sg28
Nsg29
S'Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| \r'
p11468
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p11469
sa(dp11470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p11471
sg5
S'http://bio2rdf.org/drugbank:DB08816'
p11472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11473
sg24
Nsg25
Nsg26
S'TICAGRELOR'
p11474
sg28
Nsg29
S'The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). | \r'
p11475
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASPIRIN'
p11476
sa(dp11477
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00501'
p11478
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p11479
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11480
sg24
Nsg25
Nsg26
S'Tikosyn'
p11481
sg28
Nsg29
S'If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.| \r'
p11482
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIMETIDINE'
p11483
sa(dp11484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p11485
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p11486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11487
sg24
Nsg25
Nsg26
S'Tikosyn'
p11488
sg28
Nsg29
S'Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| \r'
p11489
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p11490
sa(dp11491
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01018'
p11492
sg5
S'http://bio2rdf.org/drugbank:DB00373'
p11493
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11494
sg24
Nsg25
Nsg26
S'TIMOLOL'
p11495
sg28
Nsg29
S'Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.| \r'
p11496
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANFACINE'
p11497
sa(dp11498
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00903'
p11499
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11500
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11501
sg24
Nsg25
Nsg26
S'Tobi'
p11502
sg28
Nsg29
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11503
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHACRYNIC ACID'
p11504
sa(dp11505
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p11506
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11507
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11508
sg24
Nsg25
Nsg26
S'Tobi'
p11509
sg28
Nsg29
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11510
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p11511
sa(dp11512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00742'
p11513
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11515
sg24
Nsg25
Nsg26
S'Tobi'
p11516
sg28
Nsg29
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11517
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MANNITOL'
p11518
sa(dp11519
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00003'
p11520
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11521
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11522
sg24
Nsg25
Nsg26
S'Tobi'
p11523
sg28
Nsg29
S'In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. | \r'
p11524
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pulmozyme'
p11525
sa(dp11526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB03904'
p11527
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p11528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11529
sg24
Nsg25
Nsg26
S'Tobi'
p11530
sg28
Nsg29
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p11531
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'UREA'
p11532
sa(dp11533
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p11534
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p11535
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11536
sg24
Nsg25
Nsg26
S'TOLBUTAMIDE'
p11537
sg28
Nsg29
S'Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| \r'
p11538
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p11539
sa(dp11540
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p11541
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p11542
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11543
sg24
Nsg25
Nsg26
S'TOLBUTAMIDE'
p11544
sg28
Nsg29
S'The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| \r'
p11545
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atromid-S'
p11546
sa(dp11547
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00444'
p11548
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p11549
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11550
sg24
Nsg25
Nsg26
S'TOLBUTAMIDE'
p11551
sg28
Nsg29
S'In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | \r'
p11552
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TENIPOSIDE'
p11553
sa(dp11554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p11555
sg5
S'http://bio2rdf.org/drugbank:DB00500'
p11556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11557
sg24
Nsg25
Nsg26
S'Tolectin'
p11558
sg28
Nsg29
S'TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. | Caution should be used if TOLECTIN is administered concomitantly with methotrexate. | \r'
p11559
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p11560
sa(dp11561
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p11562
sg5
S'http://bio2rdf.org/drugbank:DB00500'
p11563
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11564
sg24
Nsg25
Nsg26
S'Tolectin'
p11565
sg28
Nsg29
S'TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. | Caution should be used if TOLECTIN is administered concomitantly with methotrexate. | \r'
p11566
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p11567
sa(dp11568
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00977'
p11569
sg5
S'http://bio2rdf.org/drugbank:DB00273'
p11570
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11571
sg24
Nsg25
Nsg26
S'TOPIRAMATE'
p11572
sg28
Nsg29
S'Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| \r'
p11573
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ETHINYL ESTRADIOL'
p11574
sa(dp11575
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p11576
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11577
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11578
sg24
Nsg25
Nsg26
S'Toradol'
p11579
sg28
Nsg29
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p11580
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p11581
sa(dp11582
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p11583
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11584
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11585
sg24
Nsg25
Nsg26
S'Toradol'
p11586
sg28
Nsg29
S'Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).| \r'
p11587
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p11588
sa(dp11589
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00695'
p11590
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11591
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11592
sg24
Nsg25
Nsg26
S'Toradol'
p11593
sg28
Nsg29
S'Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).| \r'
p11594
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FUROSEMIDE'
p11595
sa(dp11596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11597
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11599
sg24
Nsg25
Nsg26
S'Toradol'
p11600
sg28
Nsg29
S'Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).| \r'
p11601
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11602
sa(dp11603
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p11604
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11605
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11606
sg24
Nsg25
Nsg26
S'Toradol'
p11607
sg28
Nsg29
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p11608
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p11609
sa(dp11610
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p11611
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11612
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11613
sg24
Nsg25
Nsg26
S'Toradol'
p11614
sg28
Nsg29
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p11615
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p11616
sa(dp11617
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01623'
p11618
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p11619
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11620
sg24
Nsg25
Nsg26
S'Toradol'
p11621
sg28
Nsg29
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p11622
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THIOTHIXENE'
p11623
sa(dp11624
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p11625
sg5
S'http://bio2rdf.org/drugbank:DB00559'
p11626
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11627
sg24
Nsg25
Nsg26
S'Tracleer'
p11628
sg28
Nsg29
S'Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.| \r'
p11629
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p11630
sa(dp11631
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p11632
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p11633
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11634
sg24
Nsg25
Nsg26
S'Trecator'
p11635
sg28
Nsg29
S'Trecator has been found to temporarily raise serum concentrations of isoniazid.| \r'
p11636
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p11637
sa(dp11638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p11639
sg5
S'http://bio2rdf.org/drugbank:DB00806'
p11640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11641
sg24
Nsg25
Nsg26
S'Trental'
p11642
sg28
Nsg29
S'Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. | \r'
p11643
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p11644
sa(dp11645
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p11646
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p11647
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11648
sg24
Nsg25
Nsg26
S'Triacetyloleandomycin'
p11649
sg28
Nsg29
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p11650
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERGOTAMINE'
p11651
sa(dp11652
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p11653
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p11654
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11655
sg24
Nsg25
Nsg26
S'TRIAMTERENE'
p11656
sg28
Nsg29
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p11657
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p11658
sa(dp11659
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p11660
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p11661
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11662
sg24
Nsg25
Nsg26
S'TRIAMTERENE'
p11663
sg28
Nsg29
S'It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.| \r'
p11664
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Indocin'
p11665
sa(dp11666
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p11667
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p11668
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11669
sg24
Nsg25
Nsg26
S'TRIAMTERENE'
p11670
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p11671
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p11672
sa(dp11673
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p11674
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11675
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11676
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p11677
sg28
Nsg29
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p11678
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p11679
sa(dp11680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p11681
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11683
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p11684
sg28
Nsg29
S'The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| \r'
p11685
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p11686
sa(dp11687
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p11688
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11689
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11690
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p11691
sg28
Nsg29
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p11692
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p11693
sa(dp11694
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11695
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11696
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11697
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p11698
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11699
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR MESYLATE'
p11700
sa(dp11701
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p11702
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11703
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11704
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p11705
sg28
Nsg29
S'Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| \r'
p11706
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SAQUINAVIR'
p11707
sa(dp11708
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p11709
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p11710
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11711
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p11712
sg28
Nsg29
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p11713
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TIAGABINE'
p11714
sa(dp11715
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01023'
p11716
sg5
S'http://bio2rdf.org/drugbank:DB00776'
p11717
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11718
sg24
Nsg25
Nsg26
S'Trileptal'
p11719
sg28
Nsg29
S'Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].| \r'
p11720
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Felodipine'
p11721
sa(dp11722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11723
sg5
S'http://bio2rdf.org/drugbank:DB00776'
p11724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11725
sg24
Nsg25
Nsg26
S'Trileptal'
p11726
sg28
Nsg29
S'Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.| \r'
p11727
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11728
sa(dp11729
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00648'
p11730
sg5
S'http://bio2rdf.org/drugbank:DB01108'
p11731
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p11732
sg24
Nsg25
Nsg26
S'TRILOSTANE'
p11733
sg28
Nsg29
S'Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).| \r'
p11734
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mitotane'
p11735
sa(dp11736
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11737
sg5
S'http://bio2rdf.org/drugbank:DB00440'
p11738
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11739
sg24
Nsg25
Nsg26
S'TRIMETHOPRIM'
p11740
sg28
Nsg29
S'Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. | Trimethoprim may inhibit the hepatic metabolism of phenytoin. | \r'
p11741
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11742
sa(dp11743
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p11744
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11745
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11746
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p11747
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11748
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p11749
sa(dp11750
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p11751
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11752
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11753
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p11754
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11755
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p11756
sa(dp11757
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11758
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11759
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11760
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p11761
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11762
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p11763
sa(dp11764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p11765
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11767
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p11768
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11769
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p11770
sa(dp11771
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p11772
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p11773
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11774
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p11775
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p11776
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p11777
sa(dp11778
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p11779
sg5
S'http://bio2rdf.org/drugbank:DB00792'
p11780
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11781
sg24
Nsg25
Nsg26
S'TRIPELENNAMINE'
p11782
sg28
Nsg29
S'Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. | \r'
p11783
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAZOCINE, (-)-'
p11784
sa(dp11785
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p11786
sg5
S'http://bio2rdf.org/drugbank:DB00427'
p11787
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11788
sg24
Nsg25
Nsg26
S'TRIPROLIDINE'
p11789
sg28
Nsg29
S'Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. | \r'
p11790
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALCOHOL'
p11791
sa(dp11792
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p11793
sg5
S'http://bio2rdf.org/drugbank:DB01169'
p11794
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11795
sg24
Nsg25
Nsg26
S'Trisenox'
p11796
sg28
Nsg29
S'Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).| \r'
p11797
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p11798
sa(dp11799
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p11800
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p11801
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11802
sg24
Nsg25
Nsg26
S'TROLEANDOMYCIN'
p11803
sg28
Nsg29
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p11804
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p11805
sa(dp11806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p11807
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p11808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11809
sg24
Nsg25
Nsg26
S'TROLEANDOMYCIN'
p11810
sg28
Nsg29
S'Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | \r'
p11811
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p11812
sa(dp11813
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p11814
sg5
S'http://bio2rdf.org/drugbank:DB00685'
p11815
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11816
sg24
Nsg25
Nsg26
S'TROVAFLOXACIN'
p11817
sg28
Nsg29
S'Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. | \r'
p11818
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MORPHINE'
p11819
sa(dp11820
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p11821
sg5
S'http://bio2rdf.org/drugbank:DB01199'
p11822
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11823
sg24
Nsg25
Nsg26
S'TUBOCURARINE'
p11824
sg28
Nsg29
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p11825
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coly-Mycin M'
p11826
sa(dp11827
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p11828
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11829
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11830
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11831
sg28
Nsg29
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p11832
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXTROMETHORPHAN'
p11833
sa(dp11834
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p11835
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11836
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11837
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11838
sg28
Nsg29
S'Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.| \r'
p11839
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p11840
sa(dp11841
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p11842
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11843
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11844
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11845
sg28
Nsg29
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p11846
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p11847
sa(dp11848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p11849
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11851
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11852
sg28
Nsg29
S'Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.| \r'
p11853
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLYBURIDE'
p11854
sa(dp11855
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11856
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11857
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11858
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11859
sg28
Nsg29
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p11860
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p11861
sa(dp11862
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p11863
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11864
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11865
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11866
sg28
Nsg29
S'Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.| \r'
p11867
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p11868
sa(dp11869
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p11870
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11871
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11872
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11873
sg28
Nsg29
S'Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.| \r'
p11874
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p11875
sa(dp11876
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p11877
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11878
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11879
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11880
sg28
Nsg29
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p11881
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENARSAZINE CHLORIDE'
p11882
sa(dp11883
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11884
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11885
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11886
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11887
sg28
Nsg29
S'Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| \r'
p11888
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11889
sa(dp11890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p11891
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p11892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11893
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p11894
sg28
Nsg29
S'Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| \r'
p11895
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p11896
sa(dp11897
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p11898
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11899
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11900
sg24
Nsg25
Nsg26
S'Valproate'
p11901
sg28
Nsg29
S'Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| \r'
p11902
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p11903
sa(dp11904
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p11905
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11906
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11907
sg24
Nsg25
Nsg26
S'Valproate'
p11908
sg28
Nsg29
S'Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.| \r'
p11909
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TIAGABINE'
p11910
sa(dp11911
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p11912
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11913
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11914
sg24
Nsg25
Nsg26
S'VALPROIC ACID'
p11915
sg28
Nsg29
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p11916
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p11917
sa(dp11918
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p11919
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11920
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11921
sg24
Nsg25
Nsg26
S'VALPROIC ACID'
p11922
sg28
Nsg29
S'Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | \r'
p11923
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p11924
sa(dp11925
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00853'
p11926
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p11927
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11928
sg24
Nsg25
Nsg26
S'VALPROIC ACID'
p11929
sg28
Nsg29
S'Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | \r'
p11930
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TEMOZOLOMIDE'
p11931
sa(dp11932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p11933
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11935
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11936
sg28
Nsg29
S'It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.| \r'
p11937
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p11938
sa(dp11939
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11940
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11941
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11942
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11943
sg28
Nsg29
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| \r'
p11944
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p11945
sa(dp11946
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11947
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11948
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11949
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11950
sg28
Nsg29
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| \r'
p11951
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR ANHYDROUS'
p11952
sa(dp11953
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11954
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11955
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11956
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11957
sg28
Nsg29
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| \r'
p11958
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p11959
sa(dp11960
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p11961
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11962
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11963
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11964
sg28
Nsg29
S'It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| \r'
p11965
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INDINAVIR'
p11966
sa(dp11967
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p11968
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11969
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11970
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11971
sg28
Nsg29
S'A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.| Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.| \r'
p11972
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p11973
sa(dp11974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p11975
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p11977
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11978
sg28
Nsg29
S'The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p11979
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p11980
sa(dp11981
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p11982
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11983
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p11984
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11985
sg28
Nsg29
S'The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p11986
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p11987
sa(dp11988
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00706'
p11989
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p11990
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11991
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p11992
sg28
Nsg29
S'In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.| Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.| \r'
p11993
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TAMSULOSIN'
p11994
sa(dp11995
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p11996
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p11997
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p11998
sg24
Nsg25
Nsg26
S'Verapamil'
p11999
sg28
Nsg29
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p12000
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Adenocard'
p12001
sa(dp12002
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p12003
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12004
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12005
sg24
Nsg25
Nsg26
S'Verapamil'
p12006
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p12007
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p12008
sa(dp12009
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p12010
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12011
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12012
sg24
Nsg25
Nsg26
S'Verapamil'
p12013
sg28
Nsg29
S'In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p12014
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p12015
sa(dp12016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p12017
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12019
sg24
Nsg25
Nsg26
S'Verapamil'
p12020
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p12021
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p12022
sa(dp12023
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p12024
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12025
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12026
sg24
Nsg25
Nsg26
S'Verapamil'
p12027
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p12028
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p12029
sa(dp12030
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01195'
p12031
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p12032
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12033
sg24
Nsg25
Nsg26
S'Verapamil'
p12034
sg28
Nsg29
S'Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.| \r'
p12035
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tambocor'
p12036
sa(dp12037
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p12038
sg5
S'http://bio2rdf.org/drugbank:DB01591'
p12039
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12040
sg24
Nsg25
Nsg26
S'Vesicare'
p12041
sg28
Nsg29
S'Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. | \r'
p12042
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p12043
sa(dp12044
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p12045
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12046
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12047
sg24
Nsg25
Nsg26
S'Videx'
p12048
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| \r'
p12049
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p12050
sa(dp12051
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p12052
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12053
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12054
sg24
Nsg25
Nsg26
S'Videx'
p12055
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p12056
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p12057
sa(dp12058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01004'
p12059
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12061
sg24
Nsg25
Nsg26
S'Videx'
p12062
sg28
Nsg29
S'Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| \r'
p12063
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GANCICLOVIR'
p12064
sa(dp12065
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p12066
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p12067
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12068
sg24
Nsg25
Nsg26
S'Videx'
p12069
sg28
Nsg29
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p12070
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p12071
sa(dp12072
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p12073
sg5
S'http://bio2rdf.org/drugbank:DB01080'
p12074
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12075
sg24
Nsg25
Nsg26
S'Vigabatrin'
p12076
sg28
Nsg29
S'A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. | \r'
p12077
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CARBAMAZEPINE'
p12078
sa(dp12079
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p12080
sg5
S'http://bio2rdf.org/drugbank:DB01080'
p12081
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12082
sg24
Nsg25
Nsg26
S'Vigabatrin'
p12083
sg28
Nsg29
S'In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. | \r'
p12084
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p12085
sa(dp12086
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p12087
sg5
S'http://bio2rdf.org/drugbank:DB00309'
p12088
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p12089
sg24
Nsg25
Nsg26
S'VINDESINE'
p12090
sg28
Nsg29
S"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine| \r"
p12091
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYTOIN'
p12092
sa(dp12093
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00542'
p12094
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12095
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12096
sg24
Nsg25
Nsg26
S'Vioxx'
p12097
sg28
Nsg29
S'In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.| \r'
p12098
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BENAZEPRIL'
p12099
sa(dp12100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p12101
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12103
sg24
Nsg25
Nsg26
S'Vioxx'
p12104
sg28
Nsg29
S'Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| \r'
p12105
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM CATION'
p12106
sa(dp12107
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01356'
p12108
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12109
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12110
sg24
Nsg25
Nsg26
S'Vioxx'
p12111
sg28
Nsg29
S'Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| \r'
p12112
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LITHIUM'
p12113
sa(dp12114
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p12115
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12116
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12117
sg24
Nsg25
Nsg26
S'Vioxx'
p12118
sg28
Nsg29
S'Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| \r'
p12119
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p12120
sa(dp12121
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00563'
p12122
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12123
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12124
sg24
Nsg25
Nsg26
S'Vioxx'
p12125
sg28
Nsg29
S'Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| \r'
p12126
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHOTREXATE'
p12127
sa(dp12128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p12129
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12131
sg24
Nsg25
Nsg26
S'Vioxx'
p12132
sg28
Nsg29
S'Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.| \r'
p12133
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p12134
sa(dp12135
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p12136
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12137
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12138
sg24
Nsg25
Nsg26
S'Vioxx'
p12139
sg28
Nsg29
S'Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.| Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| \r'
p12140
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p12141
sa(dp12142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p12143
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p12144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12145
sg24
Nsg25
Nsg26
S'Vioxx'
p12146
sg28
Nsg29
S'Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.| Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| \r'
p12147
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p12148
sa(dp12149
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p12150
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12151
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12152
sg24
Nsg25
Nsg26
S'Viracept'
p12153
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12154
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p12155
sa(dp12156
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p12157
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12158
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12159
sg24
Nsg25
Nsg26
S'Viracept'
p12160
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.| \r'
p12161
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p12162
sa(dp12163
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p12164
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12165
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12166
sg24
Nsg25
Nsg26
S'Viracept'
p12167
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12168
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p12169
sa(dp12170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p12171
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12173
sg24
Nsg25
Nsg26
S'Viracept'
p12174
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12175
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p12176
sa(dp12177
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00908'
p12178
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12179
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12180
sg24
Nsg25
Nsg26
S'Viracept'
p12181
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12182
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'QUINIDINE'
p12183
sa(dp12184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p12185
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12187
sg24
Nsg25
Nsg26
S'Viracept'
p12188
sg28
Nsg29
S'Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin| \r'
p12189
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p12190
sa(dp12191
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p12192
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12193
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12194
sg24
Nsg25
Nsg26
S'Viracept'
p12195
sg28
Nsg29
S'VIRACEPT and rifampin should not be coadministered.| Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12196
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p12197
sa(dp12198
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p12199
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p12200
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12201
sg24
Nsg25
Nsg26
S'Viracept'
p12202
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p12203
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p12204
sa(dp12205
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p12206
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12207
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12208
sg24
Nsg25
Nsg26
S'Vistide'
p12209
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12210
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIKACIN'
p12211
sa(dp12212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p12213
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12215
sg24
Nsg25
Nsg26
S'Vistide'
p12216
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12217
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p12218
sa(dp12219
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p12220
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12221
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12222
sg24
Nsg25
Nsg26
S'Vistide'
p12223
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12224
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FOSCARNET'
p12225
sa(dp12226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p12227
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12229
sg24
Nsg25
Nsg26
S'Vistide'
p12230
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12231
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p12232
sa(dp12233
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p12234
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12235
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12236
sg24
Nsg25
Nsg26
S'Vistide'
p12237
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12238
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOBRAMYCIN'
p12239
sa(dp12240
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p12241
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p12242
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12243
sg24
Nsg25
Nsg26
S'Vistide'
p12244
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p12245
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VANCOMYCIN'
p12246
sa(dp12247
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p12248
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p12249
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p12250
sg24
Nsg25
Nsg26
S'Vitamin B1'
p12251
sg28
Nsg29
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p12252
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p12253
sa(dp12254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p12255
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p12256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12257
sg24
Nsg25
Nsg26
S'Vitamin B12'
p12258
sg28
Nsg29
S'Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.| \r'
p12259
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMINOSALICYLIC ACID'
p12260
sa(dp12261
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00158'
p12262
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p12263
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p12264
sg24
Nsg25
Nsg26
S'Vitamin B12'
p12265
sg28
Nsg29
S'Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.| \r'
p12266
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FOLIC ACID'
p12267
sa(dp12268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p12269
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p12270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12271
sg24
Nsg25
Nsg26
S'Welchol'
p12272
sg28
Nsg29
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p12273
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Calan SR'
p12274
sa(dp12275
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p12276
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p12277
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12278
sg24
Nsg25
Nsg26
S'Welchol'
p12279
sg28
Nsg29
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p12280
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p12281
sa(dp12282
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00915'
p12283
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12284
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12285
sg24
Nsg25
Nsg26
S'Wellbutrin'
p12286
sg28
Nsg29
S'Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.| \r'
p12287
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMANTADINE'
p12288
sa(dp12289
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p12290
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12291
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p12292
sg24
Nsg25
Nsg26
S'Wellbutrin'
p12293
sg28
Nsg29
S'Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| \r'
p12294
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cyclophosphamide'
p12295
sa(dp12296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01235'
p12297
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12299
sg24
Nsg25
Nsg26
S'Wellbutrin'
p12300
sg28
Nsg29
S'Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.| \r'
p12301
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVODOPA'
p12302
sa(dp12303
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p12304
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p12305
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12306
sg24
Nsg25
Nsg26
S'Wellbutrin'
p12307
sg28
Nsg29
S'Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.| \r'
p12308
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THEOPHYLLINE'
p12309
sa(dp12310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p12311
sg5
S'http://bio2rdf.org/drugbank:DB01083'
p12312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12313
sg24
Nsg25
Nsg26
S'Xenical'
p12314
sg28
Nsg29
S'Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. | \r'
p12315
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSPORINE'
p12316
sa(dp12317
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p12318
sg5
S'http://bio2rdf.org/drugbank:DB00549'
p12319
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12320
sg24
Nsg25
Nsg26
S'ZAFIRLUKAST'
p12321
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p12322
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p12323
sa(dp12324
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p12325
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12326
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12327
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12328
sg28
Nsg29
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p12329
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p12330
sa(dp12331
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p12332
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12333
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12334
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12335
sg28
Nsg29
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p12336
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAMIVUDINE'
p12337
sa(dp12338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p12339
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12341
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12342
sg28
Nsg29
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p12343
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAMIVUDINE'
p12344
sa(dp12345
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p12346
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12347
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12348
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12349
sg28
Nsg29
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p12350
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM CATION'
p12351
sa(dp12352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01378'
p12353
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12355
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12356
sg28
Nsg29
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p12357
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MAGNESIUM'
p12358
sa(dp12359
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p12360
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12361
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12362
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12363
sg28
Nsg29
S'Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.| \r'
p12364
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p12365
sa(dp12366
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p12367
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p12368
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12369
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p12370
sg28
Nsg29
S'Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).| \r'
p12371
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZDV'
p12372
sa(dp12373
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p12374
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p12375
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12376
sg24
Nsg25
Nsg26
S'ZALEPLON'
p12377
sg28
Nsg29
S'Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.| \r'
p12378
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERYTHROMYCIN'
p12379
sa(dp12380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00053'
p12381
sg5
S'http://bio2rdf.org/drugbank:DB00419'
p12382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12383
sg24
Nsg25
Nsg26
S'Zavesca'
p12384
sg28
Nsg29
S'While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. | \r'
p12385
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cerezyme'
p12386
sa(dp12387
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p12388
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p12389
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12390
sg24
Nsg25
Nsg26
S'Zebeta'
p12391
sg28
Nsg29
S'In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| \r'
p12392
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONIDINE'
p12393
sa(dp12394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00343'
p12395
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p12396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12397
sg24
Nsg25
Nsg26
S'Zebeta'
p12398
sg28
Nsg29
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p12399
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DILTIAZEM'
p12400
sa(dp12401
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p12402
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p12403
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12404
sg24
Nsg25
Nsg26
S'Zebeta'
p12405
sg28
Nsg29
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p12406
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p12407
sa(dp12408
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p12409
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p12410
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12411
sg24
Nsg25
Nsg26
S'Zemplar'
p12412
sg28
Nsg29
S'Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. | \r'
p12413
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p12414
sa(dp12415
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p12416
sg5
S'http://bio2rdf.org/drugbank:DB00728'
p12417
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12418
sg24
Nsg25
Nsg26
S'Zemuron'
p12419
sg28
Nsg29
S'If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. | \r'
p12420
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p12421
sa(dp12422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p12423
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12425
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p12426
sg28
Nsg29
S'Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| \r'
p12427
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p12428
sa(dp12429
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p12430
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12431
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12432
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p12433
sg28
Nsg29
S'Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. | \r'
p12434
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p12435
sa(dp12436
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p12437
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12438
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12439
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p12440
sg28
Nsg29
S'A dose adjustment is not needed when zidovudine is administered with VIRACEPT.| \r'
p12441
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p12442
sa(dp12443
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p12444
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p12445
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12446
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p12447
sg28
Nsg29
S'Therefore, use of zidovudine in combination with ZERIT should be avoided. | \r'
p12448
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zerit'
p12449
sa(dp12450
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p12451
sg5
S'http://bio2rdf.org/drugbank:DB01593'
p12452
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12453
sg24
Nsg25
Nsg26
S'ZINC'
p12454
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p12455
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p12456
sa(dp12457
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p12458
sg5
S'http://bio2rdf.org/drugbank:DB01593'
p12459
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p12460
sg24
Nsg25
Nsg26
S'ZINC'
p12461
sg28
Nsg29
S'Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p12462
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p12463
sa(dp12464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p12465
sg5
S'http://bio2rdf.org/drugbank:DB02546'
p12466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12467
sg24
Nsg25
Nsg26
S'Zolinza'
p12468
sg28
Nsg29
S'Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | \r'
p12469
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIPHENOLIC ACID'
p12470
sa(dp12471
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p12472
sg5
S'http://bio2rdf.org/drugbank:DB02546'
p12473
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12474
sg24
Nsg25
Nsg26
S'Zolinza'
p12475
sg28
Nsg29
S'Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | \r'
p12476
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALPROIC ACID'
p12477
sa(dp12478
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p12479
sg5
S'http://bio2rdf.org/drugbank:DB01198'
p12480
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p12481
sg24
Nsg25
Nsg26
S'Zopiclone'
p12482
sg28
Nsg29
S'Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.| \r'
p12483
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFAMPIN'
p12484
sa(dp12485
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01205'
p12486
sg5
S'http://bio2rdf.org/drugbank:DB01198'
p12487
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p12488
sg24
Nsg25
Nsg26
S'Zopiclone'
p12489
sg28
Nsg29
S'The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.| \r'
p12490
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Romazicon'
p12491
sa.